U.S. patent application number 12/141228 was filed with the patent office on 2009-01-08 for non-basic melanin concentrating hormone receptor-1 antagonists and methods.
This patent application is currently assigned to Bristol-Myers Squibb Company. Invention is credited to Saleen Ahmad, Sharon N. Bisaha, Khehyong Ngu, Philip D. Stein, William N. Washburn.
Application Number | 20090011994 12/141228 |
Document ID | / |
Family ID | 40221936 |
Filed Date | 2009-01-08 |
United States Patent
Application |
20090011994 |
Kind Code |
A1 |
Stein; Philip D. ; et
al. |
January 8, 2009 |
NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND
METHODS
Abstract
The present application provides compounds, including all
stereoisomers, solvates, prodrugs and pharmaceutically acceptable
forms thereof according to Formula I ##STR00001## wherein
##STR00002## R.sup.1, R.sup.2, R.sup.3, R.sup.8, and R.sup.9 are
defined herein. Additionally, the present application provides
pharmaceutical compositions containing at least one compound
according to Formula I and optionally at least one additional
therapeutic agent. Finally, the present application provides
methods for treating a patient suffering from an MCHR-1 modulated
disease or disorder such as, for example, obesity, diabetes,
depression or anxiety by administration of a therapeutically
effective dose of a compound according to Formula I.
Inventors: |
Stein; Philip D.;
(Pennington, NJ) ; Bisaha; Sharon N.;
(Lambertville, NJ) ; Ahmad; Saleen; (Wall, NJ)
; Ngu; Khehyong; (Pennington, NJ) ; Washburn;
William N.; (Titusville, NJ) |
Correspondence
Address: |
LOUIS J. WILLE;BRISTOL-MYERS SQUIBB COMPANY
PATENT DEPARTMENT, P O BOX 4000
PRINCETON
NJ
08543-4000
US
|
Assignee: |
Bristol-Myers Squibb
Company
|
Family ID: |
40221936 |
Appl. No.: |
12/141228 |
Filed: |
June 18, 2008 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
60948213 |
Jul 6, 2007 |
|
|
|
Current U.S.
Class: |
514/6.7 ;
514/161; 514/253.12; 514/255.02; 514/85; 544/359; 544/385 |
Current CPC
Class: |
A61P 25/00 20180101;
A61P 25/18 20180101; C07D 241/18 20130101; A61P 3/06 20180101; A61P
17/00 20180101; A61P 43/00 20180101; C07D 401/12 20130101; A61P
9/00 20180101; A61P 25/24 20180101; A61P 19/02 20180101; A61P 3/10
20180101; A61P 25/30 20180101; A61P 9/12 20180101; A61P 25/22
20180101; A61P 9/10 20180101; A61P 3/04 20180101; A61P 25/16
20180101 |
Class at
Publication: |
514/12 ; 544/385;
514/255.02; 514/253.12; 544/359; 514/85; 514/161 |
International
Class: |
A61K 38/22 20060101
A61K038/22; A61K 31/4965 20060101 A61K031/4965; C07D 241/18
20060101 C07D241/18; A61K 31/497 20060101 A61K031/497; A61P 3/04
20060101 A61P003/04; A61P 3/10 20060101 A61P003/10; A61K 31/60
20060101 A61K031/60; C07D 401/04 20060101 C07D401/04; A61K 31/675
20060101 A61K031/675 |
Claims
1. A compound of Formula I or a pharmaceutically acceptable salt
thereof ##STR00678## wherein ##STR00679## is a phenylene ring or a
heteroaryl ring which contains one or two nitrogen atoms or one
oxygen atom; R.sup.1 is Z-Y--X--, wherein ##STR00680## Y is a bond,
a 3- to 6-membered cycloalkyl, an alkyl chain; and Z is aryl or
heteroaryl; R.sup.2 is -E-G-(J).sub.m, with m being an integer from
1 to 3; E is O, S or a bond; G is lower alkyl, phenylalkyl,
cycloalkyl, cycloalkylalkyl, alkylcycloalkyl, cycloalkoxy,
alkylcycloalkoxy, or cycloalkoxyalkyl, and each J is independently
hydrogen, hydroxyl, CN, --SO.sub.2R.sup.7, --SR.sup.7, --SOR.sup.7,
lower alkyl, lower alkoxy, CF.sub.3, CF.sub.3O--, --COOR.sup.5, or
--CO--NR.sup.5aR.sup.6, wherein R.sup.5a and R.sup.6 are each
independently selected from the group consisting of H, C.sub.1-3
alkyl, and cycloalkyl, or R.sup.5a and R.sup.6 taken together can
be propanediyl, butanediyl or pentanediyl with the N atom to which
they are attached to form a 4-, 5- or 6-membered cyclic amine which
may be optionally substituted; R.sup.5 is H, C.sub.1-6 alkyl, or
cycloalkyl; R.sup.7 is lower alkyl; and R.sup.3 is C.sub.1-6 alkyl,
cycloalkyl, C.sub.1-6 alkoxy, halogen, hydrogen, --S--C.sub.1-6
alkyl, CN, CF.sub.3O, or CF.sub.3; and wherein R.sup.2 and R.sup.3
can be taken together to form a 5- to 7-membered ring which is
saturated or partially unsaturated and may optionally include an E
heteroatom which is O or 0, 1 or 2 N atoms, which ring is
substituted with one or two --O-G-(J).sub.m groups wherein at least
one J is OH, and which may optionally be substituted with other
substituents as set out for "alkyl" or "heteroaryl"; with the
proviso that where ##STR00681## is a phenylene group, E-G and
R.sup.3 are not identical unsubstituted lower alkoxy groups, and
when G is lower alkyl and J is H, R.sup.3 is not hydrogen; and
R.sup.8 and R.sup.9 are each independently hydrogen, halogen, or
lower alkyl; including esters thereof, prodrugs thereof, solvates
thereof, and all stereoisomers thereof.
2. The compound as defined in claim 1 wherein ##STR00682## is a
phenylene or wherein ##STR00683## is a monocyclic or bicyclic
heteroaryl ring.
3. The compound as defined in claim 1 wherein ##STR00684## is
##STR00685##
4. The compound as defined in claim 1 wherein ##STR00686## is
##STR00687##
5. The compound as defined in claim 1 having the structure
##STR00688## or a pharmaceutically acceptable salt thereof or
prodrug of any of the above.
6. The compound as defined in claim 4 wherein X is O or S; and/or
R.sup.1 is Z-Y--X, wherein Y is a bond or an alkylene chain of 1 to
3 atoms; and/or wherein Z is phenyl or aryl; wherein Z is
heteroaryl; and/or wherein R.sup.2 is -E-G-J; and/or wherein E is O
or S; and/or wherein G is an alkylene chain or alkylcycloalkyl;
and/or wherein J is H, OH, SO.sub.2R.sup.7, lower alkyl, lower
alkoxy, or CF.sub.3; and/or R.sup.3 is C.sub.1-6 alkyl, C.sub.1-6
alkoxy, H, or halo; and or R.sup.8 is H or alkyl; and/or R.sup.9 is
H; and or R.sup.2 and R.sup.3 may optionally be taken together to
form a 5- to 7-membered ring which is saturated, unsaturated or
partially unsaturated, and may include an O atom or 1 or 2 N atoms,
which ring is substituted with one or two --O-G-(J).sub.m groups
wherein at least one J is OH, and which may be optionally
substituted with other substituents as set out for "alkyl" or
"heteroaryl".
7. The compound as defined in claim 1 or a pharmaceutically
acceptable salt thereof ##STR00689##
8. The compound as defined in claim 7 wherein R.sup.1 is Z-Y--X; X
is S; and/or Y is a bond or alkylene chain; and/or Z is phenyl or
pyridyl; and/or E is O; and/or G is an alkylene chain or
alkylcycloalkyl; and/or J is H or OH; and/or R.sup.3 is H, alkoxy,
alkyl, or halo; and/or R.sup.8 is H or CH.sub.3; and/or R.sup.9 is
H; wherein R.sup.2 and R.sup.3 may be taken together to form a 5-
to 7-membered ring which is saturated, unsaturated or partially
unsaturated, and may include an O atom or 1 or 2 N atoms, which
ring is substituted with 1 or 2 --O-G-(J).sub.m groups wherein at
least one J is OH, and which may be further optionally substituted
with alkyl and/or OH.
9. The compound as defined in claim 1 wherein Z is aryl or
heteroaryl, with any of the foregoing Z moieties either
unsubstituted or substituted with 1, 2 or 3 of amino, halo,
C.sub.1-6 alkyl, C.sub.1-3 alkylamino, di-C.sub.1-3 alkylamino,
C.sub.1-3 alkoxy, C.sub.1-3 thioalkyl, C.sub.1-3 trifluoroalkoxy,
trifluoromethyl, cycloalkyl, cycloalkoxy, or heteroaryl; and or J
is hydrogen, hydroxyl, CN, --SO.sub.2R.sup.7, --SR.sup.7,
--SOR.sup.7, lower alkyl, lower alkoxy, CF.sub.3, CF.sub.3O--,
--COOR.sup.5, or --CO--NR.sup.5aR.sup.6, wherein R.sup.5a and
R.sup.6 are each independently selected from the group consisting
of H, C.sub.1-3 alkyl, and cycloalkyl, or R.sup.5a and R.sup.6
taken together can be propanediyl, butanediyl or pentanediyl with
the N atom to which they are attached to form a 4-, 5- or
6-membered cyclic amine optionally substituted with lower alkyl,
lower alkoxy, hydroxyl, CF.sub.3, or CF.sub.3O.
10. The compound of claim 1 wherein: Z is (1) aryl, which is
optionally substituted with: a) halogen, b) alkyl, c) alkoxy, d)
polyhaloalkyl, e) polyhaloalkoxy, f) amino, alkylamino or
dialkylamino, g) alkylthio, h) OH, i) an ester, or j) aryl, (2)
heteroaryl which is: a) pyridinyl, b) pyrazinyl, or c) pyrimidinyl,
each of a), b) or c) being optionally substituted with alkyl,
polyhaloalkyl, alkoxy, or halogen, (3) benzothiazole optionally
substituted with halo or alkoxy, (4) benzoxazole optionally
substituted with halo, (5) benzimidazole, (6) thiazole optionally
substituted with aryl or alkyl, (7) indanyl, (8) quinolinyl
optionally substituted with CF.sub.3, or (9) imidazolidinyl; and/or
Y is a bond or alkylene; and/or X is S, O, SO, or SO.sub.2; and/or
J is (1) H, (2) --CO--NR.sup.5aR.sup.6 wherein R.sup.5a and R.sup.6
together with the N to which they are attached form a pyrrolidinyl
ring, (3) OH, (4) COOH, (5) COOalkyl, (6) SO.sub.2R.sup.7, or (7)
prodrug esters which are selected from glycine ##STR00690## valine
##STR00691## and phosphate ##STR00692## and/or m is 1 or 2; and/or
G is a bond or CH.sub.2, (CH.sub.2).sub.2, (CH.sub.2).sub.3,
##STR00693## ##STR00694## , cycloalkyl which is ##STR00695## or
cycloalkoxy which is ##STR00696## E is O; and/or wherein R.sup.2
and R.sup.3 can be optionally taken together to form a 5- or
6-membered unsaturated or aromatic ring containing one or two N
atoms, which ring is optionally substituted with hydroxyalkyl which
is ##STR00697## and is ##STR00698## and wherein R.sup.2 and R.sup.3
can optionally be taken together to form a 6-membered saturated or
partially unsaturated O-containing ring, which ring is optionally
substituted with hydroxyalkyl, alkyl, and/or OH; and/or R.sup.3 is
H, alkoxy, hydroxyalkyl, alkyl, halo, or hydroxyalkoxy; and/or
R.sup.8 is H, halo or alkyl; and/or R.sup.9 is H.
11. The compound of claim 7, wherein Z is selected from the group
consisting of phenyl, naphthyl, pyridinyl, pyrimidinyl, pyrazinyl,
benzimidazolyl, and benzoxazolyl.
12. The compound of claim 7, wherein R.sup.3 is C.sub.1-C.sub.6
alkoxy or C.sub.1-6 alkyl.
13. The compound of claim 7, wherein R.sup.1 is selected from the
group consisting of: ##STR00699## ##STR00700##
14. The compound of claim 7 wherein ##STR00701## is a phenylene;
and/or ##STR00702## and/or R.sup.3 is methoxy or methyl; R.sup.1 is
selected from the group consisting of: ##STR00703## ##STR00704##
##STR00705## ##STR00706##
15. The compound as defined in claim 7 wherein X is S; Y is a bond
or (CH.sub.2).sub.2; ##STR00707## R.sup.3 is CH.sub.3O or CH.sub.3;
R.sup.8 is H; and R.sup.9 is H.
16. The compound as defined in claim 1 having the following
formula: ##STR00708##
17. The compound of claim 1 in a prodrug ester form, wherein
R.sup.2 is ##STR00709##
18. A compound of Formula IB or a pharmaceutically acceptable salt
thereof having the structure ##STR00710##
19. The compound as defined in claim 18 wherein R.sup.1 is Z-Y--X--
wherein X is S, Y is an alkyl chain of 1 to 3 carbons or a bond, Z
is heteroaryl or phenyl, each of which Z is optionally substituted
with CF.sub.3, CF.sub.3O, or halo; R.sup.2 is -E-G-J wherein E is
O, G is lower alkyl or alkylcycloalkyl, and J is OH; R.sup.3 is
alkoxy, alkyl or halo; R.sup.8 is H or alkyl; and R.sup.9 is H.
20. The compound as defined in claim 18 wherein X is S; Y is a bond
or (CH.sub.2).sub.2; ##STR00711## ##STR00712## R.sup.3 is H, Cl,
CH.sub.3, or CH.sub.3O; and R.sup.8 and R.sup.9 are each H.
21. The compound of claim 1 wherein ##STR00713## is a heteroaryl
ring; ##STR00714## R.sup.3 is methoxy, Cl, H, or methyl; and
R.sup.1 is selected from the group consisting of: ##STR00715##
22. A pharmaceutical composition comprising a therapeutically
effective amount of a compound as defined in claim 1, alone or in
combination with at least one additional therapeutic agent, in
association with a pharmaceutically acceptable carrier or
diluent.
23. A pharmaceutical combination comprising: at least one compound
according to claim 1, and at least one additional therapeutic
agent.
24. The combination as defined in claim 23 wherein the additional
therapeutic agent is an acetyl-cholinesterase inhibitor, a
muscarinic receptor-1 agonist, a nicotinic agonist, a glutamic acid
receptor (AMPA and NMDA) modulator, a nootropic agent, an agent for
Alzheimer's disease, an agent for treatment of Parkinson's disease,
anti-hyperlipidemia agent, an anti-obesity agent; anti-diabetic
agent, appetite suppressant; cholesterol/lipid-lowering agent,
HDL-raising agent, cognition enhancing agent, an agent used to
treat neurodegeneration, an agent used to treat respiratory
conditions, an agent used to treat bowel disorders, an
anti-inflammatory agent; anti-anxiety agent; an anti-depressant; an
anti-hypertensive agent; an anti-sleep disorder agent; a cardiac
glycoside; or an anti-tumor agent.
25. The combination as defined in claim 24 wherein the anti-obesity
agent is a melanocortin receptor (MC4R) agonist, a cannabinoid
receptor modulator, a growth hormone secretagogue receptor (GHSR)
antagonist, a galanin receptor modulator, an orexin antagonist, a
CCK agonist, a GLP-1 agonist, a Pre-proglucagon-derived peptides;
an NPY1 or NPY5 antagonist, an NPY2 or NPY4 modulator, a
corticotropin releasing factor agonist, a histamine receptor-3 (H3)
modulator, an aP2 inhibitor, a PPAR gamma modulator, a PPAR delta
modulator, an acetyl-CoA carboxylase (ACC) inhibitor, an
11-.beta.-HSD-1 inhibitor, an adinopectin receptor modulator; a
beta 3 adrenergic agonist, a thyroid receptor beta modulator, a
lipase inhibitor, a serotonin receptor agonist, a monoamine
reuptake inhibitor or releasing agent, an anorectic agent, a CNTF
(ciliary neurotrophic factor), a BDNF (brain-derived neurotrophic
factor), a leptin and leptin receptor modulator, or a cannabinoid-1
receptor antagonist, and the antidiabetic agent is an insulin
secretagogue or insulin sensitizer, which is a biguanide, a
sulfonyl urea, a glucosidase inhibitor, an aldose reductase
inhibitor, a PPAR .gamma. agonist, a PPAR .alpha. agonist, a PPAR
.delta. antagonist or agonist, a PPAR .alpha./.gamma. dual agonist,
anl 1-.beta.-HSD-1 inhibitor, a dipeptidyl peptidase IV (DP4)
inhibitor, a SGLT2 inhibitor, a glycogen phosphorylase inhibitor, a
meglitinide, a glucagon-like peptide-1 (GLP-1), a GLP-1 agonist,
and/or a PTP-1B inhibitor (protein tyrosine phosphatase-1B
inhibitor), and wherein the additional therapeutic agent is an
anti-hyperlipidemia agent, or agent used to treat arteriosclerosis,
which is an HMG CoA reductase inhibitor, a squalene synthetase
inhibitor, a fibric acid derivative, aspirin, a bile acid
sequestrant, an ACAT inhibitor, an upregulator of LDL receptor
activity, a cholesterol absorption inhibitor, a cholesteryl
transfer protein (CETP) inhibitor, an ileal Na+/bile acid
cotransporter inhibitor, a phytoestrogen, a beta-lactam cholesterol
absorption inhibitor, an HDL upregulator, a PPAR .alpha.-agonist
and/or an FXR agonist; an LDL catabolism promoter such, a
sodium-proton exchange inhibitor, an LDL-receptor inducer or a
steroidal glycoside, an anti-oxidant, or an antihomocysteine agent,
isoniazid, an HMG-CoA synthase inhibitor, or a lanosterol
demethylase inhibitor, a PPAR .delta. agonist, or a sterol
regulating element binding protein-I (SREBP-1), and the
anti-hypertensive agent, which is a beta adrenergic blocker, a
calcium channel blocker (L-type and/or T-type), a diuretic, a renin
inhibitor, an ACE inhibitor, an AT-1 receptor antagonist, an ET
receptor antagonist, a Dual ET/AII antagonist, a neutral
endopeptidase (NEP) inhibitor, a vasopeptidase inhibitor (dual
NEP-ACE inhibitor) or a nitrate; the sleep disorder agent is a
melatonin analog, a melatonin receptor antagonist, an ML 1 B
agonist, a GABA receptor modulator, an NMDA receptor modulator, a
histamine-3 (H3) receptor modulator, a dopamine agonist or an
orexin receptor modulator; an agent for treating substance abuse
or, addictive disorders which is a cannabinoid receptor modulator,
a selective serotonin reuptake inhibitor (SSRI), methadone,
buprenorphine, nicotine or bupropion; the anti-anxiety agents or
antidepressants, which is a benzodiazepine, a 5HT1A receptor
agonist, or a corticotropin releasing factor (CRF) antagonist; or a
norepinephrine reuptake inhibitor (tertiary and secondary amine
tricyclics), a selective serotonin reuptake inhibitor (SSRI), a
monoamine oxidase inhibitor (MAOI), a reversible inhibitor of
monoamine oxidase (RIMA), a serotonin and norepinephrine reuptake
inhibitor (SNRI), a corticotropin releasing factor (CRF) receptor
antagonist, an alpha-adrenoreceptor antagonist, or an atypical
antidepressant.
26. A method for treating obesity, diabetes, arteriosclerosis,
hypertension, polycystic ovary disease, cardiovascular disease,
osteoarthritis, dermatological disorders, impaired glucose
hemostasis, insulin resistance, hypercholesterolemia,
hypertriglyceridemia, choletithiasis, dyslipidemia, bulimia nervosa
and compulsive eating disorders; sleep disorders; and psychiatric
disorders, depression, anxiety, schizophrenia, substance abuse,
cognition-enhancement or Parkinson's disease, which comprises
administering to a patient in need of treatment, a compound as
defined in claim 1.
27. The method as defined in claim 26 for treating obesity or Type
II diabetes.
28. A method of treating Type II diabetes, which comprises
administering to a patient in need of treatment a compound as
defined in claim 1.
29. Use of a compound as defined in claim 1 in the manufacture of a
medicament for the treatment of diabetes.
30. Use of a compound as defined in claim 1 in the manufacture of a
medicament for treatment of diabetes, in which such treatment
comprises a combination with another therapeutic agent, for
concurrent or sequential use, in any order.
31. Combination of a compound as defined in claim 1 and another
therapeutic agent as a medicament for the treatment of diabetes.
Description
FIELD OF THE INVENTION
[0001] The present invention relates to non-basic melanin
concentrating hormone receptor-1 (MCHR1) antagonists,
pharmaceutical compositions containing MCHR1 antagonists and
methods of treating diabetes, obesity and related diseases
employing such MCHR1 antagonists.
BACKGROUND OF THE INVENTION
[0002] Several lines of pharmacological and genetic evidence
support the role of Melanin Concentrating Hormone Receptor-1
(hereafter "MCHR1") as a modulator of food intake and body weight.
Central administration of melanin concentrating hormone (MCH)
increases food intake and body weight both in rats and in mice.
Chronic ICV infusion of MCH causes increased food intake and
ultimately obesity in mice, while infusion of an MCH peptide
antagonist blocks MCH-induced food intake and results in weight
loss and decreased feeding in diet-induced obese mice.
[0003] The expression of both the MCH peptide and receptor are
modulated by nutritional status. MCH mRNA is upregulated both in
hyperphagic obese mice (ob/ob), and fasted animals. Targeted
disruption of the gene for MCH peptide results in hypophagia and
leanness. Disruption of the MCHR1 gene causes leanness, altered
metabolism, and hyperlocomotion accompanied by mild hyperphagia.
Conversely, over-expression of MCH peptide results in hyperphagia,
obesity and diabetes. Small molecule MCHR1 antagonists have been
shown to cause weight loss in rodent weight and feeding models
after both oral and intraperitoneal administration; Eur. J.
Pharmacol., 438:129-135 (2002), Nat. Med., 8:825-830 (2002), Eur.
J. Pharmacol., 497:41-47 (2004).
[0004] Numerous non-peptide MCHR1 antagonists have been disclosed.
The scope of the genus for each reflects a common perception
regarding the criteria required for ligand recognition as MCHR1
agonists. A recent review of MCHR1 patent disclosures emphasized
the commonality of these structures by the following description;
"Ubiquitous throughout the MCH patent literature are molecules
consisting of a central scaffold to which linkers to an aryl or
heteroaryl group and a basic amino functionality are attached."
(Kowalski, T. J. et al., Expert Opin. Investig. Drugs, 13:1113-1122
(2004)). Pharmacophore models of these geni consistently envision a
presumed prerequisite electrostatic interaction between a basic
amine center of the antagonist ligand and aspartic acid 123 of the
receptor which presumably is envisaged to emulate the mandatory
interaction between arginine 14 of MCH peptide agonists with
aspartic acid 123 of the MCHR1 receptor. (Ulven, T., J. Med. Chem.,
48:5684-5697 (2005)) However, incorporation of this basic amine in
a MCHR1 antagonist increases substantially the probability of
binding to off-target ion-channels and biogenic amine
receptors.
[0005] In accordance with the present invention, there is provided
a series of novel high affinity selective MCHR1 antagonists for
which binding affinity is not dependent upon inclusion of a basic
amine functionality that is common to most of the disclosed MCHR
antagonists. As a consequence, the absence of the basic center
greatly reduces the probability of off-target interactions such as
binding to other biogenic amine receptors as well as binding to ion
channels such as the HERG receptor in the heart. The
reduction/abolition of affinity for the HERG receptor is especially
important since ligand occupancy is associated with initiation of
fatal arrhythmias.
SUMMARY OF THE INVENTION
[0006] In one embodiment of the present invention, a compound of
the Formula I or a pharmaceutically acceptable salt thereof is
provided
##STR00003##
wherein
##STR00004##
[0007] is a phenylene ring or a heteroaryl ring which is a
monocyclic ring or a bicyclic ring which contains one or two
nitrogen atoms or one oxygen atom;
[0008] R.sup.1 is Z-Y--X--, wherein
##STR00005## [0009] Y is a bond, a 3- to 6-membered cycloalkyl, or
an alkyl chain; and
[0010] Z is aryl such as phenyl and naphthyl, or heteroaryl such as
pyridinyl, pyridimidinyl, pyrazinyl, benzimidazolyl,
benzothiazolyl, benzoxazolyl, or other "heteroaryl";
[0011] R.sup.2 is -E-G-(J).sub.m, with m being an integer from 1 to
3;
[0012] E is O, S, or a bond;
[0013] G is lower alkyl, phenylalkyl, cycloalkyl, cycloalkylalkyl,
alkylcycloalkyl, cycloalkoxy, alkylcycloalkoxy, or
cycloalkoxyalkyl;
[0014] each J is independently hydrogen, hydroxyl, CN,
--SO.sub.2R.sup.7, --SR.sup.7 --SOR.sup.7, lower alkyl, lower
alkoxy, CF.sub.3, CF.sub.3O--, --COOR.sup.5 (wherein R.sup.5 is H,
C.sub.1-3 alkyl, or cycloalkyl), or --CO--NR.sup.5aR.sup.6 wherein
R.sup.5a and R.sup.6 are each independently selected from H,
C.sub.1-3 alkyl, or cycloalkyl, or R.sup.5a and R.sup.6 taken
together can be propanediyl, butanediyl or pentanediyl to form with
the N atom to which they are attached a 4-, 5- or 6-membered cyclic
amine, such as azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl,
or piperazinyl, optionally substituted with substituents as set out
for "heterocyclo";
[0015] R.sup.7 is lower alkyl;
[0016] R.sup.3 is C.sub.1-6 alkyl, cycloalkyl, C.sub.1-6 alkoxy,
halogen, hydrogen, --S--C.sub.1-6 alkyl, CN, CF.sub.3O, or
CF.sub.3;
[0017] and wherein R.sup.2 and R.sup.3 can be taken together to
form a 5- to 7-membered ring which is saturated, unsaturated, or
partially unsaturated and may include an E heteroatom, which is O,
or 0, 1 or 2 N atoms, which ring is substituted with one or two of
--O-G-(J).sub.m groups, wherein at least one J is OH, and
optionally other substituents as set out for "alkyl", "aryl", or
"heteroaryl", such as alkyl and/or OH;
[0018] with the proviso that where
##STR00006##
is a phenylene ring, E-G and R.sup.3 are not identical
unsubstituted lower alkoxy groups, and when G is lower alkyl and J
is H, R.sup.3 is not hydrogen; and
[0019] R.sup.8 and R.sup.9 are each independently hydrogen,
halogen, or lower alkyl;
[0020] including esters thereof, prodrugs thereof, solvates
thereof, and all stereoisomers thereof.
[0021] Any of the foregoing Z moieties may either be unsubstituted
or substituted with 1, 2 or 3 of amino, halo, C.sub.1-6 alkyl,
C.sub.1-3 alkylamino, di-C.sub.1-3 alkylamino, C.sub.1-3 alkoxy,
C.sub.1-3 thioalkyl, C.sub.1-3 trifluoroalkoxy, trifluoromethyl,
cycloalkyl, cycloalkoxy, or heteroaryl such as pyridyl or
substituted with any of the substituents as set out for "aryl",
"heteroaryl", or "alkyl".
[0022] Examples of substituents for the J group in the form of a
cyclic amine include but are not limited to lower alkyl, lower
alkoxy, OH, CF.sub.3, or CF.sub.3O, or other substituents as set
out for "alkyl" and "heteroaryl".
[0023] In a further aspect of the invention, there is provided a
pharmaceutical composition which contains a therapeutically
effective amount of the compound of the invention Formula I as
defined above, in association with a pharmaceutically acceptable
carrier or diluent.
[0024] There is also provided a method for the treatment of
diabetes, obesity and other related conditions involving the MCHR1
in a mammal (such as a human, dog or cat) in need thereof, which
includes the steps of administering to the mammal a therapeutically
effective amount of the compound of Formula I of the invention as
defined above.
[0025] The invention also sets forth one or more methods for making
the compound of Formula I of the invention. In one embodiment,
there is provided a process for the preparation of the compound of
Formula I of the invention, wherein the compound a
##STR00007##
is reacted with the alkali metal salt of Z-Y--X.sup.1H (b)
(X.sup.1.dbd.O or S), preferably Z-(CH.sub.2).sub.n--X.sup.1H (n=0,
1, 2 or 3).
[0026] In another embodiment of the invention, there is provided a
process for the preparation of the compound of Formula I of the
invention, wherein the compound c
##STR00008##
is reacted with Z-Y13 X.sup.1H (b), preferably
Z-(CH.sub.2).sub.n--X.sup.1H (n=0, 1, 2 or 3), and preferably in
the presence of an activating agent.
[0027] The present invention is directed to these, as well as other
important ends, hereinafter described.
DETAILED DESCRIPTION OF THE INVENTION
[0028] The present application provides compounds, including all
stereoisomers, solvates, prodrugs and pharmaceutically acceptable
forms thereof according to Formula I. Additionally, the present
application provides pharmaceutical compositions containing at
least one compound according to Formula I of the invention alone
and optionally at least one additional therapeutic agent. Finally,
the present application provides methods for treating a patient
suffering from an MCHR-1 modulated disease or disorder such as, for
example, obesity, diabetes, depression or anxiety by administration
of a therapeutically effective dose of a compound according to
Formula I of the invention as defined above.
DEFINITIONS
[0029] Unless otherwise indicated, the term "lower alkyl" as may be
employed herein alone or as part of another group includes both
straight and branched chain hydrocarbons containing 1 to 8 carbons,
and the terms "alkyl", "alk", "alkyl chain", "alkylene", or
"alkylene chain" as may be employed herein alone or as part of
another group includes both straight and branched chain
hydrocarbons containing 1 to 20 carbons, preferably 1 to 10
carbons, more preferably 1 to 8 carbons, in the normal chain, such
as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl,
pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl,
2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl, the various
branched chain isomers thereof, and the like as well as such groups
including 2 free bonds and thus are linking groups, namely
"alkylene", as well as such groups including 1 to 4 substituents
such as halo, for example F, Br, Cl or I or CF.sub.3, alkyl,
alkoxy, aryl, aryloxy, aryl(aryl) or diaryl, arylalkyl,
arylalkyloxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl,
cycloalkylalkyl, cycloalkylalkyloxy, hydroxy, hydroxyalkyl, acyl,
alkanoyl, heteroaryl, heteroaryloxy, cycloheteroalkyl,
arylheteroaryl, arylalkoxycarbonyl, heteroarylalkyl,
heteroarylalkoxy, aryloxyalkyl, aryloxyaryl, alkylamido,
alkanoylamino, arylcarbonylamino, nitro, cyano, thiol, haloalkyl,
trihaloalkyl and/or alkylthio.
[0030] Unless otherwise indicated, the term "cycloalkyl" or "lower
cycloalkyl" as may be employed herein alone or as part of another
group includes saturated or partially unsaturated (containing 1 or
2 double bonds) cyclic hydrocarbon groups containing 1 to 3 rings,
any one of which may optionally be a spiro substituted cycloalkyl,
including monocycloalkyl, bicycloalkyl and tricycloalkyl,
containing a total of 3 to 20 carbons forming the rings, preferably
3 to 10 carbons, forming the ring and which may be fused to 1 or 2
aromatic rings as described for aryl, which include cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl,
cyclodecyl and cyclododecyl, cyclohexenyl,
##STR00009##
as well as such groups including 2 free bonds and thus are linking
groups, any of which groups may be optionally substituted with 1 to
4 substituents such as halogen, alkyl, alkoxy, hydroxy, aryl,
aryloxy, arylalkyl, cycloalkyl, alkylamido, alkanoylamino, oxo,
acyl, arylcarbonylamino, nitro, cyano, thiol and/or alkylthio
and/or any of the substituents set for "alkyl".
[0031] Unless otherwise indicated, the term "cycloalkoxy" or "lower
cycloalkoxy" as employed herein alone or as part of another group,
represents a 4-, 5- or 6-membered saturated ring containing an
oxygen in the ring and includes
##STR00010##
as well as such groups including 2 free bonds and thus are linking
groups, and which may be optionally substituted with 1 or two of
any of the substituents as set out for cycloalkyl.
[0032] The term "heterocyclo", "heterocycle", "heterocyclyl",
"heterocyclic" or "cycloheteroalkyl" ring, as may be used herein,
represents an unsubstituted or substituted stable 4- to 7-membered
monocyclic ring system which may be saturated or unsaturated,
preferably saturated or partially unsaturated, and which consists
of carbon atoms, with one to four heteroatoms selected from
nitrogen, oxygen or sulfur, and wherein the nitrogen and sulfur
heteroatoms may optionally be oxidized, and the nitrogen heteroatom
may optionally be quatemized, and including any bicyclic group in
which the heterocyclic ring is fused to a benzene ring. The
heterocyclic ring may be attached at any heteroatom or carbon atom
which results in the creation of a stable structure. Examples of
such heterocyclic groups include, but is not limited to,
piperidinyl, piperazinyl, oxopiperazinyl, oxopiperidinyl,
oxopyrrolidinyl, oxoazepinyl, azepinyl, pyrrolyl, pyrrolidinyl,
furanyl, thienyl, pyrazolyl, pyrazolidinyl, imidazolyl,
imidazolinyl, imidazolidinyl, pyridyl, pyrazinyl, pyrimidinyl,
pyridazinyl, oxazolyl, oxazolidinyl, isooxazolyl, isoxazolidinyl,
morpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, thiadiazolyl,
tetrahydropyranyl, thiamorpholinyl, thiamorpholinyl sulfoxide,
thiamorpholinyl sulfone, oxadiazolyl,
##STR00011##
and other heterocycles described in Katritzky, A. R. et al., eds.,
Comprehensive Heterocyclic Chemistry: The Structure, Reactions,
Synthesis and Uses of Heterocyclic Compounds, Pergamon Press, New
York, N.Y., publ. (1984); and Katritzky, A. R. et al., eds.,
Comprehensive Heterocyclic Chemistry II: A Review of the Literature
1982-1995, Elsevier Science, Inc., Tarrytown, N.Y., publ. (1996);
and references therein, as well as such groups including 2 free
bonds and thus are linking groups, as well as such groups
optionally substituted with 1 to 3 of F, Br, Cl or I or CF.sub.3,
alkyl, alkoxy, aryl, aryloxy, aryl(aryl) or diaryl, arylalkyl,
arylalkyloxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl,
cycloalkylalkyl, cycloalkylalkyloxy, hydroxy, hydroxyalkyl, acyl,
alkanoyl, heteroaryl, heteroaryloxy, cycloheteroalkyl,
arylheteroaryl, arylalkoxycarbonyl, heteroarylalkyl,
heteroarylalkoxy, aryloxyalkyl, aryloxyaryl, alkylamido,
alkanoylamino, arylcarbonylamino, nitro, cyano, thiol, haloalkyl,
trihaloalkyl, and/or alkylthio.
[0033] The term "alkanoyl" as may be used herein alone or as part
of another group refers to alkyl linked to a carbonyl group.
[0034] The term "halogen" or "halo" as may be used herein alone or
as part of another group refers to chlorine, bromine, fluorine, and
iodine, with chlorine or fluorine being preferred.
[0035] The term "metal ion" refers to alkali metal ions such as
sodium, potassium or lithium and alkaline earth metal ions such as
magnesium and calcium, as well as zinc and aluminum.
[0036] Unless otherwise indicated, the term "aryl" or "Aryl" as may
be employed herein alone or as part of another group refers to
monocyclic and bicyclic aromatic groups containing 6 to 10 carbons
in the ring portion (such as phenyl or naphthyl including
1-naphthyl and 2-naphthyl) and may optionally include one to three
additional rings fused to a carbocyclic ring or a heterocyclic ring
(such as aryl, cycloalkyl, heteroaryl or cycloheteroalkyl rings),
for example
##STR00012##
and as well as such groups including 2 free bonds and thus are
linking groups, and may be optionally substituted through available
carbon atoms with 1, 2, or 3 groups selected from hydrogen, halo,
haloalkyl, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl,
trifluoromethyl, trifluoromethoxy, alkynyl, cycloalkyl-alkyl,
cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl,
arylalkyl, aryloxy, aryloxyalkyl, arylalkoxy, alkoxycarbonyl,
arylcarbonyl, arylalkenyl, aminocarbonylaryl, arylthio,
arylsulfinyl, arylazo, heteroarylalkyl, heteroarylalkenyl,
heteroarylheteroaryl, heteroaryloxy, hydroxy, nitro, cyano, thiol,
alkylthio, arylthio, heteroarylthio, arylthioalkyl, alkoxyarylthio,
alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, arylaminocarbonyl,
alkoxycarbonyl, aminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy,
alkylcarbonylamino, arylcarbonylamino, arylsulfinyl,
arylsulfinylalkyl, arylsulfonylamino and arylsulfonaminocarbonyl
and/or any of the substituents for "alkyl" set out herein.
[0037] Unless otherwise indicated, the term "heteroaryl" as may be
used herein alone or as part of another group refers to a 5- or
6-membered aromatic ring which includes 1, 2, 3 or 4 hetero atoms
such as nitrogen, oxygen or sulfur. Such rings may be fused to an
aryl, cycloalkyl, heteroaryl or heterocyclyl and include possible
N-oxides as described in Katritzky, A. R. et al., eds.,
Comprehensive Heterocyclic Chemistry: The Structure, Reactions,
Synthesis and Uses of Heterocyclic Compounds, Pergamon Press, New
York, N.Y., publ. (1984); and Katritzky, A. R. et al., eds.,
Comprehensive Heterocyclic Chemistry II: A Review of the Literature
1982-1995, Elsevier Science, Inc., Tarrytown, N.Y., publ. (1996);
and references therein as well as such groups including 2 free
bonds and thus are linking groups. Further, "heteroaryl", as
defined herein, may optionally be substituted with one or more
substituents such as the substituents included above for "alkyl"
and/or "aryl". Examples of heteroaryl groups include the
following:
##STR00013##
and the like.
[0038] Unless otherwise indicated, the term "lower alkoxy",
"alkoxy", "aryloxy" or "aralkoxy" as may be employed herein alone
or as part of another group includes any of the above alkyl,
aralkyl or aryl groups linked to an oxygen atom.
[0039] Unless otherwise indicated, the term "lower alkylthio",
alkylthio", "arylthio" or "aralkylthio" as may be employed herein
alone or as part of another group includes any of the above alkyl,
aralkyl or aryl groups linked to a sulfur atom.
[0040] The term "polyhaloalkyl" as may be used herein refers to an
"alkyl" group as defined above which includes from 2 to 9,
preferably from 2 to 5, halo substituents, such as F or Cl,
preferably F, such as CF.sub.3CH.sub.2, CF.sub.3 or
CF.sub.3CF.sub.2CH.sub.2.
[0041] The term "polyhaloalkyloxy" as may be used herein refers to
an "alkoxy" or "alkyloxy" group as defined above which includes
from 2 to 9, preferably from 2 to 5, halo substituents, such as F
or Cl, preferably F, such as CF.sub.3CH.sub.2O, CF.sub.3O or
CF.sub.3CF.sub.2CH.sub.2O.
[0042] Unless otherwise indicated, the term "alkenyl" as used
herein alone or as part of another group refers to straight or
branched chain radicals of 2 to 20 carbons, preferably 2 to 12
carbons, and more preferably 1 to 8 carbons in the normal chain,
which include one to six double bonds in the normal chain, such as
vinyl, 2-propenyl, 3-butenyl, 2-butenyl, 4-pentenyl, 3-pentenyl,
2-hexenyl, 3-hexenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl,
3-octenyl, 3-nonenyl, 4-decenyl, 3-undecenyl, 4-dodecenyl,
4,8,12-tetradecatrienyl, and the like. Optionally, said alkenyl
group may be substituted with one or substituents, such as those
substituents disclosed for alkyl.
[0043] Unless otherwise indicated, the term "alkynyl" as used
herein alone or as part of another group refers to straight or
branched chain radicals of 2 to 20 carbons, preferably 2 to 12
carbons and more preferably 2 to 8 carbons in the normal chain,
which include one triple bond in the normal chain, such as
2-propynyl, 3-butynyl, 2-butynyl, 4-pentynyl, 3-pentynyl,
2-hexynyl, 3-hexynyl, 2-heptynyl, 3-heptynyl, 4-heptynyl,
3-octynyl, 3-nonynyl, 4-decynyl,3-undecynyl, 4-dodecynyl and the
like. Optionally, said alkynyl group may be substituted with one or
substituents, such as those substituents disclosed for alkyl.
[0044] The term "cycloalkenyl" as employed herein alone or as part
of another group refers to partially unsaturated cyclic
hydrocarbons containing 3 to 12 carbons, preferably 5 to 10 carbons
and 1 or 2 double bonds. Exemplary cycloalkenyl groups include
cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl,
cyclooctenyl, cyclohexadienyl, and cycloheptadienyl. Optionally,
said cycloalkenyl group may be substituted with one or
substituents, such as those substituents disclosed for alkyl.
[0045] The term "bicycloalkyl" as employed herein alone or as part
of another group includes saturated bicyclic ring groups such as,
without limitation, [3.3.0]bicyclooctane, [4.3.0]bicyclononane,
[4.4.0]bicyclodecane (decalin), [2.2.2]bicyclooctane, and so
forth.
[0046] The term "polycycloalkyl" as employed herein alone or as
part of another group includes two or more cycloalkyl ring systems,
as defined herein, wherein at least one carbon atom is a part of at
least two separately identifiable ring systems. The polycycloalkyl
group may contain bridging between two carbon atoms, for example,
bicyclo[ 1. 1.0]butyl, bicyclo[3.2. 1]octyl, bicyclo[5.2.0]nonyl,
tricycl[2.2.1.0.sup.1]heptyl, norbornyl and pinanyl. The
polycycloalkyl group may contain one or more fused ring systems,
for example, decalinyl (radical from decalin) and
perhydroanthracenyl. The polycycloalkyl group may contain a spiro
union, in which a single atom is the only common member of two
rings, for example, spiro[3.4]octyl, spiro[3.3]heptyl and
spiro[4.5]decyl.
[0047] The term "acyl" as employed herein by itself or part of
another group, as defined herein, refers to an organic radical
linked to a carbonyl
##STR00014##
group; examples of acyl groups include a substituent group attached
to a carbonyl, such as alkanoyl, alkenoyl, aroyl, aralkanoyl,
heteroaryl, cycloalkanoyl, cycloheteroalkanoyl and the like.
[0048] "Optional" or "optionally" means that the subsequently
described event or circumstance may or may not occur, and that the
description includes, without limitation, instances where said
event or circumstance occurs and instances in which it does not.
For example, optionally substituted alkyl means that alkyl may or
may not be substituted by those groups enumerated in the definition
of substituted alkyl.
[0049] "Substituted," as used herein, whether express or implied
and whether preceded by "optionally" or not, means that any one or
more hydrogen on the designated atom (C, N, etc.) is replaced with
a selection from the indicated group, provided that the designated
atom's normal valency is not exceeded, and that the substitution
results in a stable compound. For instance, when a CH.sub.2 is
substituted by a keto substituent (.dbd.O), then 2 hydrogens on the
atom are replaced. Combinations of substituents and/or variables
are permissible only if such combinations result in stable
compounds. Further, when more than one position in a given
structure may be substituted with a substituent selected from a
specified group, the substituents may be either the same or
different at every position.
[0050] The designation
##STR00015##
attached to a ring or other group refers to a free bond or linking
group.
Specific Embodiments
[0051] The
##STR00016##
group may be phenylene or a heteroaryl which is monocyclic or
bicyclic and includes rings such as
##STR00017##
[0052] The Formula I compound of the invention may have the
structure
##STR00018##
[0053] In the compound of Formula I of the invention, it is desired
that
##STR00019##
is phenylene or pyridinyl;
[0054] X is O or S; and/or
[0055] Y is a bond or an alkylene chain of 1, 2 or 3 atoms;
and/or
[0056] Z is phenyl; or
[0057] Z is a heteroaryl such as pyridinyl or benzothiazole;
and/or
[0058] R.sup.2 is E-G-J; and/or
[0059] E is O or S; and/or
[0060] G is a lower alkyl or alkylcycloalkyl; and/or
[0061] J is H, OH, SO.sub.2R.sup.7, lower alkyl, lower alkoxy, or
CF.sub.3, more preferably OH; and/or
[0062] R.sup.3 is C.sub.1-6 alkyl, C.sub.1-6 alkoxy, H, or halo;
and/or
[0063] R.sup.8 and R.sup.9 are independently H or CH.sub.3;
and/or
[0064] wherein R.sup.2 and R.sup.3 can be taken together to form a
5- to 7-membered ring which is saturated, unsaturated, or partially
unsaturated and may include an E heteroatom, which is O, or 0, 1 or
2 N atoms, which ring is substituted with one or two of
--O-G-(J).sub.m groups, wherein at least one J is OH and optionally
other substituents as set out for "alkyl", "aryl", or "heteroaryl",
such as alkyl and/or OH.
[0065] The above groups may be substituted as indicated herein.
[0066] Examples of the various groups of the compounds of Formula I
of the invention are set out below:
##STR00020##
is phenylene or pyridinyl;
[0067] Z is [0068] (1) aryl, such as phenyl or naphthyl, each of
which is optionally substituted with: [0069] a) halogen such as Cl,
Br or F, [0070] b) alkyl such as CH.sub.3, C.sub.2H.sub.5 or
i-C.sub.3H.sub.7, [0071] c) alkoxy such as CH.sub.3O, [0072] d)
polyhaloalkyl such as CF.sub.3, [0073] e) polyhaloalkoxy such as
CF.sub.3O, [0074] f) amino, alkylamino or dialkylamino such as
[0074] ##STR00021## [0075] g) alkylthio such as CH.sub.3S, [0076]
h) OH, [0077] i) esters such as --COOCH.sub.3, or [0078] j) aryl
such as phenyl, [0079] (2) monocyclic heteroaryl such as [0080] a)
pyridinyl, [0081] b) pyrazinyl, or [0082] c) pyrimidinyl, [0083]
each of a), b) or c) being optionally substituted with alkyl such
as methyl, polyhaloalkyl such as trifluoromethyl, halogen such as
Cl or F, or alkoxy such as CH.sub.3O; [0084] (3) benzothiazole
optionally substituted with halo such as F, Cl, alkoxy such as
CH.sub.3O, [0085] (4) benzoxazole optionally substituted with halo
such as Cl, [0086] (5) benzimidazole, [0087] (6) thiazole
optionally substituted with aryl such as phenyl, and alkyl such as
t-C.sub.4H.sub.9, [0088] (7) indanyl, [0089] (8) quinolinyl
optionally substituted with CF.sub.3, or [0090] (9) imidazolidinyl;
and/or
[0091] Y is a bond or alkylene such as methylene, or ethylene or
propylene; and/or
[0092] X is S, O, SO, or SO.sub.2; and/or
[0093] J is [0094] (1) H, [0095] (2) --CO--NR.sup.5aR.sup.6 where
R.sup.5a and R.sup.6 together with the N to which they are attached
form a pyrrolidinyl ring, [0096] (3) OH, [0097] (4) COOH, [0098]
(5) COOalkyl such as COOCH.sub.3, [0099] (6) SO.sub.2R.sup.7 such
as SO.sub.2C.sub.2H.sub.5, or [0100] (7) prodrug esters such as
glycine
##STR00022##
[0100] phosphate
##STR00023##
and the corresponding Na salt thereof), and valine
##STR00024##
and/or
[0101] m is 1 or 2; and/or
[0102] G is CH.sub.2, (CH.sub.2).sub.2, (CH.sub.2).sub.3,
##STR00025##
##STR00026##
cycloalkyl such as
##STR00027##
cycloalkoxy such as
##STR00028##
or alkylcycloalkyl such as
##STR00029##
##STR00030##
and/or
[0103] E is O; and/or
[0104] R.sup.3 is H, alkoxy such as CH.sub.3O, hydroxyalkyl such as
HOCH.sub.2CH.sub.2--, alkyl such as CH.sub.3 or C.sub.2H.sub.5,
halo such as F or Cl, CN, or hydroxyalkoxy such as
HOCH.sub.2CH.sub.2O--; and/or
[0105] R.sup.2 and R.sup.3 can be optionally taken together to form
a 5- or 6-membered unsaturated or aromatic ring containing one or
two N atoms, which ring is optionally substituted with hydroxyalkyl
such as
##STR00031##
for example
##STR00032##
[0106] or where R.sup.2 and R.sup.3 can be optionally taken
together to form a 6-membered saturated, unsaturated or partially
unsaturated O-containing ring, which ring is optionally substituted
with hydroxyalkyl such as
##STR00033##
, alkyl such as CH.sub.3 and OH, for example
##STR00034##
and/or
[0107] R.sup.8 is H, halo such as F and Cl, or alkyl such as
methyl; and/or
[0108] R.sup.9 is H.
[0109] In a further embodiment of the compound of Formula I of the
invention, X.dbd.O and
##STR00035##
is phenylene or pyridinyl. In another embodiment, X.dbd.S and
##STR00036##
is phenylene.
[0110] In a further embodiment in Formula I of the invention, Y is
a bond. Also in a further embodiment, Y is methylene, ethylene or
propylene. In addition, the alkyl chain or alkyl moiety in Y may be
attached to the ortho-position of Z to generate a bicyclic moiety.
In this embodiment, the bicyclic moiety is preferably 1-indanyl or
2-indanyl when Z is phenyl.
[0111] In a further embodiment, Z is selected from phenyl,
naphthyl, pyridinyl, pyrazinyl, benzimidazolyl, benzothiazolyl, and
benzoxazolyl, preferably phenyl and pyridinyl.
[0112] Furthermore, in the embodiment wherein R.sup.5 and R.sup.6
taken together form a 4-, 5- or 6-membered cyclic amine, it is
preferred that this component be selected from the group consisting
of azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, and
piperazinyl.
[0113] Also preferred is the embodiment wherein R.sup.3 is
C.sub.1-C.sub.6 alkoxy. Especially preferred is the embodiment
wherein R.sup.3 is C.sub.1-C.sub.3 alkoxy or C.sub.1-C.sub.3 alkyl.
Even more preferably, R.sup.3 is methoxy or methyl.
[0114] In one embodiment of the invention, R.sup.1 may be selected
from the group consisting of:
##STR00037##
[0115] It is also desirable that in Formula I, R.sup.2 is
--O-2-hydroxy-propane, R.sup.3 is methoxy, and R.sup.1 is selected
from the group consisting of:
##STR00038##
[0116] In another embodiment of the invention, it is desirable
that
##STR00039##
is phenylene;
##STR00040##
or
[0117] R.sup.2 and R.sup.3 can be optionally taken together to form
a 5- or 6-membered unsaturated or aromatic ring containing one or
two N atoms, which ring is optionally substituted with hydroxyalkyl
such as
##STR00041##
for example
##STR00042##
and
[0118] R.sup.3 is methoxy or methyl, and R.sup.1 is selected from
the group consisting of:
##STR00043## ##STR00044## ##STR00045##
[0119] Also desired is the prodrug embodiment, hereinafter
described, wherein in Formula I,
[0120] R.sup.2 is E-G-hydroxyl-.sup.Pro-Drug or more preferably
##STR00046##
##STR00047##
[0121] R.sup.3 is methoxy; and
[0122] R.sup.1 is selected from
##STR00048##
[0123] Also desired are compounds of Formula I wherein
##STR00049##
is phenylene;
[0124] R.sup.1 is Z-Y--X-- wherein [0125] X is S, [0126] Y is an
alkyl chain of 1 to 3 carbons or a bond, [0127] Z is heteroaryl or
phenyl, [0128] each of which Z is optionally substituted with
CF.sub.3, CF.sub.3O, or halo;
[0129] R.sup.2 is -E-G-J wherein [0130] E is O, [0131] G is lower
alkyl such as
##STR00050##
[0131] or alkylcycloalkyl such as
##STR00051##
and [0132] J is OH;
[0133] R.sup.3 is H, alkoxy such as CH.sub.3O, or alkyl such as
CH.sub.3;
[0134] R.sup.8 and R.sup.9 are independently H or CH.sub.3; and
[0135] R.sup.2 and R.sup.3 can be optionally taken together to form
a 5- or 6-membered unsaturated or aromatic ring containing one or
two N atoms, which ring is optionally substituted with hydroxyalkyl
such as
##STR00052##
for example
##STR00053##
[0136] In still more preferred compounds of Formula I,
##STR00054##
is phenylene;
[0137] X is S;
[0138] Y is a bond or (CH.sub.2).sub.2;
##STR00055##
[0139] R.sup.3 is CH.sub.3O or CH.sub.3;
[0140] R.sup.8 and R.sup.9 are each H; and
[0141] R.sup.2 and R.sup.3 can be optionally taken together to form
a 5- or 6-membered unsaturated or aromatic ring containing one or
two N atoms, which ring is optionally substituted with hydroxyalkyl
such as
##STR00056##
for example
##STR00057##
[0142] Some preferred compounds of the invention include the
following:
##STR00058##
[0143] Also desired are compounds of Formula I wherein
##STR00059##
[0144] R.sup.1 is Z-Y--X-- wherein [0145] X is S, [0146] Y is an
alkyl chain of 1 to 3 carbons such as (CH.sub.2).sub.2 or a bond,
[0147] Z is heteroaryl such as 2-pyridyl or phenyl, [0148] each of
which Z is optionally substituted with CF.sub.3, CF.sub.3O, or halo
such as F,
[0149] so that R.sup.1 can be selected from:
##STR00060##
[0150] R.sup.2 is -E-G-J wherein [0151] E is O, [0152] G is lower
alkyl or alkylcycloalkyl, and [0153] J is OH [0154] for
example,
##STR00061##
[0155] R.sup.3 is alkoxy such as CH.sub.3O, alkyl such as CH.sub.3,
or halo such as Cl; and
[0156] R.sup.8 and R.sup.9 are independently H or CH.sub.3.
[0157] In still more desired compounds of Formula I,
##STR00062##
[0158] X is S;
[0159] Y is a bond or (CH.sub.2).sub.2;
##STR00063##
##STR00064##
and
[0160] R.sup.3 is CH.sub.3, H or Cl.
Methods of Preparation
[0161] The compounds of Formula I according to the various
embodiments herein described can be prepared as shown in the
following non-limiting reaction schemes and description thereof, as
well as relevant published literature procedures that may be used
by one skilled in the art.
[0162] Scheme 1 below portrays a generalized reaction sequence for
the synthesis of compounds of Formula I.
[0163] Compounds of Formula I, for which R.sup.1 is Z-Y--O or
Z-Y--S and R.sup.2 does not contain a tertiary alcohol, can be
prepared by condensation of compounds of Formula II in a solvent
such as THF with alkali metal salts such as Na.sup.+ or K.sup.+ of
compounds of Formula III. The alkali salts of compounds of Formula
III had been previously prepared by addition of compounds of
Formula III to a stirred dispersion of NaH or KH in a solvent such
as THF under an inert atmosphere of N.sub.2 or Ar. Compounds of
Formula II can be prepared by treatment of compounds of Formula IV
with thionyl chloride in a solvent such as DMF. Compounds of
Formula III are commercially available or may be readily prepared
by one skilled in the arts.
[0164] Alternatively, a general synthesis of compounds of Formula
I, for which R.sup.1 is Z-Y--O, Z-Y--S or Z-Y--NR.sup.4H, entails
condensation of compounds of Formula IV with compounds of Formula
III by stirring these components in a solvent such as DMF
containing benzotriazo-1-yl-oxy-trispyrrolidinophosphonium
hexafluoroborate (PyBOP) as an activating agent, DMAP and a
hindered amine such as Et(iPr).sub.2N. Other activating agents may
be utilized by the skilled artisan.
[0165] Compounds of Formula IV can be prepared by heating compounds
of Formula V to 120-150.degree. C. in microwave in a 1:1.1 mixture
of HOAc/TFA. Compounds of Formula V can be prepared by stirring
compounds of Formula VI with 2,2-dimethoxyethylamine in a solvent
such as EtOAc. Compounds of Formula VI can be prepared by treatment
of compounds of Formula VII with ethyl oxalyl chloride in a mixture
of EtOAC and water containing a weak base such as potassium
carbonate. Compounds of Formula VII are either commercially
available or can be prepared as described in U.S. Ser. No.
11/586,255.
[0166] Compounds of Formula I for which R.sup.1 is Z-Y--SO or
Z-Y--SO.sub.2 can be prepared by treatment of compounds of Formula
I where R.sup.1 is Z-Y--S with one or two equivalents of an oxidant
such as m-chloroperbenzoic acid in a solvent such as
CH.sub.2Cl.sub.2.
##STR00065##
[0167] Alternatively compounds of formula I can be prepared as
outlined in Scheme 2. by Cu catalyzed arylation of compounds of
formula X by heating X with aryl halides or iodides of formula XI
in a solvent such as dioxane containing a cuprous salt such as
cuprous iodide along with potassium tribasic phosphate and a
chelating agent such as N-methyl, N'-methyl ethylene diamine.
Compounds of formula X can be prepared by heating compounds of
formula IX in TFA. Compounds of formula IX can be prepared by
condensation of compound of Formula VIII with compounds of Formula
III by stirring these components in a solvent such as DMF
containing benzotriazo-1-yl-oxy-trispyrrolidinophosphonium
hexafluoroborate (PyBOP) as an activating agent, DMAP and a
hindered amine such as Et(iPr).sub.2N. Compound of formula VIII is
readily obtained from p-methoxybenzyl amine utilizing the chemistry
described in Scheme 1. Aryl halides of formula XI are readily
prepared by one skilled in the arts by alkylation of the
corresponding commercially available halogenated phenol.
##STR00066## ##STR00067##
[0168] Other methods of preparing the compounds of Formula I are
within the scope of the invention as well.
Prodrugs, Salts, Esters and Stereoisomers
[0169] The compounds of the invention also include "prodrugs". The
term "prodrug" as used herein encompasses both the term "prodrug
esters" and the term "prodrug ethers". The term "prodrug esters" as
employed herein includes esters and carbonates formed by reacting
one or more hydroxyls of compounds of Formula I with either alkyl,
alkoxy, or aryl substituted acylating agents or phosphorylating
agent employing procedures known to those skilled in the art to
generate acetates, pivalates, methylcarbonates, benzoates, amino
acid esters, phosphates, half acid esters such as malonates,
succinates or glutarates, and the like. In certain embodiments,
amino acid esters may be especially preferred.
[0170] Examples of such prodrug esters include
##STR00068##
R=H or isopropyl or other alkyl group) (for example,
##STR00069##
(where R.sup.1 is H or an alkali metal such as Na), that is
##STR00070##
[0171] The term "prodrug ethers" include both phosphate acetals and
O-glucosides. Representative examples of such prodrug ethers
include
##STR00071##
[0172] The compounds of Formula I can also be present as salts,
which are further within the scope of this invention.
Pharmaceutically acceptable (i.e., non-toxic, physiologically
acceptable) salts are preferred. If the compounds of Formula I
have, for example, at least one basic center, they can form acid
addition salts. These are formed, for example, with strong
inorganic acids, such as mineral acids, for example sulfuric acid,
phosphoric acid (phosphate ester) or a hydrohalic acid, with
organic carboxylic acids, such as alkanecarboxylic acids of 1 to 4
carbon atoms, for example acetic acid, which are unsubstituted or
substituted, for example, by halogen as chloroacetic acid, such as
saturated or unsaturated dicarboxylic acids, for example oxalic,
malonic, succinic, maleic, fumaric, phthalic or terephthalic acid,
such as hydroxycarboxylic acids, for example ascorbic, glycolic,
lactic, malic, tartaric or citric acid, such as amino acids, (for
example aspartic acid, glutamic acid, glycine, valine, lysine, or
arginine), or benzoic acid, or with organic sulfonic acids, such as
(C.sub.1-C.sub.4) alkyl or arylsulfonic acids which are
unsubstituted or substituted, for example by halogen, for example
methyl- or p-toluene- sulfonic acid. Corresponding acid addition
salts can also be formed having, if desired, an additionally
present basic center. The compounds of Formula I having at least
one acid group (for example COOH) can also form salts with bases.
Suitable salts with bases are, for example, metal salts, such as
alkali metal or alkaline earth metal salts, for example sodium,
potassium or magnesium salts, or salts with ammonia or an organic
amine, such as morpho line, thiomorpho line, piperidine,
pyrrolidine, a mono, di or tri-lower alkylamine, for example ethyl,
tert-butyl, diethyl, diisopropyl, triethyl, tributyl or
dimethyl-propylamine, or a mono, di or trihydroxy lower alkylamine,
for example mono, di or triethanolamine. Corresponding internal
salts may furthermore be formed. Salts which are unsuitable for
pharmaceutical uses but which can be employed, for example, for the
isolation or purification of free compounds of Formula I or their
pharmaceutically acceptable salts, are also included.
[0173] Preferred salts of the compounds of Formula I which contain
a basic group include monohydrochloride, hydrogensulfate,
methanesulfonate, phosphate, nitrate or acetate.
[0174] Preferred salts of the compounds of Formula I which contain
an acid group include sodium, potassium and magnesium salts and
pharmaceutically acceptable organic amines.
[0175] All stereoisomers of the compounds of the invention are
contemplated, either in admixture or in pure or substantially pure
form. The compounds of the present application can have asymmetric
centers at any of the carbon atoms including any one of the R
substituents. Consequently, compounds of Formula I can exist in
enantiomeric or diastereomeric forms or in mixtures thereof The
processes for preparation can utilize racemates, enantiomers or
diastereomers as starting materials. When diastereomeric or
enantiomeric products are prepared, they can be separated by
conventional methods for example, chromatographic or fractional
crystallization.
Utility
[0176] The compounds of the present application can be administered
to mammals, preferably humans, for the treatment of a variety of
conditions and disorders, including, but not limited to metabolic
and eating disorders as well as conditions associated with
metabolic disorders (e.g., obesity, diabetes, arteriosclerosis,
hypertension, polycystic ovary disease, cardiovascular disease,
osteoarthritis, dermatological disorders, impaired glucose
hemostasis, insulin resistance, hypercholesterolemia,
hypertriglyceridemia, choletithiasis, dislipidemic conditions,
bulimia nervosa and compulsive eating disorders); sleep disorders;
and psychiatric disorders, such as depression, anxiety,
schizophrenia, substance abuse, cognition-enhancement and
Parkinson's disease.
[0177] The compounds described in the present application could be
used to enhance the effects of cognition-enhancing agents, such as
acetylcholinesterase inhibitors (e.g., tacrine), muscarinic
receptor-1 agonists (e.g., milameline), nicotinic agonists,
glutamic acid receptor (AMPA and NMDA) modulators, and nootropic
agents (e.g., piracetam, levetiracetam). Examples of suitable
therapies for treatment of Alzheimer's disease and cognitive
disorders for use in combination with the compounds of the present
application include donepezil, tacrine, revastigraine, 5HT6, gamma
secretase inhibitors, beta secretase inhibitors, SK channel
blockers, Maxi-K blockers, and KCNQs blockers.
[0178] The compounds described in the present application could be
used to enhance the effects of agents used in the treatment of
Parkinson's Disease. Examples of agents used to treat Parkinson's
Disease include: levadopa with or without a COMT inhibitor,
antiglutamatergic drugs (amantadine, riluzole), alpha-2 adrenergic
antagonists such as idazoxan, opiate antagonists, such as
naltrexone, other dopamine agonists or transporter modulators, such
as ropinirole, or pramipexole or neurotrophic factors such as glial
derived neurotrophic factor (GDNF).
Pharmaceutical Combinations
[0179] The present application includes within its scope
pharmaceutical compositions comprising, as an active ingredient, a
therapeutically effective amount of at least one of the compounds
of Formula I, alone or in combination with a pharmaceutical carrier
or diluent. Optionally, compounds of the present application can be
used alone, in combination with other suitable therapeutic agents
useful in the treatment of the aforementioned disorders including:
anti-obesity agents; anti-diabetic agents, appetite suppressants;
cholesterol/lipid-lowering agents, HDL-raising agents, cognition
enhancing agents, agents used to treat neurodegeneration, agents
used to treat respiratory conditions, agents used to treat bowel
disorders, anti-inflammatory agents; anti-anxiety agents;
anti-depressants; anti-hypertensive agents; cardiac glycosides; and
anti-tumor agents.
[0180] Such other therapeutic agent(s) may be administered prior
to, simultaneously with, or following the administration of the
melanin-concentrating hormone receptor (MCHR) antagonists in
accordance with the application.
[0181] Examples of suitable anti-obesity agents for use in
combination with the compounds of the present application include
melanocortin receptor (MC4R) agonists, cannabinoid receptor
modulators, growth hormone secretagogue receptor (GHSR)
antagonists, galanin receptor modulators, orexin antagonists, CCK
agonists, GLP-1 agonists, and other Pre-proglucagon-derived
peptides; NPY1 or NPY5 antagonist, NPY2 and NPY4 modulators,
corticotropin releasing factor agonists, histamine receptor-3 (H3)
modulators, aP2 inhibitors, PPAR gamma modulators, PPAR delta
modulators, acetyl-CoA carboxylase (ACC) inhibitors,
11-.beta.-HSD-1 inhibitors, adinopectin receptor modulators; beta 3
adrenergic agonists, such as AJ9677 (Takeda/Dainippon), L750355
(Merck), or CP331648 (Pfizer) or other known beta 3 agonists as
disclosed in U.S. Pat. Nos. 5,541,204, 5,770,615, 5,491,134,
5,776,983 and 5,488,064, a thyroid receptor beta modulator, such as
a thyroid receptor ligand as disclosed in WO 97/21993 (U. Cal SF),
WO 99/00353 (KaroBio) and WO 00/039077 (KaroBio), a lipase
inhibitor, such as orlistat or ATL-962 (Alizyme), serotonin
receptor agonists, (e.g., BVT-933 (Biovitrum)), monoamine reuptake
inhibitors or releasing agents, such as fenfluramine,
dexfenfluramine, fluvoxamine, fluoxetine, paroxetine, sertraline,
chlorphentermine, cloforex, clortermine, picilorex, sibutramine,
dexamphetamine, phentermine, phenylpropanolamine or mazindol,
anorectic agents such as topiramate (Johnson & Johnson), CNTF
(ciliary neurotrophic factor)/Axokine.RTM. (Regeneron), BDNF
(brain-derived neurotrophic factor), leptin and leptin receptor
modulators, or cannabinoid-1 receptor antagonists, such as
SR-141716 (Sanofi) or SLV-319 (Solvay).
[0182] Examples of suitable anti-diabetic agents for use in
combination with the compounds of the present application include:
insulin secretagogues or insulin sensitizers, which may include
biguanides, sulfonyl ureas, glucosidase inhibitors, aldose
reductase inhibitors, PPAR .gamma. agonists such as
thiazolidinediones, PPAR .alpha. agonists (such as fibric acid
derivatives), PPAR .delta. antagonists or agonists, PPAR
.alpha./.gamma. dual agonists, 11-.beta.-HSD-1 inhibitors,
dipeptidyl peptidase IV (DP4) inhibitors including saxagliptin,
SGLT2 inhibitors including dapagliflozin and serglifozin, glycogen
phosphorylase inhibitors, and/or meglitinides, as well as insulin,
and/or glucagon-like peptide-1 (GLP-1), GLP-1 agonist, incretin
modulators, AMP kinase activators, glucocortical antagonists,
fructose bis 1,6-phosphatase inhibitors, glucokinase inhibitors
and/or a PTP-1B inhibitor (protein tyrosine phosphatase-1B
inhibitor).
[0183] The antidiabetic agent may be an oral antihyperglycemic
agent preferably a biguanide such as metformin or phenformin or
salts thereof, preferably metformin HCl. Where the antidiabetic
agent is a biguanide, the compounds of the present application will
be employed in a weight ratio to biguanide within the range from
about 0.001:1 to about 10:1, preferably from about 0.01:1 to about
5:1.
[0184] The antidiabetic agent may also preferably be a sulfonyl
urea such as glyburide (also known as glibenclamide), glimepiride
(disclosed in U.S. Pat. No. 4,379,785), glipizide, gliclazide or
chlorpropamide, other known sulfonylureas or other
antihyperglycemic agents which act on the ATP-dependent channel of
the beta-cells, with glyburide and glipizide being preferred, which
may be administered in the same or in separate oral dosage forms.
The oral antidiabetic agent may also be a glucosidase inhibitor
such as acarbose (disclosed in U.S. Pat. No. 4,904,769) or miglitol
(disclosed in U.S. Pat. No. 4,639,436), which may be administered
in the same or in a separate oral dosage forms.
[0185] The compounds of the present application may be employed in
combination with a PPAR .gamma. agonist such as a thiazolidinedione
oral anti-diabetic agent or other insulin sensitizers (which has an
insulin sensitivity effect in NIDDM patients) such as rosiglitazone
(SKB), pioglitazone (Takeda), Mitsubishi's MCC-555 (disclosed in
U.S. Pat. No. 5,594,016), Glaxo-Wellcome's GL-262570, englitazone
(CP-68722, Pfizer) or darglitazone (CP-86325, Pfizer, isaglitazone
(MIT/J&J), JTT-501 (JPNT/P&U), L-895645 (Merck), R-119702
(Sankyo/WL), NN-2344 (Dr. Reddy/NN), or YM-440 (Yamanouchi),
preferably rosiglitazone and pioglitazone.
[0186] The compounds of the present application may also be
employed with a PPAR.alpha./.gamma. dual agonist such as
MK-767/KRP-297 (Merck/Kyorin; as described in Yajima, K. et al.,
Am. J. Physiol. EndocrinoL Metab., 284:E966-E971 (2003)), AZ-242
(tesaglitazar; Astra-Zeneca; as described in Ljung, B. et al., J.
Lipid Res., 43:1855-1863 (2002)); muraglitazar; or the compounds
described in U.S. Pat. No. 6,414,002.
[0187] The compounds of the present invention may be employed in
combination with anti-hyperlipidemia agents, or agents used to
treat arteriosclerosis. An example of an hypolipidemic agent would
be an HMG CoA reductase inhibitor which includes, but is not
limited to, mevastatin and related compounds as disclosed in U.S.
Pat. No. 3,983,140, lovastatin (mevinolin) and related compounds as
disclosed in U.S. Pat. No. 4,231,938, pravastatin and related
compounds such as disclosed in U.S. Pat. No. 4,346,227, simvastatin
and related compounds as disclosed in U.S. Pat. Nos. 4,448,784 and
4,450,171. Other HMG CoA reductase inhibitors which may be employed
herein include, but are not limited to, fluvastatin, disclosed in
U.S. Pat. No. 5,354,772, cerivastatin disclosed in U.S. Pat. Nos.
5,006,530 and 5,177,080, atorvastatin disclosed in U.S. Pat. Nos.
4,681,893, 5,273,995, 5,385,929 and 5,686,104, pitavastatin
(Nissan/Sankyo's nisvastatin (NK-104) or itavastatin), disclosed in
U.S. Pat. No. 5,011,930, Shionogi-Astra/Zeneca rosuvastatin
(visastatin (ZD-4522)) disclosed in U.S. Pat. No. 5,260,440, and
related statin compounds disclosed in U.S. Pat. No. 5,753,675,
pyrazole analogs of mevalonolactone derivatives as disclosed in
U.S. Pat. No. 4,613,610, indene analogs of mevalonolactone
derivatives as disclosed in PCT application WO 86/03488,
6-[2-(substituted-pyrrol-1-yl)-alkyl)pyran-2-ones and derivatives
thereof as disclosed in U.S. Pat. No. 4,647,576, Searle's SC-45355
(a 3-substituted pentanedioic acid derivative) dichloroacetate,
imidazole analogs of mevalonolactone as disclosed in PCT
application WO 86/07054, 3-carboxy-2-hydroxy-propane-phosphonic
acid derivatives as disclosed in French Patent No. 2,596,393,
2,3-disubstituted pyrrole, furan and thiophene derivatives as
disclosed in European Patent Application No. 0221025, naphthyl
analogs of mevalonolactone as disclosed in U.S. Pat. No. 4,686,237,
octahydronaphthalenes such as disclosed in U.S. Pat. No. 4,499,289,
keto analogs of mevinolin (lovastatin) as disclosed in European
Patent Application No.0142146 A2, and quinoline and pyridine
derivatives disclosed in U.S. Pat. Nos. 5,506,219 and 5,691,322. In
addition, phosphinic acid compounds useful in inhibiting HMG CoA
reductase suitable for use herein are disclosed in GB 2205837.
[0188] The squalene synthetase inhibitors suitable for use herein
include, but are not limited to, .alpha.-phosphono-sulfonates
disclosed in U.S. Pat. No. 5,712,396, those disclosed by Biller, et
al., J. Med. Chem., 31:1869-1871 (1998) including isoprenoid
(phosphinyl-methyl)phosphonates as well as other known squalene
synthetase inhibitors, for example, as disclosed in U.S. Pat. Nos.
4,871,721 and 4,924,024 and in Biller, S. A. et al., Current
Pharmaceutical Design, 2:1-40 (1996).
[0189] In addition, other squalene synthetase inhibitors suitable
for use herein include the terpenoid pyrophosphates disclosed by
Ortiz de Montellano, P. et al., J. Med. Chem., 20:243-249 (1977),
the famesyl diphosphate analog A and presqualene pyrophosphate
(PSQ-PP) analogs as disclosed by Corey et al., J. Am. Chem. Soc.,
98:1291-1293 (1976), phosphinylphosphonates reported by McClard, R.
W. et al., J. Am. Chem. Soc., 109:5544 (1987) and cyclopropanes
reported by Capson, T. L., Ph.D., dissertation, June, 1987, Dept.
Med. Chem., U. of Utah, Abstract, Table of Contents, pp. 16, 17,
40-43, 48-51, Summary.
[0190] Other hypolipidemic agents suitable for use herein include,
but are not limited to, fibric acid derivatives, such as
fenofibrate, gemfibrozil, clofibrate, bezafibrate, ciprofibrate,
clinofibrate and the like, probucol, and related compounds as
disclosed in U.S. Pat. No. 3,674,836, probucol and gemfibrozil
being preferred, bile acid sequestrants such as cholestyramine,
colestipol and DEAE-Sephadex (SECHOLEX, POLICEXIDE) and cholestagel
(Sankyo/Geltex), as well as lipostabil (Rhone-Poulenc), Eisai
E-5050 (an N-substituted ethanolamine derivative), imanixil
(HOE-402), tetrahydrolipstatin (THL),
istigmastanylphosphorylcholine (SPC, Roche), aminocyclodextrin
(Tanabe Seiyoku), Ajinomoto AJ-814 (azulene derivative), melinamide
(Sumitomo), Sandoz 58-035, American Cyanamid CL-277,082 and
CL-283,546 (disubstituted urea derivatives), nicotinic acid
(niacin), acipimox, acifran, neomycin, p-aminosalicylic acid,
aspirin, poly(diallylmethylamine) derivatives such as disclosed in
U.S. Pat. No. 4,759,923, quaternary amine
poly(diallyldimethylammonium chloride) and ionenes such as
disclosed in U.S. Pat. No. 4,027,009, and other known serum
cholesterol lowering agents.
[0191] The other hypolipidemic agent may be an ACAT inhibitor
(which also has anti-atherosclerosis activity) such as disclosed
in, Drugs of the Future, 24:9-15 (1999), (Avasimibe); Nicolosi et
al., "The ACAT inhibitor, Cl-1011 is effective in the prevention
and regression of aortic fatty streak area in hamsters",
Atherosclerosis (Shannon, Irel.), 137(1):77-85 (1998); Ghiselli,
G., "The pharmacological profile of FCE 27677: a novel ACAT
inhibitor with potent hypolipidemic activity mediated by selective
suppression of the hepatic secretion of ApoB100-containing
lipoprotein", Cardiovasc. Drug Rev., 16(1):16-30 (1998); Smith, C.
et al., "RP 73163: a bioavailable alkylsulfinyl-diphenylimidazole
ACAT inhibitor", Bioorg. Med. Chem. Lett., 6(1):47-50 (1996);
Krause, B. R. et al., Chapter 6: "ACAT Inhibitors: Physiologic
Mechanisms for Hypolipidemic and Anti-Atherosclerotic Activities in
Experimental Animals", Inflammation: Mediators and Pathways, CRC
Press, Inc., publ., Ruffolo, Jr., R. R. et al., eds., pp. 173-198
(1995); Sliskovic et al., "ACAT inhibitors: potential
anti-atherosclerotic agents", Curr. Med. Chem., 1(3):204-225
(1994); Stout et al., "Inhibitors of acyl-CoA:cholesterol O-acyl
transferase (ACAT) as hypocholesterolemic agents. 6. The first
water-soluble ACAT inhibitor with lipid-regulating activity.
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7.
Development of a series of substituted
N-phenyl-N'-[(1-phenylcyclopentyl)-methyl]ureas with enhanced
hypocholesterolemic activity", Chemtracts: Org. Chem., 8(6):359-362
(1995), or TS-962 (Taisho Pharmaceutical Co. Ltd), as well as
F-1394, CS-505, F-12511, HL-004, K-10085 and YIC-C8-434.
[0192] The hypolipidemic agent may be an upregulator of LDL
receptor activity such as MD-700 (Taisho Pharmaceutical Co. Ltd)
and LY295427 (Eli Lilly). The hypolipidemic agent may be a
cholesterol absorption inhibitor preferably Schering-Plough's
SCH48461 (ezetimibe) as well as those disclosed in Atherosclerosis,
115:45-63 (1995) and J. Med. Chem., 41:973 (1998).
[0193] The other lipid agent or lipid-modulating agent may be a
cholesteryl transfer protein inhibitor (CETP) such as Pfizer's
CP-529,414 as well as those disclosed in WO/0038722 and in EP
818448 (Bayer) and EP 992496, and Pharmacia's SC-744 and SC-795, as
well as CETi-1 and JTT-705.
[0194] The hypolipidemic agent may be an ileal Na.sup.+/bile acid
co-transporter inhibitor such as disclosed in Drugs of the Future,
24:425-430 (1999). The ATP citrate lyase inhibitor which may be
employed in the combination of the application may include, for
example, those disclosed in U.S. Pat. No. 5,447,954.
[0195] The other lipid agent also includes a phytoestrogen compound
such as disclosed in WO 00/30665 including isolated soy bean
protein, soy protein concentrate or soy flour as well as an
isoflavone such as genistein, daidzein, glycitein or equol, or
phytosterols, phytostanol or tocotrienol as disclosed in WO
2000/015201; a beta-lactam cholesterol absorption inhibitor such as
disclosed in EP 675714; an HDL upregulator such as an LXR agonist,
a PPAR .alpha.-agonist and/or an FXR agonist; an LDL catabolism
promoter such as disclosed in EP 1022272; a sodium-proton exchange
inhibitor such as disclosed in DE 19622222; an LDL-receptor inducer
or a steroidal glycoside such as disclosed in U.S. Pat. No.
5,698,527 and GB 2304106; an anti-oxidant such as beta-carotene,
ascorbic acid, .alpha.-tocopherol or retinol as disclosed in WO
94/15592 as well as Vitamin C and an antihomocysteine agent such as
folic acid, a folate, Vitamin B6, Vitamin B12 and Vitamin E;
isoniazid as disclosed in WO 97/35576; a cholesterol absorption
inhibitor, an HMG-CoA synthase inhibitor, or a lanosterol
demethylase inhibitor as disclosed in WO 97/48701; a PPAR .delta.
agonist for treating dyslipidemia; or a sterol regulating element
binding protein-1 (SREBP-1) as disclosed in WO 2000/050574, for
example, a sphingolipid, such as ceramide, or neutral
sphingomyelenase (N-SMase) or fragment thereof. Preferred
hypolipidemic agents are pravastatin, lovastatin, simvastatin,
atorvastatin, fluvastatin, pitavastatin and rosuvastatin, as well
as niacin and/or cholestagel.
[0196] The compounds of the present invention may also be employed
in combination with anti-hypertensive agents. Examples of suitable
anti-hypertensive agents for use in combination with the compounds
of the present application include beta adrenergic blockers,
calcium channel blockers (L-type and/or T-type; e.g., diltiazem,
verapamil, nifedipine, amlodipine and mybefradil), diuretics (e.g.,
chlorothiazide, hydrochlorothiazide, flumethiazide,
hydroflumethiazide, bendroflumethiazide, methylchlorothiazide,
trichloromethiazide, polythiazide, benzthiazide, ethacrynic acid
tricrynafen, chlorthalidone, furosemide, musolimine, bumetanide,
triamtrenene, amiloride, spironolactone), renin inhibitors, ACE
inhibitors (e.g., captopril, zofenopril, fosinopril, enalapril,
ceranopril, cilazopril, delapril, pentopril, quinapril, ramipril,
lisinopril), AT-1 receptor antagonists (e.g., losartan, irbesartan,
valsartan), ET receptor antagonists (e.g., sitaxsentan, atrsentan
and compounds disclosed in U.S. Pat. Nos. 5,612,359 and 6,043,265),
Dual ET/AII antagonist (e.g., compounds disclosed in WO 00/01389),
neutral endopeptidase (NEP) inhibitors, vasopepsidase inhibitors
(dual NEP-ACE inhibitors) (e.g., omapatrilat and gemopatrilat), and
nitrates.
[0197] MCHR1 antagonists could also be useful in treating other
diseases associated with obesity, including sleep disorders.
Therefore, the compounds described in the present application could
be used in combination with therapeutics for treating sleep
disorders. Examples of suitable therapies for treatment of sleeping
disorders for use in combination with the compounds of the present
application include melatonin analogs, melatonin receptor
antagonists, ML 1 B agonists, GABA receptor modulators; NMDA
receptor modulators, histamine-3 (H3) receptor modulators, dopamine
agonists and orexin receptor modulators.
[0198] MCHR1 antagonists may reduce or ameliorate substance abuse
or addictive disorders. Therefore, combination of cannabinoid
receptor modulators with agents used to treat addictive disorders
may reduce the dose requirement or improve the efficacy of current
addictive disorder therapeutics. Examples of agents used to treat
substance abuse or addictive disorders are: selective serotonin
reuptake inhibitors (SSRI), methadone, buprenorphine, nicotine and
bupropion.
[0199] MCHR1 antagonists may reduce anxiety or depression;
therefore, the compounds described in this application may be used
in combination with anti-anxiety agents or antidepressants.
Examples of suitable anti-anxiety agents for use in combination
with the compounds of the present application include
benzodiazepines (e.g., diazepam, lorazepam, oxazepam, alprazolam,
chlordiazepoxide, clonazepam, chlorazepate, halazepam and
prazepam), 5HT1A receptor agonists (e.g., buspirone, flesinoxan,
gepirone and ipsapirone), and corticotropin releasing factor (CRF)
antagonists.
[0200] Examples of suitable classes of anti-depressants for use in
combination with the compounds of the present application include
norepinephrine reuptake inhibitors (tertiary and secondary amine
tricyclics), selective serotonin reuptake inhibitors (SSRIs)
(fluoxetine, fluvoxamine, paroxetine and sertraline), monoamine
oxidase inhibitors (MAOIs) (isocarboxazid, phenelzine,
tranylcypromine, selegiline), reversible inhibitors of monoamine
oxidase (RIMAs) (moclobemide), serotonin and norepinephrine
reuptake inhibitors (SNRIs) (venlafaxine), corticotropin releasing
factor (CRF) receptor antagonists, alpha-adrenoreceptor
antagonists, and atypical antidepressants (bupropion, lithium,
nefazodone, trazodone and viloxazine).
[0201] The combination of a conventional antipsychotic drug with a
MCHR1 antagonist could also enhance symptom reduction in the
treatment of psychosis or mania. Further, such a combination could
enable rapid symptom reduction, reducing the need for chronic
treatment with antipsychotic agents. Such a combination could also
reduce the effective antipsychotic dose requirement, resulting in
reduced probability of developing the motor dysfunction typical of
chronic antipsychotic treatment.
[0202] Examples of suitable antipsychotic agents for use in
combination with the compounds of the present application include
the phenothiazine (chlorpromazine, mesoridazine, thioridazine,
acetophenazine, fluphenazine, perphenazine and trifluoperazine),
thioxanthine (chlorprothixene, thiothixene), heterocyclic
dibenzazepine (clozapine, olanzepine and aripiprazole),
butyrophenone (haloperidol), diphenylbutylpiperidine (pimozide) and
indolone (molindolone) classes of antipsychotic agents. Other
antipsychotic agents with potential therapeutic value in
combination with the compounds in the present application include
loxapine, sulpiride and risperidone.
[0203] Combination of the compounds in the present application with
conventional antipsychotic drugs could also provide an enhanced
therapeutic effect for the treatment of schizophrenic disorders, as
described above for manic disorders. As used here, schizophrenic
disorders include paranoid, disorganized, catatonic,
undifferentiated and residual schizophrenia, schizophreniform
disorder, schizoaffective disorder, delusional disorder, brief
psychotic disorder and psychotic disorder not specified. Examples
of suitable antipsychotic drugs for combination with the compounds
in the present application include the antipsychotics mentioned
above, as well as dopamine receptor antagonists, muscarinic
receptor agonists, 5HT2A receptor antagonists and 5HT2A/dopamine
receptor antagonists or partial agonists (e.g., olanzepine,
aripiprazole, risperidone, ziprasidone).
Dosage Forms
[0204] The compounds of the present invention can be administered
in oral dosage form The dosage form for said pharmaceutical
composition includes such oral dosage forms as granules, powders,
tablets, capsules, syrups, emulsions, suspensions, etc. and such
non-oral dosage forms as injections (e.g., subcutaneous,
intravenous, intramuscular and intraperitoneal injections), drip
infusions, external application forms (e.g., nasal spray
preparations, transdermal preparations, ointments, etc.), and
suppositories (e.g., rectal and vaginal suppositories).
[0205] These dosage forms can be manufactured by the per se known
technique conventionally used in pharmaceutical procedures. The
specific manufacturing procedures are as follows.
[0206] To manufacture an oral dosage form, an excipient (e.g.,
lactose, sucrose, starch, mannitol, etc.), a disintegrator (e.g.,
calcium carbonate, carboxymethylcellulose calcium, etc.), a binder
(e.g., .alpha.-starch, gum arabic, carboxymethylcellulose,
polyvinylpyrrolidone, hydroxypropylcellulose, etc.), and a
lubricant (e.g., talc, magnesium stearate, polyethylene glycol
6000, etc.), for instance, are added to the active component or
components and the resulting composition is compressed. Where
necessary, the compressed product is coated, by the per se known
technique, for masking the taste or for enteric dissolution or
sustained release. The coating material that can be used includes,
for instance, ethylcellulose, hydroxymethylcellulose,
polyoxyethylene glycol, cellulose acetate phthalate,
hydroxypropylmethylcellulose phthalate, and Eudragit (Rohm &
Haas, Germany, methacrylic-acrylic copolymer).
[0207] Injections can be manufactured typically by the following
procedure. The active component or components are dissolved,
suspended or emulsified in an aqueous vehicle (e.g., distilled
water, physiological saline, Ringer's solution, etc.) or an oily
vehicle (e.g., vegetable oil such as olive oil, sesame oil,
cottonseed oil, corn oil, etc. or propylene glycol) together with a
dispersant, e.g., Tween 80 (Atlas Powder, U.S.A.), HCO 60 (Nikko
Chemicals), polyethylene glycol, carboxymethylcellulose, sodium
alginate, etc.), a preservative (e.g., methyl p-hydroxybenzoate,
propyl p-hydroxybenzoate, benzyl alcohol, chlorobutanol, phenol,
etc.), an isotonizing agent (e.g., sodium chloride, glycerol,
sorbitol, glucose, inverted sugar, etc.) and other additives. If
desired, a solubilizer (e.g., sodium salicylate, sodium acetate,
etc.), a stabilizer (e.g., human serum albumin), a soothing agent
(e.g., benzalkonium chloride, procaine hydrochloride, etc.) and
other additives can also be added.
[0208] A dosage form for external application can be manufactured
by processing the active component or components into a solid,
semi-solid or liquid composition. To manufacture a solid
composition, for instance, the active component or components,
either as they are or in admixture with an excipient (e.g.,
lactose, mannitol, starch, microcrystalline cellulose, sucrose,
etc.), a thickener (e.g., natural gums, cellulose derivatives,
acrylic polymers, etc.), etc., are processed into powders. The
liquid composition can be manufactured in substantially the same
manner as the injections mentioned above. The semi-solid
composition is preferably provided in a hydrous or oily gel form or
an ointment form. These compositions may optionally contain a pH
control agent (e.g., carbonic acid, phosphoric acid, citric acid,
hydrochloric acid, sodium hydroxide, etc.), and a preservative
(e.g., p-hydroxybenzoic acid esters, chlorobutanol, benzalkonium
chloride, etc.), among other additives.
[0209] Suppositories can be manufactured by processing the active
component or components into an oily or aqueous composition,
whether solid, semi-solid or liquid. The oleaginous base that can
be used includes, for instance, higher fatty acid glycerides [e.g.,
cacao butter, Witepsols (Dinamit-Nobel), etc.], medium-chain fatty
acids [e.g., Migriols (Dinamit-Nobel), etc.], vegetable oils (e.g.,
sesame oil, soybean oil, cotton-seed oil, etc.), etc. The
water-soluble base includes, for instance, polyethylene glycols
propylene glycol, etc. The hydrophilic base includes, for instance,
natural gums, cellulose derivatives, vinyl polymers, and acrylic
polymers, etc.
Dosages
[0210] The dosage of the pharmaceutical composition of the present
invention may be appropriately determined with reference to the
dosages recommended for the respective active components and can be
selected appropriately according to the recipient, the recipient's
age and body weight, current clinical status, administration time,
dosage form, method of administration, and combination of the
active components, among other factors. For example, the dosage of
the compound of Formula I of the invention for a human adult can be
selected from the clinical oral dose range of 0.01 to 30 mg/kg body
weight (preferably 0.05 to 10 mg/kg body weight, more preferably
0.05 to 5 mg/kg body weight) or the clinical parenteral dose range
of 0.005 to 10 mg/kg body weight (preferably 0.01 to 10 mg/kg body
weight, more preferably 0.01 to 1 mg/kg body weight) or 1 to 1000
mg/day. The other active component or components having different
modes of action for use in combination can also be used in dose
ranges selected by referring to the respective recommended clinical
dose ranges. Administration is generally carried out in a single
dose/day or in divided doses, for example, 2 to 4 times a day.
Abbreviations
[0211] The following abbreviations may be employed herein: [0212]
Ph=phenyl [0213] Bn=benzyl [0214] t-Bu=tertiary butyl [0215]
Me=methyl [0216] Et=ethyl [0217] TMS=trimethylsilyl [0218]
TBS=tert-butyldimethylsilyl [0219] Et.sub.2O=diethyl ether [0220]
EtOAc=ethyl acetate [0221] MeOH=methanol [0222] EtOH=ethanol [0223]
i-PrOH=isopropanol [0224] HOAc or AcOH=acetic acid [0225]
i-Pr.sub.2NEt=diisopropylethylamine [0226] Et.sub.3N=triethylamine
[0227] DMAP=4-dimethylaminopyridine [0228] NaBH.sub.4=sodium
borohydride [0229] n-BuLi=n-butyllithium [0230] Pd/C=palladium on
carbon [0231] KOH=potassium hydroxide [0232] NaOH=sodium hydroxide
[0233] LiOH=lithium hydroxide [0234] K.sub.2CO.sub.3=potassium
carbonate [0235] NaHCO.sub.3=sodium bicarbonate [0236] Ar=argon
[0237] N.sub.2=nitrogen [0238] min=minute(s) [0239] h or hr=hour(s)
[0240] L=liter [0241] mL=milliliter [0242] .mu.L=microliter [0243]
g=gram(s) [0244] mg=milligram(s) [0245] mol=moles [0246]
mmol=millimole(s) [0247] meq=milliequivalent [0248] RT=room
temperature [0249] sat or sat'd=saturated [0250] aq.=aqueous [0251]
TLC=thin layer chromatography [0252] HPLC=high performance liquid
chromatography [0253] LC/MS=high performance liquid
chromatography/mass spectrometry [0254] MS or Mass Spec=mass
spectrometry [0255] NMR=nuclear magnetic resonance [0256]
mp=melting point
EXAMPLES
[0257] The following examples are provided to illustrate various
preferred embodiments of the invention, and should not be construed
as limiting the scope thereof.
General Experimental Information Section
[0258] In the following examples, nomenclature conforms to either
IUPAC or CAS guidelines; was generated using (or is consistent
with) the Autonom.RTM. module (version 2.1) distributed with
ChemDraw Ultra 6.0.RTM.; or are taken from vendor literature.
[0259] brine=saturated aqueous sodium chloride [0260]
DIC=diisopropylcarbodiimide [0261] DMF=N,N-dimethylformamide [0262]
HOBT=Hydroxybenzotriazole [0263]
PyBOP=benzotriazo-1-yl-oxy-trispyrrolidinophosphonium
hexafluoroborate [0264] TFA=trifluoroacetic acid [0265]
THF=tetrahydrofuranyl [0266]
WSC=1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide
hydrochloride
Analytical Chromatography Methods
[0267] HPLC: column:
[0268] Method 1: Phenom-Luna (ODS) S-5, 4.6 mm.times.50 mm;
flow-5.0 mL/min.; detection at 220 nm; solvent--A=10%
methanol/water+0.2% phosphoric acid, B=90% methanol/water+0.2%
phosphoric acid; gradient-linear, 0% B to 100% B over 4 min and
100% B for 1 min.
[0269] Method 2: YMC Combiscreen S-5, 4.6 mm.times.50 mm; flow-4.0
mL/min.; detection at 220 nm; solvent--A=10% methanol/water+0.2%
phosphoric acid, B=90% methanol/water+0.2% phosphoric acid;
gradient-linear, 0% B to 100% B over 4 min and 100% B for 1
min.
[0270] LC MS: column-Phen-Luna (S5 ODS column) 4.6 mm.times.30 mm;
detection at 220 nm; flow-4 mL/min; solvent--A=10%
methanol/water+0.1% TFA, B=90% methanol/water+0.1% TFA; linear
gradient, 0% B to 100% B over 2 min and 100% B for 1 min.
Preparative HPLC Chromatography Method
[0271] Phenomenex Luna C18, S5, 21.times.100 mm; flow--20 mL/min,
detection at 220 nm; solvent--A=10% methanol/water+0.1% TFA, B=90%
methanol/water+0.1% TFA; gradient-linear, 10% B to 90% B over 20
min.
General Experimental Procedures for Preparation of
3-(Arylthio)-1-(aryl)pyrazin-2(1H)-one
Preparation of 1-Aryl pyrazine-2,3(1H,4H)-dione
Part A
##STR00072##
[0273] Ethyl oxalyl chloride (7.8 g, 6.8 mL, 57 mmol) was added to
a mixture of 3,4-dimethoxyaniline (4.4 g, 29 mmol) and
K.sub.2CO.sub.3 (14 g, 140 mmol) in EtOAc (44 mL) and water (12 mL)
at 0.degree. C. After stirring at 0.degree. C. for 10 min, water
(18 mL) was added; whereupon the mixture was transferred to a
separatory funnel and extracted with EtOAc (2.times.40 mL). The
combined EtOAc were filtered through Na.sub.2SO.sub.4 and
evaporated to about 30 mL. After addition of
2,2-dimethoxyethylamine (3.8 g, 3.9 mL, 36 mmol), the reaction was
stirred at ambient temperature overnight. The resultant white solid
was filtered and then washed with hexane to afford
N1-(2,2-dimethoxyethyl)-N2-(3,4-dimethoxyphenyl)oxalamide as a
light purple-grey solid (6.3 g, 71% yield). HPLC 33% 2.47 min and
63% at 2.79 min. LC MS 1.37 min (M+1=281 and 335). H-NMR
(CDCl.sub.3) 9.15 (broad s, 1H), 7.76 (broad s, 1H), 7.41 (d, J=2.4
Hz, 1H), 7.06 (dd, J=2.4, 8.7 Hz, 1H), 6.85 (d, J=8.7 Hz, 1H), 4.45
(t, J=5.5 Hz, 1H), 3.90 (s, 3H), 3.88 (s, 3H), 3.52 (t, J=5.5 Hz,
2H), 3.42 (s, 6 H).
Part B
##STR00073##
[0275] After addition of trifluoroacetic acid (0.12 mL, 1.7 mmol)
to a mixture of the aryl oxalamide prepared in Part A (0.50 g, 1.6
mmol) in acetic acid (1.0 mL), the resulting solution was heated to
125.degree. C. for 20 min using a microwave. Following evaporation
of the solvent, the residue was triturated with EtOAc to afford
1-(3,4-dimethoxyphenyl)pyrazine-2,3(1H,4H)-dione as a white solid
(1.1 g, 92% yield). HPLC 1.83 min. LC MS 1.20 min (M+1=249). H-NMR
(CD.sub.3OD) 7.06 (m, 2H), 6.97 (m, 1H), 6.56 (d, J=5.7 Hz, 1H),
6.45 (d, J=5.7 Hz, 1H), 3.89 (s, 3H), 3.85 (s, 3H).
Preparation of Desired Substituted
3-thio-1-aryl-pyrazin-2(1H)-one
Method 1
Part C
##STR00074##
[0277] Thionyl chloride (0.28 g, 0.17 mL, 2.4 mmol) was slowly
added to a stirred solution of the 1-aryl pyrazine-2,3(1H,4H)-dione
prepared in Part B (0.54 g, 2.2 mmol) in EtOAc (0.88 mL) and DMF
(0.44 mL) at 45.degree. C. After stirring at 55 to 60.degree. C.
for 2 h, the reaction was transferred to a separatory funnel,
diluted with EtOAc and 2N KHCO.sub.3 and extracted with EtOAc
(2.times.). The combined organic layers were washed with 2N
KHCO.sub.3 and water; whereupon, the combined aqueous layers were
extracted with CH.sub.2Cl.sub.2. All of the organic layers were
combined prior to drying over MgSO.sub.4 to afford
3-chloro-1-(3,4-dimethoxyphenyl)pyrazin-2(1H)-one (0.34 g, 59%
yield). HPLC 2.33 min. LC MS 1.00 min (M+1=267/269). The
chloropyrazinone was used in the subsequent steps without further
purification.
Part D
##STR00075##
[0279] 4-Chlorobenzylmercaptan (71 mg, 0.059 mL, 0.45 mmol) was
added to a stirred THF (1.0 mL) suspension of sodium hydride (60%
oil dispersion, 18 mg, 0.45 mmol), that had been previously washed
with hexane 3.times.. The reaction was stirred at ambient
temperature for 20 min until it became a solid mass; whereupon, the
chloropyrazinone prepared in Part C (100 mg, 0.38 mmol) in THF (5
mL) was added resulting in gas evolution. After stirring at ambient
temperature for 40 min, the reaction was diluted with
CH.sub.2Cl.sub.2/H.sub.2O, extracted with CH.sub.2Cl.sub.2
(2.times.) and dried over MgSO.sub.4 to afford 220 mg of crude
product after evaporation of the solvent. The desired was purified
by chromatography on silica gel (12 g) employing gradient elution
(0-100% EtOAc/hexane over 12 min) to elute the desired
3-(4-chlorobenzylthio)-1-(3,4-dimethoxyphenyl)pyrazin-2(1H)-one
(130 mg, 89% yield).
Method 2
[0280] A solution of the 1-aryl pyrazine-2,3(1H,4H)-dione prepared
in Part B (67 mg, 0.27 mmol), diisopropylethyl amine (0.15 mL, 0.81
mmol), pyBOP (0.23 g, 0.46 mmol), and dimethylaminopyridine (13 mg)
in DMF (1.2 mL) was stirred at ambient temperature for 15 min.
After addition of 2-pyridylethyl mercaptan (28 mg, 0.40 mmol), the
reaction was stirred at ambient temperature for 2.5 h prior to
quenching by addition of H.sub.2O and extraction with EtOAc. The
EtOAc extracts were washed with water (2.times.), brine, dried over
MgSO.sub.4 and concentrated to yield 204 mg of crude product.
Chromatography on silica employing a gradient elution with
hexane/EtOAc afforded the desired product
1-(3,4-dimethoxyphenyl)-3-(2-(pyrazin-2-yl)ethylthio)pyrazin-2(1H)-one
(17 mg, 17% yield).
Method 2a
[0281] The same procedure was employed as that described in Method
2 except that the reaction was run for 18 hr.
Method 3
[0282] Following preparation of the oxalamide as described in Part
A, ring closure can be effected by prolonged thermal heating in
TFA/HOAc at 78.degree. C. for 1d. In the case of
3-methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)aniline which contained a
basic amine, the reaction was brought to pH 6 to 7 with saturated
NaHCO.sub.3 and then evaporated in vacuo. The residue was absorbed
on silica gel and purified by flash chromatography (5 to 15% 2N
NH.sub.3 in MeOH/CH.sub.2Cl.sub.2) to afford the desired 1-aryl
pyrazine-2,3(1H,4H)-dione in 36% yield. This material was
subsequently converted to final product following the procedure
described in Method 2.
Method 4
[0283] If the oxalamide as described in Part A contained a primary
or secondary alcohol, prolonged thermal heating in TFA/HOAc at
78.degree. C. for 1 day not only effected ring closure but also
converted the alcohol moiety to an acetate. The resulting 1-aryl
pyrazine-2,3(1H,4H)-dione was converted to the desired 3-thio
substituted-1-arylpyrazin-2-one employing Method 1. Following
workup and purification as described in Method 1, the acetylated
product was converted to the desired 3-thio
substituted-1-arylpyrazin-2-one (19 mg, 0.041 mmol) bearing a free
hydroxyl by dissolution in MeOH (1.0 mL) and H.sub.2O (0.1 mL) and
stirring at ambient temperature for 1 h after addition of potassium
carbonate (30 mg). The reaction was then diluted with
CH.sub.2Cl.sub.2/H.sub.2O prior to extraction with CH.sub.2Cl.sub.2
(2.times.). After drying the combined organic layers over
MgSO.sub.4, concentration afforded the desired final product (16
mg, 93% yield).
Method 5
[0284] For weakly nucleophilic thiols more forcing conditions were
required effect PyBOP mediated conversion of the 1-aryl
pyrazine-2,3(1H,4H)-dione to a 3-thio
substituted-1-arylpyrazin-2-ones. Accordingly, a DMF solution (0.4
mL) containing the 1-aryl pyrazine-2,3(1H,4H)-dione prepared in
Part B (92 mg, 0.30 mmol), PyBOP (0.27 g, 0.53 mmol) and
diisopropylethylamine (0.16 mL, 0.9 mmol) was stirred for 3 h
before addition of a DMF solution prepared by stirring
5-methoxybenzo[d]thiazole-2-thiol (296 mg, 1.502 mmol) with NaH
(60.1 mg, 1.502 mmol, rinsed with hexane 2.times.) in DMF (0.2 mL)
at ambient temperature for 10 min. After stirring at ambient
temperature for 7 days, the reaction mixture was diluted with EtOAc
and washed sequentially with water (2.times.) and brine prior to
drying over MgSO.sub.4. After evaporation of the solvent,
CH.sub.2Cl.sub.2 (10 mL) was added to the 0.30 g of crude product.
Filtration to remove any residual solids followed by evaporation of
the filtrate afforded 0.10 g crude product. Final purification
required flash chromatography on 12 g silica gel using gradient
elution (0 to 100% EtOAc/CH.sub.2Cl.sub.2) followed by preparatory
HPLC (YMC S5 ODS 20.times.100 mm, 20 mL/min, 30 to 100% B in A over
10 min, Solvent A=10% MeOH/H.sub.2O-0.1% TFA, Solvent B=90%
MeOH/H.sub.2O-0.1% TFA) to afford pure desired product (6.3 mg, 4%
yield).
Method 6
General Experimental Procedures for Preparation of
1-(4-(2-Hydroxy-2-methylpropoxy)-3-methylphenyl)-3-(4-(trifluoromethoxy)p-
henylthio)pyrazin-2(1H)-one
##STR00076##
[0285] Part A.
N1-(2,2-Dimethoxyethyl)-N2-(4-methoxybenzyl)oxalamide
##STR00077##
[0287] To a mixture of (4-methoxyphenyl)methanamine (9.90 g, 72.2
mmol) in THF (40 mL) was slowly added ethyl 2-chloro-2-oxoacetate
(10.84 g, 79 mmol). After stirring the reaction at RT for 15 min, a
solution of 2,2-dimethoxyethanamine (9.10 g, 87 mmol) and
N,N-diisopropylethylamine (37.8 mL, 217 mmol) in EtOAc (40.0 mL)
was added. The reaction was heated at reflux for 18 hours;
whereupon, after cooling to RT, saturated NaHCO.sub.3 (50 ml) was
added and the mixture extracted with EtOAc (50 ml). The EtOAc layer
was dried over Na.sub.2SO.sub.4 and concentrated. The crude product
was purified by silica gel chromatography employing a solvent
gradient (CH.sub.2Cl.sub.2 to 5% MeOH/CH.sub.2Cl.sub.2) to elute
N1-(2,2-dimethoxyethyl)-N2-(4-methoxybenzyl)oxalamide (7.50 g, 25.3
mmol, 35.1% yield) as white solid. 1H NMR (400 MHz, chloroform-d)
.delta. ppm 9.07 (1 H, s), 7.69 (1 H, t, J=5.65 Hz), 7.59 (1 H, d,
J=8.78 Hz), 6.74 (1 H, d, J=8.78 Hz), 4.46 (1 H, t, J=5.40 Hz),
3.79 (2 H, s), 3.53 (2 H, t), 3.44 (6 H, s), 2.23 (6 H, d, J=5.27
Hz), 1.37 (6 H, s).
Part B. 3-Hydroxy-1-(4-methoxybenzyl)pyrazin-2(1H)-one
##STR00078##
[0289] A solution of
N1-(2,2-dimethoxyethyl)-N2-(4-methoxybenzyl)oxalamide (7.5 g, 25.3
mmol) and TFA (2.340 mL, 30.4 mmol) in AcOH (160 mL) was stirred at
135.degree. C. in a seal tube for 1.5 hours. After cooling to RT
and removal of the volatiles under vacuum, ethyl ether (150 ml) and
sat. aq. NaHCO.sub.3 solution (150 ml) were added. The resulting
precipitate was collected by filtration, washed with H.sub.2O (50
ml) and ether (50 ml) prior to drying under high vacuum to yield
3-hydroxy-1-(4-methoxybenzyl)pyrazin-2(1H)-one (5.30 g, 21.68 mmol,
86% yield) as brown solid. 1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 11.17 (1 H, br. s.), 7.18 (2 H, d), 6.81 (2 H, d), 6.46 (1 H,
d, J=5.77 Hz), 6.23 (1 H, br. s.), 4.74 (2 H, s), 3.24 (1 H,
s).
Part C.
1-(4-Methoxybenzyl)-3-(4-(trifluoromethoxy)phenylthio)pyrazin-2(1H-
)-one
##STR00079##
[0291] A mixture of 3-hydroxy-1-(4-methoxybenzyl)pyrazin-2(1H)-one
(2.0 g, 8.61 mmol), PyBOP (7.84 g, 15.07 mmol) and
N,N-diisopropylethylamine (4.51 mL, 25.8 mmol) in DMF (40 mL) was
stirred at RT under N.sub.2 for 3 hours whereupon
4-(trifluoromethoxy)benzenethiol (2.007 g, 10.33 mmol) was added.
After having stirred for 18 additional hours, the reaction was
diluted with saturated aq. NaHCO.sub.3 (65 ml) and was then
extracted with EtOAc (60 ml). The EtOAc layer was dried over
Na.sub.2SO.sub.4 and concentrated. The crude product was purified
by silica gel chromatography employing a solvent gradient (hexane
to 75% EtOAc/hexane) to elute
1-(4-methoxybenzyl)-3-(4-(trifluoromethoxy)phenylthio)pyrazin-2(1
H)-one (2.76 g, 6.42 mmol, 74.6% yield) as white solid. 1H NMR (400
MHz, chloroform-d) .delta. ppm 7.58 (2 H, d, J=8.78 Hz), 7.21-7.35
(4 H, m), 7.02 (1 H, d, J=4.52 Hz (2 H, d, J=8.78 Hz), 6.85 (1 H,
d, J=4.27 Hz), 5.03 (2 H, s), 3.81 (3 H, s).
Part D. 3-(4-(Trifluoromethoxy)phenylthio)pyrazin-2(1H)-one
##STR00080##
[0293] A solution of
1-(4-methoxybenzyl)-3-(4-(trifluoromethoxy)phenylthio)-pyrazin-2(1H)-one
(2.76 g, 6.76 mmol) in TFA (25 mL) was stirred at reflux for 2
days. Since LC-MS analysis revealed that 28% SM remained, the
reaction was stirred for 7 days. After removal of the TFA under
vacuum, the crude product was purified by silica gel chromatography
employing a solvent gradient (hexane to 100% EtOAc to elute
3-(4-(trifluoromethoxy)phenylthio)pyrazin-2(1H)-one (1.60 g, 5.27
mmol, 78% yield) as off-white solid. 1H NMR (400 MHz, chloroform-d)
.delta. ppm 7.61 (2 H, d, J=9.03 Hz), 7.29 (2 H, d, J=7.78 Hz),
7.24 (1 H, d, J=4.02 Hz), 7.07 (1 H, d).
Part E.
1-(4-(2-Hydroxy-2-methylpropoxy)-3-methylphenyl)-3-(4-(trifluorome-
thoxy)phenylthio)pyrazin-2(1H)-one
##STR00081##
[0295] A mixture of
3-(4-(trifluoromethoxy)phenylthio)pyrazin-2(1H)-one (100 mg, 0.347
mmol), 1-(4-bromo-2-methylphenoxy)-2-methylpropan-2-ol (90 mg,
0.347 mmol), N1,N2-dimethylethane-1,2-diamine (92 mg, 1.041 mmol),
copper(I) iodide (19.82 mg, 0.104 mmol) and K.sub.3PO.sub.4 (221
mg, 1.041 mmol) in dioxane (1.0 mL) was stirred at 115.degree. C.
in a sealed tube for 2 hours. After removal of the precipitate by
filtration, the filtrate was concentrated. The crude product was
purified by silica gel chromatography employing a solvent gradient
(hexane to 100% EtOAc) to elute
1-(4-(2-hydroxy-2-methylpropoxy)-3-methylphenyl)-3-(4-(trifluoromet-
hoxy)phenylthio)-pyrazin-2(1H)-one (18.65 mg, 0.040 mmol, 11.52%
yield) as off-white solid. 1H NMR (500 MHz, methanol-d.sub.3)
.delta. ppm 7.62-7.68 (2 H, m), 7.37 (2 H, d, J=7.97 Hz), 7.21-7.28
(3 H, m), 7.16 (1 H, d, J=4.40 Hz), 7.02 (1 H, d, J=8.25 Hz), 3.84
(2 H, s), 2.31 (3 H, s), 1.36 (6 H, s).
Method 7
General Experimental Procedures for Preparation of
3-(4-Chlorophenethoxy)-1-(4-(2-hydroxy-2-methylpropoxy)phenyl)pyrazin-2(1-
H)-one
##STR00082##
[0296] Part A. 2-(4-Chlorophenethoxy)-3-methoxypyrazine
##STR00083##
[0298] To a mixture of 2-(4-chlorophenyl)ethanol (1.246 g, 7.96
mmol) in THF was added 1.0 M sodium bis(trimethylsilyl)amide in THF
(6.92 mL, 6.92 mmol). After stirring at RT under nitrogen for 18
hours, the reaction was diluted with a solution of saturated
NaHCO.sub.3 (65 ml) and extracted with EtOAc 720 ml). The ethyl
acetate layer was dried over Na.sub.2SO.sub.4 and concentrated. The
crude product was purified by silica gel chromatography employing a
solvent gradient (hexane to 30% ethyl acetate) to elute
2-(4-chlorophenethoxy)-3-methoxypyrazine (1.25 g, 4.72 mmol, 68.3%
yield) as clear oil. 1H NMR (500 MHz, CDCl.sub.3) .delta. ppm
7.61-7.64 (1 H, m), 7.59-7.61 (1 H, m), 7.26-7.30 (2 H, m),
7.20-7.24 (2 H, m), 7.15 (1 H, d, J=8.52 Hz), 4.49-4.63 (2 H, m),
4.02 (3 H, s), 3.12 (2 H, t, J=7.29 Hz).
Part B. 3-(4-Chlorophenethoxy)pyrazin-2(1H)-one
##STR00084##
[0300] A mixture of benzo[d]thiazole-2-thiol (1.264 g, 7.56 mmol),
2-(4-chlorophenethoxy)-3-methoxypyrazine (1.00 g, 3.78 mmol) and
NaHCO.sub.3 (1.587 g, 18.89 mmol) in DMA (10 mL) was stirred at
135.degree. C. for 6 hours. After cooling to RT, the mixture was
diluted with a solution of saturated NaHCO.sub.3 (55 ml) and was
then extracted with EtOAc (60 ml). The EtOAc layer was dried over
Na.sub.2SO.sub.4 and concentrated. The crude product was purified
by silica gel chromatography employing a solvent gradient (hexane
to 100% EtOAc) to elute 3-(4-chlorophenethoxy)pyrazin-2(1H)-one
(477 mg, 1.808 mmol, 47.9% yield) as off-white solid. 1H NMR (400
MHz, chloroform-d) .delta. ppm 7.27-7.31 (2 H, m), 7.19-7.25 (2 H,
m), 6.95 (1 H, d, J=4.27 Hz), 6.89 (1 H, d, J=4.52 Hz), 4.54 (2 H,
J=7.53 Hz), 3.14 (2 H, t, J=7.40 Hz).
Part C.
3-(4-Chlorophenethoxy)-1-(4-(2-hydroxy-2-methylpropoxy)phenyl)pyra-
zin-2(1H)-one
##STR00085##
[0302] A mixture of 3-(4-chlorophenethoxy)pyrazin-2(1H)-one (25 mg,
0.100 mmol), K.sub.3PO.sub.4 (63.5 mg, 0.299 mmol), copper (1)
iodide (18.99 mg, 0.100 mmol),
1-(4-bromophenoxy)-2-methylpropan-2-ol and
N,N'-dimethylethylenediamine (0.032 mL, 0.299 mmol) in dioxane (1.0
mL) was stirred at 110.degree. C. for 60 min. After removal of the
precipitate by filtration, the filtrate was concentrated. The crude
product was purified by silica gel chromatography employing a
solvent gradient (CH.sub.2Cl.sub.2 to 10% MeOH/CH.sub.2Cl.sub.2) to
elute
3-(4-chlorophenethoxy)-1-(4-(2-hydroxy-2-methylpropoxy)phenyl)pyrazin-2(1-
H)-one (31.82 mg, 0.073 mmol, 73.1% yield) as white solid. 1H NMR
(500 MHz, chloroform-d) .delta. ppm 7.32 (2 H, d), 7.23-7.29 (4 H,
m), 7.02 (2 H, d), 6.84 (2 H, s), 4.51 (2 H, t, J=7.29 Hz), 3.83 (2
H, s), 3.13 (2 H, t, J=7.15 Hz), 1.36 (6 H, s).
TABLE-US-00001 TABLE 1 3-Thio substituted-1-arylpyrazin-2(1H)-ones
##STR00086## Ex. Aniline/Bromide No. Structure Component 1
##STR00087## ##STR00088## 2 ##STR00089## ##STR00090## 3
##STR00091## ##STR00092## 4 ##STR00093## ##STR00094## 5
##STR00095## ##STR00096## 6 ##STR00097## ##STR00098## 7
##STR00099## ##STR00100## 8 ##STR00101## ##STR00102## 9
##STR00103## ##STR00104## 10 ##STR00105## ##STR00106## 11
##STR00107## ##STR00108## 12 ##STR00109## ##STR00110## 13
##STR00111## 14 ##STR00112## ##STR00113## 15 ##STR00114##
##STR00115## 16 ##STR00116## ##STR00117## 17 ##STR00118##
##STR00119## 18 ##STR00120## ##STR00121## 19 ##STR00122##
##STR00123## 20 ##STR00124## ##STR00125## 21 ##STR00126## 22
##STR00127## 23 ##STR00128## 24 ##STR00129## 25 ##STR00130##
##STR00131## 26 ##STR00132## ##STR00133## 27 ##STR00134##
##STR00135## 28 ##STR00136## ##STR00137## 29 ##STR00138##
##STR00139## 30 ##STR00140## ##STR00141## 31 ##STR00142##
##STR00143## 32 ##STR00144## ##STR00145## 33 ##STR00146##
##STR00147## 34 ##STR00148## ##STR00149## 35 ##STR00150##
##STR00151## 36 ##STR00152## ##STR00153## 37 ##STR00154##
##STR00155## 38 ##STR00156## ##STR00157## 39 ##STR00158##
##STR00159## 40 ##STR00160## ##STR00161## 41 ##STR00162##
##STR00163## 42 ##STR00164## ##STR00165## 43 ##STR00166##
##STR00167## 44 ##STR00168## ##STR00169## 45 ##STR00170##
##STR00171## 46 ##STR00172## ##STR00173## 47 ##STR00174##
##STR00175## 48 ##STR00176## ##STR00177## 49 ##STR00178##
##STR00179## 50 ##STR00180## ##STR00181## 51 ##STR00182##
##STR00183## 52 ##STR00184## ##STR00185## 53 ##STR00186##
##STR00187## 54 ##STR00188## ##STR00189## 55 ##STR00190##
##STR00191## 56 ##STR00192## ##STR00193## 57 ##STR00194##
##STR00195## 58 ##STR00196## ##STR00197## 59 ##STR00198##
##STR00199## 60 ##STR00200## ##STR00201## 61 ##STR00202##
##STR00203## 62 ##STR00204## ##STR00205## 63 ##STR00206##
##STR00207## 64 ##STR00208## ##STR00209## 65 ##STR00210##
##STR00211## 66 ##STR00212## ##STR00213## 67 ##STR00214##
##STR00215## 68 ##STR00216## ##STR00217## 69 ##STR00218##
##STR00219## 70 ##STR00220## ##STR00221## 71 ##STR00222##
##STR00223## 72 ##STR00224## ##STR00225## 73 ##STR00226##
##STR00227## 74 ##STR00228## ##STR00229## 75 ##STR00230##
##STR00231## 76 ##STR00232## ##STR00233## 77 ##STR00234##
##STR00235## 78 ##STR00236## ##STR00237## 79 ##STR00238##
##STR00239## 80 ##STR00240## ##STR00241## 81 ##STR00242##
##STR00243## 82 ##STR00244## ##STR00245## 83 ##STR00246##
##STR00247## 84 ##STR00248## ##STR00249## 85 ##STR00250##
##STR00251## 86 ##STR00252## ##STR00253## 87 ##STR00254##
##STR00255## 88 ##STR00256## ##STR00257## 89 ##STR00258##
##STR00259## 90 ##STR00260## ##STR00261## 91 ##STR00262##
##STR00263## 92 ##STR00264## ##STR00265## 93 ##STR00266##
##STR00267## 94 ##STR00268## ##STR00269## 95 ##STR00270##
##STR00271## 96 ##STR00272## ##STR00273## 97 ##STR00274##
##STR00275## 98 ##STR00276## ##STR00277## 99 ##STR00278##
##STR00279## 100 ##STR00280## ##STR00281## 101 ##STR00282##
##STR00283## 102 ##STR00284## ##STR00285## 103 ##STR00286##
##STR00287## 104 ##STR00288## ##STR00289## 105 ##STR00290##
##STR00291## 106 ##STR00292## ##STR00293## 107 ##STR00294##
##STR00295## 108 ##STR00296## ##STR00297## 109 ##STR00298##
##STR00299## 110 ##STR00300## ##STR00301## 111 ##STR00302##
##STR00303## 112 ##STR00304## ##STR00305## 113 ##STR00306##
##STR00307## 114 ##STR00308## ##STR00309## 115 ##STR00310##
##STR00311## 116 ##STR00312## ##STR00313## 117 ##STR00314##
##STR00315## 118 ##STR00316## ##STR00317## 119 ##STR00318##
##STR00319## 120 ##STR00320## ##STR00321## 121 ##STR00322##
##STR00323##
122 ##STR00324## ##STR00325## 123 ##STR00326## ##STR00327## 124
##STR00328## ##STR00329## 125 ##STR00330## ##STR00331## 126
##STR00332## ##STR00333## 127 ##STR00334## ##STR00335## 128
##STR00336## ##STR00337## 129 ##STR00338## ##STR00339## 130
##STR00340## ##STR00341## 131 ##STR00342## ##STR00343## 132
##STR00344## ##STR00345## HPLC Ex. Thiol Yield (Min) LC-MS H-NMR
Data No. Component Method (%) Method 1 (M + H) (CDCl.sub.3) 1
##STR00346## 1 50 4.09 389/391 7.36 (d, J = 8.4 Hz, 2 H), 7.26 (d,
J =8.4 Hz, 2 H), 7.41 (d, J = 2.4 Hz,1 H), 7.25 (d, J = 4.6 Hz, 1
H), 6.98(d, J = 4.6 Hz, 1 H), 6.94 (d, J = 2.2Hz, 1 H), 6.91 (d, J
= 8.5 Hz, 1 H),6.88 (dd, J = 2.2 and 8.5 Hz, 1 H),4.28 (s, 2 H),
3.91 (s, 3 H), 3.87 (s,3 H). 2 ##STR00347## 1 4.60 435/437
7.44-7.24 (m, 12 H), 7.05 (d, J =8.9 Hz, 2 H), 6.96 (d, J = 4.5
Hz,1 H), 5.09 (s, 2 H), 4.27 (s, 2 H). 3 ##STR00348## 1 9 4.23
403/405 7.27 (m, 6 H), 6.93 (m, 3 H), 3.92(s, 3 H), 3.89 (s, 3 H),
3.30 (t, J =7.3 Hz, 2 H), 2.98 (t, J = 7.3 Hz,2 H) 4 ##STR00349## 1
68 4.01 369 7.28 (m, 6 H), 6.92 (m, 4 H), 3.91(s, 3 H), 3.88 (s, 3
H), 3.32 (dd, J =2.2 and 7.5 Hz, 2 H), 3.02 (dd, J =2.2 and 7.5 Hz,
2 H) 5 ##STR00350## 2 11 2.36 370 CD.sub.3OD) 8.35 (dd, J = 1.0 and
4.5Hz, 1 H), 7.65 (m, 1 H), 7.27 (d, J =7.8 Hz, 1 H), 7.23 (d, J =
4.3 Hz,1 H), 7.16 (m, 1 H), 7.11 (d, J = 4.3Hz, 1 H), 6.93 (d, J =
2.3 Hz, 1 H),6.92 (d, J = 8.5 Hz, 1 H), 6.82 (dd,J = 2.3 and 8.5
Hz, 1 H), 3.74 (s,3 H), 3.69 (s, 3 H), 3.33 (t, J = 7.1Hz, 2 H),
3.06 (t, J = 7.1 Hz, 2 H). 6 ##STR00351## 2 37 3.01 371 8.45 (s, 1
H), 8.44 (d, J = 3.0 Hz,1 H), 8.33 (d, J = 3.0 Hz, 1 H), 7.22(d, J
= 4.5 Hz, 1 H), 7.12 (d, J = 4.5Hz, 1 H), 6.94 (d, J = 2.4 Hz, 1
H),6.93 (d, J = 8.5 Hz, 1 H), 6.83 (dd,J = 2.4 and 8.5 Hz, 1 H),
3.74 (s,3 H), 3.71 (s, 3 H), 3.39 (t, J = 7.2Hz, 2 H), 3.13 (t, J =
7.2 Hz, 2 H) 7 ##STR00352## 2 9 3.87 375/377 7.52 (d, J = 8.5 Hz, 2
H), 7.42 (d, J =8.5 Hz, 2 H), 7.13 (d, J = 4.5 Hz,1 H), 6.97 (d, J
= 4.5 Hz, 1 H), 6.95(m, 1 H), 6.92 (m, 2 H), 3.93 (s,3 H), 3.89 (s,
3 H). 8 ##STR00353## 2 23 3.59 375/377 7.67 (dd, J = 1.7 and 7.6
Hz, 1 H),7.57 (dd, J = 1.3 and 8.0 Hz, 1 H),7.43 (dd, J = 1.7 and
7.6 Hz, 1 H),7.35 Hz (dd, J = 1.3 and 7.5 Hz,1 H), 7.12 (d, J = 4.4
Hz, 1 H), 7.00(d, J = 1.6 Hz, 1 H), 6.98 (d, J = 4.4Hz, 1 H), 6.95
(m, 2 H), 3.93 (s,3 H), 3.91 (s, 3 H). 9 ##STR00354## 2 70 4.13 383
7.51 (d, J = 8.2 Hz, 2 H), 7.32 (d,J = 8.2 Hz, 2 H), 7.13 (d, J =
4.5 Hz,1 H), 6.99 (m, 1 H), 6.96 (d, J = 4.5Hz, 1 H), 6.91 (m, 2
H), 3.92 (s,3 H), 3.90 (s, 3 H), 2.96 (sept, J =7.7 Hz, 1 H), 1.28
(d, J = 7.7 Hz,6 H). 10 ##STR00355## 2 60 4.02 425 7.61 (d, J = 8.5
Hz, 2 H), 7.29 (d, J =8.5 Hz, 2 H), 7.13 (d, J = 4.4 Hz,1 H), 7.00
(d, J = 4.4 Hz, 1 H), 6.96(m, 1 H), 6.92 (m, 2 H), 3.93 (s,3 H),
3.90 (s, 3 H) 11 ##STR00356## 1 2.5 3.94 433/435 7.36 (m, 2 H),
7.28 (m, 3 H), 6.96(m, 3 H), 6.87 (m, 1 H), 4.72 (s,3 H), 4.28 (s,
2 H), 3.87 (s, 3 H). 12 ##STR00357## 1 8 413 9.45 (broad s, 1 H),
7.39 (m, 1 H),7.28 (m, 5 H), 6.98 (m, 2 H), 6.87(m, 2 H), 4.73 (s,
2 H), 3.85 (s, 3 H),3.34 (t, J = 8.2 Hz, 2 H), 3.01 (t, J =8.2 Hz,
2 H) 13 WSC,HOBTmediatedcouplingof Ex 15 27 3.95 466 7.30 (m, 6 H),
7.05 (d, J = 7.5 Hz,1 H), 7.01 (d, J = 1.6 Hz, 1 H), 6.96(d, J =
6.6 Hz, 1 H) 6.84 (dd, J =1.6 and 7.5 Hz, 1 H), 4.72 (s, 2 H),3.87
(s, 3 H), 3.55 (m, 4 H), 3.32 (t,J = 7.4 Hz, 2 H), 3.02 (t, J =
7.4Hz, 2 H), 1.97 (m, 2 H), 1.86 (m,2 H). 14 ##STR00358## 4 3.9
3.96 419/421 7.36 (m, 2 H), 7.26 (m, 3 H), 6.97(m, 3 H), 6.87 (m, 1
H), 4.28 (s,2 H), 4.15 (t, J = 4.2 Hz, 2 H), 3.98(t, J = 4.2 Hz, 2
H), 3.85 (s, 3 H). 15 ##STR00359## 2Method 4for esterhydrolysis 2
3.86 399 (CD.sub.3OD) 7.41 (d, J = 4.3 Hz, 1 H),7.31 (m, 4 H), 7.26
(d, J = 4.3 Hz,1 H), 7.20 (m, 1 H), 7.10 (d, J = 8.6Hz, 1 H), 7.12
(d, J = 2.4 Hz, 1 H),7.00 (dd, J = 2.4 and 8.6 Hz, 1 H),4.09 (t, J
= 4.7 Hz, 2 H), 3.92 (s,3 H), 3.90 (t, J = 4.7 Hz, 2 H), 3.33(dd, J
= 6.0 and 8.0 Hz, 2 H), 3.00(dd, J = 6.0 and 8.0 Hz, 2 H). 16
##STR00360## 4 12 3.93 419/421 7.51 (d, J = 8.5 Hz, 2 H), 7.42 (d,
J =8.5 Hz, 2 H), 7.13 (d, J = 4.5 Hz,1 H), 6.99 (m, 3 H), 6.90 (dd,
J =1.8 and 5.9 Hz, 1 H), 4.22 (m, 1 H),4.04 (dd, J = 3.0 and 9.5
Hz, 1 H),3.87 (s, 3 H), 3.84 (dd, J = 1.2 and9.5 Hz, 1 H), 2.77
(broad s, 1 H),1.28 (d, J = 6.4 Hz, 3 H). 17 ##STR00361## 4 4.06
413 7.27 (m, 6 H), 6.97 (m, 3 H), 6.89(dd, J = 2.2 and 8.4 Hz, 1
H), 4.23(m, 1 H), 4.03 (dd, J = 3.0 and 9.6Hz, 1 H), 3.86 (s, 3 H),
3.84 (dd, J =1.0 and 9.6 Hz, 1 H), 3.32 (t, J =5.4 Hz, 2 H), 3.02
(t, J = 5.4 Hz,2 H), 2.83 (broad s, 1 H), 1.27 (d, J =6.4 Hz, 3 H).
18 ##STR00362## 4 4.20 447/449 7.27 (m, 5 H), 6.98 (m, 3 H),
6.89(dd, J = 2.4 and 8.5 Hz, 1 H), 4.23(m, 1 H), 4.02 (dd, J = 3.0
and 9.6Hz, 1 H), 3.86 (s, 3 H), 3.83 (dd, J =1.0 and 9.6 Hz, 1 H),
3.30 (t, J =7.3 Hz, 2 H), 2.98 (t, J = 7.3 Hz,2 H), 2.81 (broad s,
1 H), 1.27 (d, J =6.3 Hz, 3 H). 19 ##STR00363## 4 4.13 427 7.23 (m,
6 H), 6.98 (m, 2 H), 6.97(d, J = 4.6 Hz, 1 H), 6.95 (dd, J =2.2 and
8.4 Hz, 1 H), 4.23 (m, 1 H),4.07 (dd, J = 3.0 and 9.6 Hz, 1 H),3.87
(s, 3 H), 3.84 (dd, J = 1.0 and9.6 Hz, 1 H), 3.12 (m, 2 H), 2.81(m,
2 H), 2.67 (broad s, 1 H), 2.07(m, 2 H), 1.27 (d, J = 6.5 Hz, 3 H).
20 ##STR00364## 4 2.45 414 8.57 (d, J = 4.4 Hz, 1 H), 7.62 (dd,J =
1.6 and 6.5 Hz, 1 H), 7.27 (m,2 H), 7.15 (dd, J = 1.2 and 5.5 Hz,1
H), 6.96 (m, 3 H), 6.88 (dd, J =2.4 and 8.5 Hz, 1 H), 4.22 (m, 1
H),4.02 (dd, J = 3.0 and 9.5 Hz, 1 H),3.85 (s, 3 H), 3.86 (dd, J =
1.0 and9.6 Hz, 1 H), 3.50 (t, J = 6.8 Hz,2 H), 3.22 (t, J = 6.8 Hz,
2 H), 2.98(broad s, 1 H), 1.27 (d, J = 8.6 Hz,3 H). 21
MCPBAoxidationof Ex 19 57 3.18 435/437 7.90 (d, J = 8.6 Hz, 2 H),
7.65 (d, J =4.2 Hz, 1 H), 7.44 (d, J = 8.6 Hz,2 H), 7.35 (d, J =
4.2 Hz, 1 H), 6.97(d, J = 8.5 Hz, 1 H), 6.87 (d, J = 2.1Hz, 1 H),
6.84 (dd, J = 2.1 and 8.5Hz, 1 H), 4.23 (m, 1 H), 4.01 (dd, J =2.9
and 9.4 Hz, 1 H), 3.85 (s,3 H), 3.83 (dd, J = 1.1 and 9.4 Hz,1 H)
1.27 (d, J = 6.4 Hz, 3 H). 22 MCPBAoxidationof Ex 19 10 3.18
451/453 8.12 (d, J = 8.6 Hz, 2 H), 7.60 (d, J =6.1 Hz, 1 H), 7.51
(d, J = 6.1 Hz,1 H), 7.50 (d, J = 8.6 Hz, 2 H), 6.96(d, J = 8.6 Hz,
1 H), 6.90 (d, J = 2.4Hz, 1 H), 6.84 (dd, J = 2.4 and 8.6Hz, 1 H),
4.23 (m, 1 H), 4.01 (dd, J =3.0 and 9.5 Hz, 1 H), 3.86 (s,3 H),
3.84 (dd, J = 1.2 and 9.5 Hz,1 H) 1.28 (d, J = 6.0 Hz, 3 H). 23
MCPBAoxidationof Ex 20 17 2.96 445 7.52 (d, J = 4.1 Hz, 1 H), 7.40
(d, J =4.1 Hz, 1 H), 7.20 (m, 5 H),7.00 (d, J = 8.6 Hz, 1 H), 6.90
(d, J =2.5 Hz, 1 H), 6.81 (dd, J = 2.5and 8.6 Hz, 1 H) 4.25 (m, 1
H), 4.05(dd, J = 3.1 and 9.5 Hz, 1 H), 3.88(s, 3 H), 3.86 (m, 3 H),
3.20 (t, H =7.8 Hz, 2 H), 1.29 (d, J = 6.2 Hz,3 H). 24
MCPBAoxidationof Ex 20 61 3.02 429 7.65 (d, J = 6.2 Hz, 1 H), 7.30
(d, J =6.2 Hz, 1 H), 7.20 (m, 5 H), 6.99(d, J = 8.4 Hz, 1 H), 6.85
(d, J = 1.0Hz, 1 H), 6.84 (dd, J = 1.0 and 8.4Hz, 1 H) 4.25 (m, 1
H), 4.02 (dd, J =2.9 and 9.6 Hz, 1 H), 3.87 (s,3 H), 3.85 (dd, J =
1.2 and 9.6 Hz,1 H), 3.61 (m, 2 H), 3.53 (m, 1 H),3.17 (m, 2 H),
1.28 (d, J = 6.8 Hz,3 H). 25 ##STR00365## 2a 33 4.11 427 7.28 (m, 7
H), 6.97 (d, J = 2.3 Hz,1 H), 6.97 (d, J = 8.5 Hz, 1 H), 6.88(dd, J
= 2.3, 8.5 Hz, 1 H), 3.86 (s,5 H), 3.33 (dd, J = 7.6 and 8.8 Hz,2
H), 3.02 (dd, J = 5.9 and 8.8 Hz,2 H), 1.36 (s, 6 H). 26
##STR00366## 2a 10 3.8 445 7.25 (d, J = 4.4 Hz, 1 H), 7.17 (m,2 H),
6.94 (m, 5 H), 6.84 (dd, J =2.2 and 8.5 Hz, 1 H), 3.82 (s, 3
H),3.77 (s, 2 H), 3.23 (t, J = 7.4 Hz,2 H), 2.91 (t, J = 7.4 Hz, 2
H), 1.27(s, 6 H) 27 ##STR00367## 2a 29 2.67 428 8.57 (d, J = 4.2
Hz, 1 H), 7.62 (dd,J = 5.9 and 7.6 Hz, 1 H), 7.27 (m,2 H), 7.15 (m,
1 H), 6.97 (m, 3 H),6.88 (dd, J = 2.3, 8.4 Hz, 1 H), 3.85(s, 5 H),
3.50 (t, J = 7.2 Hz, 2 H),3.22 (t, J = 7.2 Hz, 2 H), 1.36 (s,6 H).
28 ##STR00368## 2a 31 2.74 428 8.68 (d, J = 6.1 Hz, 2 H), 7.97 (d,
J =6.1 Hz, 2 H), 7.29 (d, J = 5.4 Hz,1 H), 7.21 (d, J = 5.4 Hz, 1
H), 7.00(d, J = 2.0 Hz, 1 H), 6.98 (d, J = 8.8Hz, 1 H), 6.86 (dd, J
= 2.0 and 8.8Hz, 1 H), 3.77 (s, 3 H), 3.75 (s, 2 H),3.42 (t, J =
7.2 Hz, 2 H), 3.30 (t, J =7.2 Hz, 2 H), 1.24 (s, 6 H). 29
##STR00369## 2a 12 4.02 518 8.94 (d, J = 4.5 Hz, 1 H), 8.36 (d, J
=8.8 Hz, 1 H), 8.32 (s, 1 H), 7.92(d, J = 4.5 Hz, 1 H), 7.74 (dd, J
=1.5 and 8.9 Hz, 1 H), 7.21 (d, J =4.4 Hz, 1 H), 7.06 (d, J = 2.3
Hz,1 H), 7.00 (d, J = 8.6 Hz, 1 H), 6.92(dd, J = 2.3 and 8.6 Hz, 1
H), 6.90(d, J = 4.4 Hz, 1 H), 3.79 (s, 3 H),3.75 (s, 2 H), 1.24 (s,
6 H). 30 ##STR00370## 2a 50 3.76 433/435 7.67 (dd, J = 1.4 and 7.5
Hz, 1 H),7.56 (dd, J = 1.2 and 8.0 Hz, 1 H),7.42 (dt, J = 1.4 and
7.5 Hz, 1 H),7.36 (dt, J = 1.2 and 7.5 Hz, 1 H),7.11 (d, J = 4.5
Hz, 1 H), 7.01 (d, J =2.3 Hz, 1 H), 6.96 (d, J = 8.4 Hz,1 H), 6.93
(d, J = 4.5 Hz, 1 H), 6.90(dd, J = 2.3 and 8.4 Hz, 1 H), 3.87(s, 3
H), 3.86 (s, 2 H), 2.72 (broad s,1 H), 1.36 (s, 6 H). 31
##STR00371## 2a 62 3.98 433/435 7.59 (d, J = 1.7 Hz, 1 H), 7.48
(m,1 H), 7.41 (m, 2 H), 7.14 (d, J = 4.5Hz, 1 H), 7.00 (m, 3 H),
6.90 (dd, J =2.4 and 8.5 Hz, 1 H), 3.87 (s,3 H), 3.86 (s, 2 H),
2.71 (broad s,1 H), 1.36 (s, 6 H). 32 ##STR00372## 2a 58 4.00
433/435 7.52 (dd, J = 1.9 and 6.7 Hz, 2 H),7.43 (dd, J = 1.9 and
6.7 Hz, 2 H),7.13 (d, J = 4.4 Hz, 1 H), 6.99 (d, J =2.3 Hz, 1 H),
6.98 (d, J = 4.4 Hz,1 H), 6.96 (d, J = 8.4 Hz, 1 H), 6.90(dd, J =
2.3 and 8.4 Hz, 1 H), 3.87(s, 3 H), 3.86 (s, 2 H), 2.70 (broad s,1
H), 1.36 (s, 6 H). 33 ##STR00373## 2a 70 4.11 449 8.12 (s, 1 H),
7.88 (m, 3 H), 7.61(dd, J = 1.4 and 8.6 Hz, 1 H), 7.53(m, 2 H),
7.09 (d, J = 4.5 Hz, 1 H),7.02 (d, J = 2.3 Hz, 1 H), 6.98 (d, J
=8.5 Hz, 1 H), 6.96 (d, J = 4.5 Hz,1 H), 6.91 (dd, J = 2.3 and 8.5
Hz,1 H), 3.88 (s, 3 H), 3.87 (s, 2 H),2.75 (broad s, 1 H), 1.37 (s,
6 H). 34 ##STR00374## 2a 34 3.72 417 7.56 (m, 2 H), 7.12 (m, 3 H),
6.98(m, 3 H), 6.89 (m, 1 H), 386 (s, 5 H),1.36 (s, 6 H). 35
##STR00375## 2a 39 4.24 441 7.50 (d, J = 8.2 Hz, 2 H), 7.32 (d, J
=8.2 Hz, 2 H), 7.15 (d, J = 4.5 Hz,1 H), 7.02 (d, J = 2.3 Hz, 1 H),
6.97(d, J = 4.5 Hz, 1 H), 6.96 (d, J = 8.5Hz, 1 H), 6.92 (dd, J =
2.3 and 8.5Hz, 1 H), 3.90 (s, 3 H), 3.85 (s, 2 H),2.98 (m, 1 H),
2.85 (broad s, 1 H),1.35 (s, 6 H), 1.24 (d, J = 6.8 Hz,6 H). 36
##STR00376## 2a 16 4.10 467 7.64 (d, J = 9.0 Hz, 2 H), 7.62 (d, J
=9.0 Hz, 2 H), 7.18 (d, J = 4.5 Hz,1 H), 7.04 (d, J = 4.5 Hz, 1 H),
7.00(d, J = 2.2 Hz, 1 H), 6.98 (d, J = 8.5Hz, 1 H), 6.86 (dd, J =
2.2 and 8.5Hz, 1 H), 3.75 (s, 3 H), 3.73 (s, 2 H),1.22 (s, 6 H). 37
##STR00377## 2a 50 3.96 445 7.48 (d, J = 8.4 Hz, 2 H), 7.30 (d, J
=8.4 Hz, 2 H), 7.28 (d, J = 4.5 Hz,1 H), 7.12 (d, J = 4.5 Hz, 1 H),
6.99(d, J = 8.5 Hz, 1 H), 6.96 (d, J = 2.4Hz, 1 H), 6.89 (dd, J =
2.4 and 8.5Hz, 1 H), 3.86 (s, 5 H), 2.51 (s, 3 H),1.35 (s, 6 H). 38
##STR00378## 2a 52 4.15 483 7.62 (d, J = 8.6 Hz, 2 H), 7.30 (d, J
=8.6 Hz, 2 H), 7.16 (d, J = 4.4 Hz,1 H), 7.06 (d, J = 4.4 Hz, 1 H),
7.00(d, J = 8.5 Hz, 1 H), 6.98 (d, J = 2.3Hz, 1 H), 6.93 (dd, J =
2.3 and 8.5Hz, 1 H), 3.91 (s, 3 H), 3.86 (s, 2 H),1.36 (s, 6 H). 39
##STR00379## 2a 60 3.72 429 7.37 (t, J = 8.0 Hz, 1 H), 7.18 (d, J
=8.0 Hz, 1 H), 7.14 (m, 2 H), 6.98(m, 4 H), 6.90 (m, 1 H), 3.86
(s,5 H), 3.77 (s, 3 H), 1.36 (s, 6 H). 40 ##STR00380## 2a 49 3.88
467 7.84 (d, J = 7.5 Hz, 1 H), 7.71 (d, J =7.5 Hz, 1 H), 7.62 (t, J
= 7.5 Hz,1 H), 7.60 (t, J = 7.5 Hz, 1 H), 7.05(d, J = 4.4 Hz, 1 H),
7.01 (d, J = 2.4Hz, 1 H), 6.98 (d, J = 8.5 Hz, 1 H),6.97 (d, J =
4.4 Hz, 1 H), 6.90 (dd,J = 2.4 and 8.5 Hz, 1 H), 3.88 (s,3 H), 3.86
(s, 2 H), 1.36 (s, 6 H). 41 ##STR00381## 2a 50 4.20 447/449 7.48
(d, J = 8.4 Hz, 1 H), 7.36 (d, J =2.0 Hz, 1 H), 7.24 (dd, J =
2.0and 8.4 Hz, 1 H), 7.10 (d, J = 4.5Hz, 1 H), 7.00 (d, J = 2.4 Hz,
1 H),6.98 (d, J = 8.5 Hz, 1 H), 6.96 (d, J =4.5 Hz, 1 H), 6.90 (dd,
J = 2.4and 8.5 Hz, 1 H), 3.88 (s, 3 H), 3.87(s, 2 H), 2.40 (s, 3
H), 1.38 (s, 6 H). 42 ##STR00382## 2a 60 4.04 427 7.44 (d, J = 7.9
Hz, 1 H), 7.19 (s,1 H), 7.11 (d, J = 4.5 Hz, 1 H), 7.08(d, J = 7.9
Hz, 1 H), 7.01 (d, J = 2.3Hz, 1 H), 6.97 (d, J = 8.6 Hz, 1 H),6.93
(d, J = 4.5 Hz, 1 H), 6.90 (dd,J = 2.3 and 8.6 Hz, 1 H), 3.87 (s,3
H), 3.86 (s, 2 H), 2.39 (s, 3 H),2.37 (s, 3 H), 1.36 (s, 6 H). 43
##STR00383## 2a 60 3.87 413 7.46 (d, J = 8.0 Hz, 2 H), 7.27 (d,
J
=8.0 Hz, 2 H), 7.15 (d, J = 4.4 Hz,1 H), 7.01 (d, J = 2.3 Hz, 1 H),
6.97(d, J = 8.5 Hz, 1 H), 6.96 (d, J = 4.4Hz, 1 H), 6.92 (dd, J =
2.3 and 8.5Hz, 1 H), 3.91 (s, 3 H), 3.85 (s, 2 H),2.40 (s, 3 H),
1.35 (s, 6 H). 44 ##STR00384## 2a 39 3.71 429 7.48 (d, J =8.7 Hz, 2
H), 7.14 (d, J =4.5 Hz, 1 H), 7.00 (d, J = 2.3 Hz,1 H), 6.99 (d, J
= 8.0 Hz, 2 H), 6.97(d, J = 4.5 Hz, 1 H), 6.97 (d, J = 8.5Hz, 1 H),
6.92 (dd, J = 2.3 and 8.5Hz, 1), 3.89 (s, 3 H), 3.85 (s, 5 H),1.35
(s, 6 H). 45 ##STR00385## 2a 64 4.05 427 7.45 (d, J = 8.3 Hz, 2 H),
7.25 (d, J =8.3 Hz, 2 H), 7.11 (d, J = 3.9 Hz,1 H), 6.97 (d, J =
2.2 Hz, 1 H), 6.93(d, J = 8.2 Hz, 1 H), 6.92 (d, J = 3.9Hz, 1 H),
6.87 (dd, J = 2.2 and 8.2Hz, 1 H), 3.86 (s, 3 H), 3.81 (s, 2
H),2.66 (q, J = 5.5 Hz, 2 H), 1.31 (s,6 H), 1.22 (t, J = 5.5 Hz, 3
H). 46 ##STR00386## 2a 29 4.25 441 7.27 (m, 5 H), 7.20 (m, 1 H),
6.92(m, 3 H), 6.85 (dd, J = 2.2, 8.0 Hz,1 H), 3.97 (m, 1 H), 3.84
(s, 3 H),3.81 (s, 2 H), 3.16 (dd, J = 2.0 and8.0 Hz, 1 H), 2.74
(dd, J = 5.0 and8.0 Hz, 1 H), 1.33 (s, 6 H), 1.32 (d,J = 9.3 Hz, 3
H). 47 ##STR00387## 2a 59 4.31 441 7.30 (m, 1 H), 7.21 (m, 1 H),
7.11(m, 1 H), 7.05 (m, 1 H), 6.97 (m,4 H), 6.89 (m, 1 H), 3.87 (s,
3 H),3.84 (s, 2 H), 3.31 (dd, J = 6.0 and8.3 Hz, 2 H), 2.98 (t, J =
8.3 Hz,2 H), 2.35 (s, 3 H), 1.35 (s, 6 H) 48 ##STR00388## 2a 88
4.30 441 7.26 (d, J = 4.4 Hz, 1 H), 7.19 (d, J =7.2 Hz, 1 H), 7.10
(m, 3 H), 6.95(m, 3 H), 6.84 (dd, J = 2.2 and 8.2Hz, 1 H), 3.83 (s,
3 H), 3.79 (s, 2 H),3.22 (dd, J = 5.7 and 8.5 Hz, 2 H),2.96 (dd, J
= 5.5 and 8.5 Hz, 2 H),2.34 (s, 3 H), 1.29 (s, 6 H). 49
##STR00389## 2a 51 3.62 399 7.52 (m, 2 H), 7.39 (m, 3 H), 7.05(d, J
= 4.4 Hz, 1 H), 6.92 (d, J = 2.4Hz, 1 H), 6.90 (d, J = 8.4 Hz, 1
H),6.89 (d, J = 4.4 Hz, 1 H), 6.83 (dd,J = 2.4 and 8.4 Hz, 1 H),
3.80 (s,3 H), 3.79 (s, 2 H), 1.29 (s, 6 H). 50 ##STR00390## 2a 51
3.95 413 7.43 (d, J = 7.1 Hz, 2 H), 7.30 (m,4 H), 6.96 (m, 3 H),
6.88 (dd, J =2.4 and 8.5 Hz, 1 H), 4.33 (s, 2 H),3.87 (s, 3 H),
3.84 (s, 2 H), 1.35 (s,6 H). 51 ##STR00391## 2a 6 3.63 468 8.89 (s,
1 H), 8.17 (d, J =7.2 Hz,1 H), 8.10 (d, J = 7.2 Hz, 1 H), 7.45(d, J
= 4.4 Hz, 1 H), 7.30 (d, J = 4.4Hz, 1 H), 7.15 (d, J = 2.4 Hz, 1
H),7.12 (d, J = 8.6 Hz, 1 H), 7.01 (dd,J = 2.4 and 8.6 Hz, 1 H),
3.91 (s,3 H), 3.87 (s, 2 H), 1.35 (s, 6 H). 52 ##STR00392## 2a 50
4.02 433/435 7.67 (dd, J = 1.4 and 7.5 Hz, 1 H),7.56 (dd, J = 1.2
and 8.0 Hz, 1 H),7.42 (dt, J = 1.4 and 7.5 Hz, 1 H),7.36 (dt, J =
1.2 and 7.5 Hz, 1 H),7.11 (d, J = 4.5 Hz, 1 H), 7.01 (d, J =2.3 Hz,
1 H), 6.96 (d, J = 8.4 Hz,1 H), 6.93 (d, J = 4.5 Hz, 1 H), 6.90(dd,
J = 2.3 and 8.4 Hz, 1 H), 3.87(s, 3 H), 3.86 (s, 2 H), 2.72 (broad
s,1 H), 1.36 (s, 6 H). 53 ##STR00393## 2a 62 3.76 433/435 7.59 (d,
J = 1.7 Hz, 1 H), 7.48 (m,1 H), 7.41 (m, 2 H), 7.14 (d, J = 4.5Hz,
1 H), 7.00 (m, 3 H), 6.90 (dd, J =2.4 and 8.5 Hz, 1 H), 3.87 (s,3
H), 3.86 (s, 2 H), 2.71 (broad s,1 H), 1.36 (s, 6 H). 54
##STR00394## 2a 58 3.98 433/435 7.52 (dd, J = 1.9 and 6.7 Hz, 2
H),7.43 (dd, J = 1.9 and 6.7 Hz, 2 H),7.13 (d, J = 4.4 Hz, 1 H),
6.99 (d, J =2.3 Hz, 1 H), 6.98 (d, J = 4.4 Hz,1 H), 6.96 (d, J =
8.4 Hz, 1 H), 6.90(dd, J = 2.3 and 8.4 Hz, 1 H), 3.87(s, 3 H), 3.86
(s, 2 H), 2.70 (broad s,1 H), 1.36 (s, 6 H). 55 ##STR00395## 2a 50%
2.74 442 7.67 (t, J = 7.7 Hz, 1 H), 7.38 (d, J =4.4 Hz, 1 H), 7.25
(d, J = 4.4 Hz,1 H), 7.16 (m, 2 H), 7.10 (d, J = 2.4Hz, 1 H), 7.08
(d, J = 8.6 Hz, 1 H),6.95 (dd, J = 2.4 and 8.6 Hz, 1 H),3.89 (s, 3
H), 3.86 (s, 2 H), 3.45 (t, J =7.1 Hz, 2 H), 3.15 (t, J = 7.1 Hz,2
H), 2.53 (s, 3 H), 1.34 (s, 6 H). 56 ##STR00396## 2a 44% 3.03 442
7.40 (d, J = 8.9 Hz, 2 H), 7.13 (d, J =4.8 Hz, 1 H), 7.00 (d, J =
2.3 Hz,1 H), 6.97 (d, J = 8.5 Hz, 1 H), 6.92(d, J = 4.8 Hz, 1 H),
6.90 (dd, J =2.3 and 8.5 Hz, 1 H), 6.76 (d, J =8.9 Hz, 2 H), 3.87
(s, 3 H), 3.86 (s,2 H), 3.01 (s, 6 H), 1.36 (s, 6 H). 57
##STR00397## 5 3 3.68 486 7.77 (d, J = 8.8 Hz, 1 H), 7.57 (d, J
=2.5 Hz, 1 H), 7.37 (d, J = 4.4 Hz,1 H), 7.14 (d, J = 4.4 Hz, 1 H),
7.08(dd, J = 2.5, 8.8 Hz, 1H, 7.02 (m,2 H), 6.93 (dd, J = 2.5, 8.5
Hz, 1 H),3.92 (s, 3 H), 3.90 (s, 2 H), 1.39 (s,6 H). 58
##STR00398## 5 3.64 456 7.93 (d, J = 8.3 Hz, 1 H), 7.87 (d, J =8.1
Hz, 1 H), 7.43 (t, J = 8.2 Hz,1 H), 7.35 (m, 3 H), 7.07 (d, J =
2.3Hz, 1 H), 7.01 (d, J = 8.6 Hz, 1 H),6.93 (dd, J = 2.3 and 8.5
Hz, 1 H),3.79 (s, 3 H), 3.76 (s, 2 H), 1.24 (s,6 H). 59
##STR00399## 5 3.99 490/492 7.87 (d, J = 8.6 Hz, 1 H), 7.79 (d, J
=2.0 Hz, 1 H), 7.38 (dd, J = 2.0and 8.6 Hz, 1 H), 7.30 (d, J =
4.4Hz, 1 H), 7.08 (d, J = 4.4 Hz, 1 H),6.92 (d, J = 2.5 Hz, 1 H),
6.91 (d, J =8.6 Hz, 1 H), 6.85 (dd, J = 2.5and 8.6 Hz, 1 H), 3.80
(s, 5 H), 1.30(s, 6 H). 60 ##STR00400## 5 3.67 474/476 7.71 (d, J =
2.0, 1 H), 7.45 (d, J =8.7 Hz, 1 H), 7.32 (dd, J = 2.0 and8.7 Hz, 1
H), 7.11 (d, J = 4.4 Hz,1 H), 7.04 (d, J = 4.4 Hz, 1 H), 6.91(d, J
= 8.6 Hz, 1 H), 6.90 (d, J = 2.4Hz, 1 H), 6.84 (dd, J = 2.4 and
8.6Hz, 1 H), 3.81 (s, 3 H), 3.79 (s, 2 H),1.29 (s, 6 H). 61
##STR00401## 5 2.68 439 7.71 (dd, J = 3.1 and 6.2 Hz, 2 H),7.49
(dd, J = 3.1 and 6.2 Hz, 2 H),7.43 (d, J = 4.4 Hz, 1 H), 7.22 (d, J
=4.4 Hz, 1 H), 7.04 (d, J = 2.5 Hz,1 H), 7.01 (d, J = 8.5 Hz, 1 H),
6.91(dd, J = 2.4 and 8.5 Hz, 1 H), 3.79(s, 3 H), 3.75 (s, 2 H),
1.24 (s, 6 H). 62 ##STR00402## 5 4.11 484 7.68 (d, J = 8.8 Hz, 1
H), 7.46 (d, J =2.4 Hz, 1 H), 7.27 (d, J = 4.4 Hz,1 H), 7.16 (m, 2
H), 7.04 (d, J = 4.4Hz, 1 H), 7.00 (dd, J = 2.5 and 8.7Hz, 1 H),
6.85 (d, J = 9.4 Hz, 1 H),3.82 (s, 3 H), 3.78 (s, 2 H), 2.65 (q,J =
7.5 Hz, 2 H), 1.32 (s, 6 H), 1.15(t, J = 7.5 Hz, 3 H). 63
##STR00403## 2a 4.05 465 7.64 (d, J = 8.5 Hz, 2 H), 7.62 (d, J =8.5
Hz, 2 H), 7.15 (m, 2 H) 7.04(d, J = 4.4 Hz, 1 H), 6.93 (d, J =
4.4Hz, 1 H), 6.84 (d, J = 9.2 Hz, 1 H),3.77 (s, 2 H), 2.63 (q, J =
7.5 Hz,2 H), 1.30 (s, 6 H), 1.17 (t, J = 7.5Hz, 3 H) 64
##STR00404## 2a 4.15 481 7.43 (d, J = 8.8 Hz, 2 H), 7.31 (d, J =8.8
Hz, 2 H), 7.24 (d, J = 2.4 Hz,1 H), 7.22 (d, J = 8.5 Hz, 1 H),
7.14(d, J = 4.4 Hz, 1 H), 7.00 (d, J = 4.4Hz, 1 H), 6.94 (dd, J =
2.4, 8.5 Hz,1 H), 3.86 (s, 2 H), 2.74 (q, J = 7.5Hz, 2 H), 1.41 (s,
6 H), 1.26 (t, J =7.5 Hz, 3 H). 65 ##STR00405## 2a 4.08Method 2 425
7.10 (m, 8 H), 6.84 (d, J = 4.4 Hz,1 H), 6.76 (d, J = 8.5 Hz, 1 H),
3.70(s, 2 H), 3.21 (m, 2 H), 2.90 (m,2 H), 2.59 (q, J = 7.4 Hz, 2
H), 1.26(s, 6 H), 1.12 (t, J = 7.4 Hz, 3 H) 66 ##STR00406## 2a 3.81
439 7.23 (m, 5 H), 7.14 (m, 1 H), 6.92(m, 3 H), 6.83 (dd, J = 2.4,
8.6 Hz),4.08 (dd, J = 2.6, 9.7 Hz, 1 H), 3.93(t, J = 8.2 Hz, 1 H),
3.80 (s, 3 H),3.25 (m, 3 H), 2.94 (m, 2 H), 0.88(m, 1 H), 0.57 (m,
1 H), 0.51 (m,1 H), 0.36 (m, 1 H), 0.22 (m, 1 H) 67 ##STR00407## 2a
3.87 495 7.54 (d, J = 8.8 Hz, 2 H), 7.21 (d, J =8.8 Hz, 2 H), 7.05
(d, J = 4.4 Hz,1 H), 6.93 (d, J = 8.5 Hz, 1 H), 6.92(d, J = 2.4 Hz,
1 H), 6.91 (d, J = 4.4Hz, 1 H), 6.84 (dd, J = 2.4, 8.5 Hz,1 H) 4.13
(dd, J = 2.8, 9.7 Hz, 1 H),3.96 (dd, J = 1.3, 8.2 Hz, 1 H), 3.79(s,
3 H), 3.29 (dt, J = 2.5, 9.8 Hz,1 H), 0.93 (m, 1 H), 0.57 (m, 1
H),0.51 (m, 1 H), 0.41 (m, 1 H), 0.25(m, 1 H) 68 ##STR00408## 2a
3.74Method 2 479 7.66 (d, J = 8.5 Hz, 2 H), 7.64 (d, J =8.5 Hz, 2
H), 7.51 (d, J = 4.4 Hz,1 H), 7.09 (d, J = 4.4 Hz, 1 H), 7.00(d, J
= 8.2 Hz, 1 H), 6.98 (d, J = 2.2Hz, 1 H), 6.89 (dd, J = 2.2, 8.2
Hz,1 H), 4.22 (dd, J = 2.2, 9.3 Hz, 1 H),3.96 (dd, J = 1.1, 9.4 Hz,
1 H), 3.84(s, 3 H), 3.27 (dt, J = 2.5, 9.8 Hz,1 H), 0.93 (m, 1 H),
0.57 (m, 1 H),0.51 (m, 1 H), 0.41 (m, 1 H), 0.25(m, 1 H) 69
##STR00409## 2a 3.59Method 2 481 7.64 (m, 4 H), 7.06 (d, J = 4.4
Hz,1 H), 6.98 (d, J = 2.8 Hz, 1 H), 6.95(d, J = 9.7 Hz, 1 H), 6.93
(d, J = 4.4Hz, 1 H), 6.86 (dd, J = 2.8 and 9.7Hz, 1 H), 4.63 (m, 1
H), 4.34 (m,1 H), 4.09 (m, 1 H), 3.97 (m, 2 H),3.83 (s, 3 H), 3.78
(m, 1 H), 3.07 (d,J = 6.4 Hz, 1 H). 70 ##STR00410## 2a 3.87Method 2
479 7.62 (m, 4 H), 7.05 (d, J = 4.5 Hz,1 H), 6.95 (d, J = 8.5 Hz, 1
H), 6.93(d, J = 4.5 Hz, 1 H), 6.92 (d, J = 2.4Hz, 1 H), 6.83 (dd, J
= 2.4 and 8.5Hz, 1 H), 4.42 (m, 1 H), 4.13 (m,1 H), 3.75 (s, 3 H),
3.04 (m, 1 H),1.99 (m, 1 H), 1.70 to 1.90 (m, 4 H),1.52 (m, 1 H).
71 ##STR00411## 2a 3.74Method 2 453 7.85 (d, J = 8.4 Hz, 2 H), 7.80
(d, J =8.4 Hz, 2 H), 7.48 (d, J = 4.4 Hz,1 H), 7.16 (d, J = 4.4 Hz,
1 H), 7.15(d, J = 2.4 Hz, 1 H), 7.10 (d, J = 8.6Hz, 1 H), 7.01 (dd,
J = 2.4, 8.6 Hz,1 H), 3.97 (m, 1 H), 3.90 (m, 1 H),3.81 (m, 1 H),
3.78 (s, 3 H), 1.16 (d,3 H) 72 ##STR00412## 2a 3.72Method 2 483
7.64 (m, 4 H), 7.06 (d, J = 4.5 Hz,1 H), 6.96 (d, J = 8.5 Hz, 1 H),
6.94(d, J = 4.5 Hz, 1 H), 6.92 (d, J = 2.5Hz, 1 H), 6.84 (dd, J =
2.5, 8.5 Hz,1 H), 4.04 (m, 2 H), 3.81 (s, 3 H),3.50 (m, 2 H), 3.36
(s, 3 H) 73 ##STR00413## 2a 3.62Method 2 545 7.63 (m, 4 H), 7.06
(d, J = 4.4 Hz,2 H), 6.94 (d, J = 4.4 Hz, 1 H), 6.92(d, J = 2.0 Hz,
1 H), 6.90 (d, J = 8.5Hz, 1 H), 6.83 (dd, J = 2.0 and 8.5Hz, 1 H),
4.54 (m, 1 H), 4.02 (d, J =5.4 Hz, 2 H), 3.78 (s, 3 H), 3.62 (m,1
H), 3.0 to 3.40 (m, 3 H), 1.86 (m,1 H), 1.38 (t, J = 7.4 Hz, 3 H).
74 ##STR00414## 2a 507 3.90 (s, 3 H), 4.14-4.22 (m, 1 H),4.32 (dd,
J = 10.45, 3.65 Hz, 1 H),4.36-4.47 (m, 1 H), 7.03 (dd,J = 8.56,
2.27 Hz, 1 H), 7.14-7.22(m, 3 H), 7.34 (d, J = 4.28 Hz, 1
H),7.74-7.83 (m, 4 H) 75 ##STR00415## 2a 531 .sup.1H NMR (400 MHz,
MeOD) .delta.ppm 7.69 (d, 2 H), 7.38 (d, 2 H),7.33 (d, 1 H), 7.18
(m, 3 H), 7.03 (d,1 H), 4.09 (s, 2 H), 3.91 (s, 3 H),2.93 (m, 2 H),
2.66 (m, 2 H). 76 ##STR00416## 2a 515 .sup.1H NMR (400 MHz, MeOD)
.delta.ppm 7.78 (s, 4 H), 7.34 (s, 1 H),7.19 (m, 3 H), 7.03 (d, 1
H), 4.09 (s,2 H), 3.90 (s, 3 H), 2.93_m, 2 H),2.66 (m, 2 H). 77
##STR00417## 2a 474 .sup.1H NMR (400 MHz, MeOD) .delta.ppm 7.78 (d,
1 H), 7.53 (m, 3 H),7.30 (m, 1 H), 7.20 (s, 1 H), 7.12 (m,1 H),
7.06 (d, 1 H), 3.91 (s, 3 H),3.88 (s, 2 H), 1.36 (s, 6 H). 78
##STR00418## 2a 474 .sup.1H NMR (400 MHz, MeOD) .delta.ppm 7.85 (d,
1 H), 7.53 (m, 3 H),7.21 (m, 4 H), 3.91 (s, 3 H), 3.88 (s,2 H),
1.36 (s, 6 H). 79 ##STR00419## 2a 474 .sup.1H NMR (400 MHz, MeOD)
.delta.ppm 7.97 (d, 1 H), 7.85 (d, 1 H),7.53 (d, 2 H), 7.35 (t, 1
H), 7.21 (s,1 H), 7.16 (m, 1 H), 7.07 (m, 1 H),3.91 (s, 3 H), 3.88
(s, 2 H), 1.36 (s,6 H). 80 ##STR00420## 6 479 .sup.1H NMR (400 MHz,
MeOD) .delta.ppm 7.68 (d, 2 H), 7.40 (d, 2 H),7.28 (s, 1 H), 7.17
(m, 3 H), 6.97 (d,1 H), 3.82 (s, 1 H), 2.96 (m, 2 H),2.24 (m, 1 H),
2.81 (m, 1 H), 1.33 (s,6 H). 81 ##STR00421## 6 491 .sup.1H NMR (400
MHz, MeOD) .delta.ppm 7.69 (d, 2 H), 7.40 (d, 2 H),7.28 (m, 2 H),
7.20 (m, 2 H), 6.91 (d,1 H), 5.79 (s, 1 H), 4.70 (s, 1 H),2.08 (s,
2 H), 1.31 (d, 6 H). 82 ##STR00422## 6 495 .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta.ppm 7.61 (d, 2 H), 7.59 (s, 1 H),7.28 (m, 2 H),
7.14 (m, 2 H), 6.99 (s,1 H), 6.92 (d, 1 H), 4.87 (t, 1 H),4.00 (d,
1 H), 2.36 (m, 1 H), 1.84 (q,1 H), 1.38 (d, 6 H). 83 ##STR00423## 6
433(M + H -H.sub.2O) .sup.1H NMR (400 MHz, MeOD) .delta.ppm 7.70
(d, 2 H), 7.61 (s, 1 H),7.43 (d, 2 H), 7.28 (m, 2 H), 7.20 (s,1 H),
6.95 (d, 1 H), 4.35 (m, 2 H),2.12 (br-s, 2 H), 1.62 (s, 3 H). 84
##STR00424## 6 453 1H NMR (500 MHz, chloroform-d) .delta. ppm 7.62
(2 H, d, J = 8.80 Hz),7.36 (2 H, d, J = 8.80 Hz), 7.29 (2 H,d, J =
7.97 Hz), 7.13 (1 H, d,J = 4.67 Hz), 7.04 (2 H, d J = 8.80Hz), 6.98
(1 H, d, J = 4.40 Hz), 3.84(2 H, s), 1.37 (6 H, s). 85 ##STR00425##
6 449 1H NMR (500 MHz, chloroform-d) .delta. ppm 8.31 (1 H, dd, J =
6.19,3.44 Hz), 8.00 (1 H, d, J = 8.25 Hz),7.85-7.95 (2 H, m),
7.51-7.56(3 H, m), 7.04 (1 H, d, J = 2.20 Hz),6.97-7.02 (1 H, m),
6.89-6.96 (3 H,m), 3.90 (3 H, s), 3.88 (2 H, s),1.37 (6 H, s). 86
##STR00426## 6 471 1H NMR (500 MHz, methanol-d.sub.3).delta. ppm
7.62-7.68 (2 H, m),7.34-7.39 (3 H, m), 7.21-7.29 (3 H,m), 7.15 (1
H, d, J = 4.40 Hz), 3.91(2 H, s), 1.34 (6 H, s). 87 ##STR00427## 6
467 1H NMR (500 MHz, methanol-d.sub.3).delta. ppm 7.62-7.69 (2 H,
m), 7.36 (2 H,d, J = 7.97 Hz), 7.21-7.28 (3 H,m), 7.15 (1 H, d, J =
4.40 Hz), 7.02(1 H, d, J = 8.52 Hz), 3.84 (2 H, s),2.31 (3 H, s),
1.36 (6 H, s). 88 ##STR00428## 6 487 1H NMR (500 MHz,
methanol-d.sub.3).delta. ppm 7.65 (2 H, d, J = 8.80 Hz),7.59 (1 H,
d, J = 2.75 Hz), 7.33-7.41(3 H, m), 7.27 (1 H, d, J = 4.40Hz), 7.22
(1 H, d, J = 8.80 Hz), 7.15(1 H, d, J = 4.40 Hz), 3.91 (2 H,
s),1.37 (6 H, s) 89 ##STR00429## 6 537 1H NMR (500 MHz,
methanol-d.sub.3).delta. ppm 7.66 (2 H, d), 7.52-7.56 (1 H,m), 7.46
(1 H, dd, J = 8.94, 2.61Hz), 7.37 (2 H, d, J = 7.97 Hz), 7.33(1 H,
d, J = 8.80 Hz), 7.29 (1 H, d,J = 4.40 Hz), 7.16 (1 H, d, J =
4.67Hz), 3.91 (2 H, s), 1.34 (6 H, s). 90 ##STR00430## 6 478 1H NMR
(500 MHz, methanol-d.sub.3).delta. ppm 7.85 (1 H, d, J = 2.75
Hz),7.74 (1 H, dd, J = 8.94, 2.61 Hz),7.65 (2 H, d), 7.33-7.39 (3
H, m),7.29 (1 H, d, J = 4.67 Hz), 7.16 (1 H,d, J = 4.40 Hz), 4.01
(2 H, s),1.38 (6 H, s). 91 ##STR00431## 6 489 1H NMR (500 MHz,
methanol-d.sub.3).delta. ppm 7.65 (2 H, d, J = 8.80 Hz),7.37 (2 H,
d, J = 7.97 Hz), 7.24-7.32(3 H, m), 7.15 (1 H, d, J = 4.40Hz), 4.00
(2 H, s), 1.33 (6 H, s).
92 ##STR00432## 6 501 1H NMR (500 MHz, methanol-d.sub.3).delta. ppm
7.65 (2 H, d, J = 8.80 Hz),7.45 (1 H, d, J = 2.75 Hz), 7.37 (2 H,d,
J = 7.97 Hz), 7.30 (1 H, d,J = 1.92 Hz), 7.27 (1 H, d, J = 4.40Hz),
7.15 (1 H, d, J = 4.67 Hz), 3.78(2 H, s), 2.40 (3 H, s), 1.39 (6
H,s). 93 ##STR00433## 6 521 1H NMR (500 MHz,
methanol-d.sub.3).delta. ppm 7.77 (1 H, d, J = 2.47 Hz),7.62-7.71
(3 H, m), 7.35 (3 H, dd,J = 14.57, 8.52 Hz), 7.30 (1 H, d,J = 4.40
Hz), 7.17 (1 H, d, J = 4.40Hz), 3.94 (2 H, s), 1.35 (6 H, s). 94
##STR00434## 6 505 1H NMR (500 MHz, methanol-d.sub.3).delta. ppm
7.65 (2 H, d), 7.46 -7.51 (1 H,m), 7.42 (1 H, dd, J = 11.27,2.47
Hz), 7.37 (2 H, d, J = 7.97 Hz),7.28 (1 H, d, J = 4.40 Hz), 7.15 (1
H,d, J = 4.40 Hz), 3.98 (2 H, s),1.37 (6 H, s). 95 ##STR00435## 6
452 1H NMR (500 MHz, chloroform-d) .delta. ppm 8.88 (1 H, s),
7.89-7.99(2 H, m), 7.16-7.24 (3 H, m),7.07 (1 H, d, J = 4.40 Hz),
6.90 (1 H,d, J = 8.52 Hz), 3.84 (2 H, s),2.30 (3 H, s), 1.39 (6 H,
s) 96 ##STR00436## 6 481 1H NMR (400 MHz, chloroform-d) .delta. ppm
7.62 (2 H, d, J = 8.78 Hz),7.29 (2 H, d, J = 8.03 Hz), 7.11 (1 H,d,
J = 4.52 Hz), 7.08 (2 H, s),6.96 (1 H, d, J = 4.52 Hz), 3.64 (2
H,s), 2.33 (6 H, s), 1.39 (6 H, s). 97 ##STR00437## 6 477 1H NMR
(400 MHz, MeOD) .delta.ppm 7.68 (d, 2 H), 7.39 (d, 2 H),7.28 (d, 1
H), 7.18 (m, 3 H),6.93 (d,1 H), 6.49 (s, 1 H), 1.42 (s,6 H). 98
##STR00438## 6 481 1H NMR (400 MHz, MeOD) .delta.ppm 7.69 (2 H, d),
7.39 (2 H, d,J = 8.03 Hz), 7.18 (2 H, dd), 7.08 (1 H,d, J = 8.53
Hz), 6.93 (1 H, d,J = 8.78 Hz), 3.84 (2 H, s), 2.30 (3 H,s), 2.02
(3 H, s), 1.38 (6 H, s). 99 ##STR00439## 6 441 1H NMR (500 MHz,
chloroform-d) .delta. ppm 7.23-7.31 (2 H, m),7.16-7.23 (2 H, m),
7.07 (1 H, d,J = 7.42 Hz), 6.98-7.04 (1 H, m),6.88-6.98 (3 H, m),
4.14 (1 H, dd,J = 9.35, 3.30 Hz), 4.04 (1 H, dd,J = 9.35, 7.15 Hz),
3.26-3.40 (3 H,m), 2.97-3.06 (2 H, m), 2.27 (3 H,s), 0.99-1.10 (1
H, m), 0.55-0.68(2 H, m), 0.43-0.51 (1 H,m), 0.30-0.38 (1 H, m) 100
##STR00440## 6 481 1H NMR (400 MHz, chloroform-d) .delta. ppm 7.63
(2 H, dd, J = 8.78,2.26 Hz), 7.30 (2 H, d, J = 7.78 Hz),7.11 (1 H,
dd, J = 4.27, 2.26 Hz),6.98 (1 H, s), 6.84 (1 H, dd,J = 4.52, 2.26
Hz), 6.76 (1 H, s),3.84 (2 H, br. s.), 2.24 (3 H, s),2.14 (3 H, s),
1.39 (6 H, d, J = 2.26Hz). 101 ##STR00441## 6 437 1H NMR (500 MHz,
chloroform-d) .delta. 7.71 (4 H, m), 7.36 (2 H,d, J = 8.80 Hz),
7.13 (1 H, d, J = 4.40Hz), 7.04 (2 H, d, J = 9.35 Hz), 7.00(1 H, d,
J = 4.40 Hz), 3.84 (2 H, s),1.37 (6 H, s). 102 ##STR00442## 6 455
1H NMR (500 MHz, chloroform-d) .delta. ppm 7.71 (4 H, m), 7.26 (1
H,dd, J = 11.00, 2.75 Hz), 7.11-7.19(2 H, m), 7.05-7.11 (1 H,
m),6.98 (1 H, d, J = 4.95 Hz), 3.91 (2 H,s), 1.38 (6 H, s) 103
##STR00443## 6 451 1H NMR (500 MHz, chloroform-d) .delta. ppm
7.67-7.75 (4 H, m),7.18-7.25 (2 H, m), 7.12 (1 H, d,J = 4.40 Hz),
6.99 (1 H, d, J = 4.40Hz), 6.91 (1 H, d, J = 8.25 Hz), 3.85(2 H,
s), 2.31 (3 H, s), 1.39 (6 H, s) 104 ##STR00444## 6 521 1H NMR (500
MHz, chloroform-d) .delta. ppm 7.66-7.78 (4 H, m),7.35-7.42 (2 H,
m), 7.08-7.17 (2 H,m), 6.99 (1 H, d, J = 4.40 Hz), 3.90(2 H, s),
1.38 (6 H, s) 105 ##STR00445## 6 462 1H NMR (500 MHz, chloroform-d)
.delta. ppm 7.60-7.78 (6 H, m),7.09-7.17 (2 H, m), 6.95 (1 H, d,J =
4.40 Hz), 3.97 (2 H, s), 1.43 (6 H,s) 106 ##STR00446## 6 465 1H NMR
(500 MHz, chloroform-d) .delta. ppm 7.71 (4 H, d, J = 6.05
Hz),7.07-7.14 (3 H, m), 6.98 (1 H, d,J = 4.40 Hz), 3.64 (2 H, s),
2.33 (6 H,s), 1.40 (6 H, s) 107 ##STR00447## 6 471 1H NMR (500 MHz,
chlorofrom-d) .delta. ppm 7.67-7.74 (4 H, m), 7.50(1 H, d, J = 2.47
Hz), 7.32 (1 H, dd,J = 8.80, 2.47 Hz), 7.13 (1 H, d,J = 4.67 Hz),
7.03 (1 H, d, J = 8.80Hz), 6.97 (1 H, d, J = 4.40 Hz), 3.91(2 H,
s), 1.40 (6 H, s) 108 ##STR00448## 6 463 1H NMR (500 MHz,
chloroform-d) .delta. ppm 7.64-7.77 (4 H, m),7.19-7.24 (2 H, m),
7.12 (1 H, d,J = 4.40 Hz), 7.00 (1 H, d, J = 4.40Hz), 6.94 (1 H, d,
J = 8.80 Hz), 4.16(1 H, dd J = 9.35, 3.30 Hz), 4.06 (1 H,dd, J =
9.35, 7.15 Hz),3.31-3.42 (1 H, m), 2.29 (3 H, s),0.99-1.11 (1 H,
m), 0.55-0.71 (2 H,m), 0.43-0.52 (1 H, m),0.29-0.41 (1 H, m) 109
##STR00449## 6 479 1H NMR (500 MHz, chloroform-d) .delta. ppm 7.61
(2 H, d), 7.29 (2 H,d, J = 7.97 Hz), 7.19-7.24 (2 H,m), 7.11 (1 H,
d, J = 4.67 Hz), 6.98(1 H, d, J = 4.40 Hz), 6.94 (1 H, d,J = 8.52
Hz), 4.15 (1 H, dd, J = 9.35,3.30 Hz), 4.05 (1 H, dd, J = 9.35,7.15
Hz), 3.30-3.42 (1 H, m),2.28 (3 H, s), 0.99-1.11 (1 H, m),0.55-0.70
(2 H, m), 0.42-0.52 (1 H,m), 0.30-0.39 (1 H, m) 110 ##STR00450## 6
412 1H NMR (400 MHz, MeOD) .delta.ppm 8.67 (1 H, d), 8.48 (1 H,
td,J = 7.91, 1.51 Hz), 8.02 (1 H, d,J = 8.28 Hz), 7.81-7.95 (1 H,
m),7.07-7.29 (4 H, m), 6.93 (1 H, d,J = 8.78 Hz), 3.76 (2 H, s),
3.35-3.57(4 H, m), 2.22 (3 H, s), 1.27(6 H, s) 111 ##STR00451## 6
397 1H NMR (500 MHz, methanol-d.sub.3).delta. ppm 7.32-7.40 (3 H,
m),7.25-7.29 (4 H, m), 7.16-7.23 (2 H,m), 7.08 (2 H, d, J = 8.80
Hz), 3.83(2 H, s), 3.31 (2 H, s), 2.89-3.03(2 H, m), 1.32 (6 H, s)
112 ##STR00452## 6 415 1H NMR (500 MHz, methanol-d.sub.3).delta.
ppm 7.12-7.46 (10 H, m), 3.90(1 H, s), 3.21-3.42 (2 H, m),2.90-3.03
(2 H, m), 1.33 (6 H, s) 113 ##STR00453## 6 411 1H NMR (500 MHz,
methanol-d.sub.3).delta. ppm 7.38 (1 H, d, J = 4.40 Hz),7.25-7.32
(4 H, m), 7.16-7.24 (4 H,m), 7.00 (1 H, d, J = 8.25 Hz),3.83 (1 H,
s), 3.24-3.39 (2 H, m),2.90-3.05 (2 H, m), 2.29 (3 H, s),1.35 (6 H,
s) 114 ##STR00454## 6 431 1H NMR (500 MHz, methanol-d.sub.3).delta.
ppm 7.56 (1 H, d, J = 2.20 Hz),7.33-7.42 (2 H, m), 7.17-7.31 (7
H,m), 3.90 (2 H, s), 3.23-3.42 (2 H,m), 2.89-3.08 (2 H, m), 1.36(6
H, s) 115 ##STR00455## 6 423 1H NMR (500 MHz,
methanol-d.sub.3).delta. ppm 7.37 (1 H, d, J = 4.40 Hz),7.25-7.32
(4 H, m), 7.16-7.23 (4 H,m), 7.03 (1 H, d, J = 9.35 Hz),3.99-4.17
(2 H, m), 3.25-3.39 (3 H,m), 2.91-3.04 (2 H, m), 2.28(3 H, s),
0.98-1.11 (1 H, m),0.51-0.61 (2 H, m), 0.29-0.47 (2 H,m) 116
##STR00456## 6 445 1H NMR (500 MHz, methanol-d.sub.3).delta. ppm
7.30-7.39 (2 H, m),7.20-7.27 (2 H, m), 7.01-7.13 (4 H,m), 6.95 (1
H, dd, J = 8.52, 2.47Hz), 3.86 (2 H, s), 3.24-3.39 (2 H,m),
2.97-3.11 (2 H, m), 1.32(6 H, s) 117 ##STR00457## 6 429 1H NMR (500
MHz, methanol-d.sub.3).delta. ppm 7.29-7.38 (2 H, m),7.17-7.26 (4
H, m), 6.97-7.13 (3 H,m), 3.83 (2 H, s), 3.28-3.36 (2 H,m), 3.04 (2
H, t, J = 7.42 Hz), 2.29(3 H, s), 1.35 (6 H, s) 118 ##STR00458## 6
443 1H NMR (400 MHz, chloroform-d) .delta. ppm 7.16-7.35 (5 H,
m),6.86-7.13 (4 H, m), 3.84 (2 H, s),3.26-3.41 (2 H, m), 3.07 (2 H,
t,J = 7.65 Hz), 2.71 (2 H, q, J = 7.53Hz), 1.32-1.47 (6 H, m), 1.23
(3 H,t, J = 7.65 Hz) 119 ##STR00459## 6 441 1H NMR (500 MHz,
methanol-d.sub.3).delta. ppm 7.28-7.37 (2 H, m),7.16-7.26 (4 H, m),
6.99-7.12 (3 H,m), 3.95-4.18 (2 H, m), 3.22-3.42(3 H, m), 3.04 (2
H, t, J = 7.42Hz), 2.27 (3 H, s), 0.97-1.13 (1 H,m), 0.46-0.63 (2
H, m),0.29-0.46 (2 H, m) 120 ##STR00460## 6 457 1H NMR (500 MHz,
methanol-d.sub.3).delta. ppm 7.20-7.30 (2 H, m),7.11-7.18 (2 H, m),
6.92-7.04 (4 H,m), 6.86 (1 H, dd, J = 8.52, 2.47Hz), 3.85-4.12 (2
H, m), 3.76 (3 H,s), 3.16-3.31 (3 H, m), 2.87-3.03(2 H, m),
0.82-1.00 (1 H,m), 0.38-0.54 (2 H, m),0.18-0.37 (2 H, m) 121
##STR00461## 6 426 1H NMR (400 MHz, MeOD) .delta.ppm 8.29 (1 H, d,
J = 4.02 Hz), 7.60(1 H, td, J = 7.65, 1.76 Hz), 7.16-7.26(2 H, m),
6.98-7.14 (4 H,m), 6.85 (1 H, d, J = 9.03 Hz), 3.66(2 H, s), 3.29
(2 H, t, J = 7.28 Hz),3.02 (2 H, t, J = 7.40 Hz), 2.56 (2 H,q, J =
7.53 Hz), 1.18 (6 H, s),1.05 (3 H, t, J = 7.53 Hz) 122 ##STR00462##
6 395 1H NMR (400 MHz, chloroform-d) .delta. ppm 7.62 (2 H, d, J =
8.78 Hz),7.30 (2 H, d, J = 8.03 Hz), 7.16 (1 H,d, J = 4.52 Hz),
7.10 (1 H, d,J = 2.01 Hz), 6.91-7.05 (2 H, m),6.70 (1 H, d, J =
8.53 Hz), 6.22(1 H, s), 2.21 (3 H, s) 123 ##STR00463## 6 449 1H NMR
(500 MHz, chloroform-d) .delta. ppm 7.47 (1 H, d, J = 2.47
Hz),7.21-7.32 (4 H, m), 6.97-7.04 (3 H,m), 6.93 (1 H, d, J = 4.67
Hz),3.89 (2 H, s), 3.30 (2 H, t J = 7.70Hz), 2.98 (2 H, t, J = 7.84
Hz), 1.40(6 H, s) 124 ##STR00464## 6 429 1H NMR (500 MHz,
chloroform-d) .delta. ppm 7.22-7.29 (3 H, m),7.16-7.22 (2 H, m),
6.99 (2 H, t,J = 8.66 Hz), 6.95 (1 H, d, J = 4.40Hz), 6.88 (1 H, d,
J = 8.52 Hz), 3.84(2 H, s), 3.21-3.36 (2 H, m),2.90-3.08 (2 H, m),
2.29 (3 H, s), 1.38(6 H, s) 125 ##STR00465## 6 443 1H NMR (500 MHz,
chloroform-d) .delta. ppm 7.22-7.29 (3 H, m),7.17-7.22 (2 H, m),
6.94-7.03 (3 H,m), 6.90 (1 H, d, J = 8.25 Hz), 3.84(2 H, s)
3.25-3.35 (2 H, m),2.92-3.05 (2 H, m), 2.71 (2 H, q),1.39 (6 H, s),
1.23 (3 H, t, J = 7.56 Hz) 126 ##STR00466## 6 457 1H NMR (500 MHz,
chloroform-d) .delta. ppm 7.23-7.28 (2 H, m),6.95-7.03 (6 H, m),
6.90 (1 H, dd,J = 8.52, 2.20 Hz), 4.20 (1 H, dd,J = 9.62, 2.75 Hz),
4.03 (1 H, dd,J = 9.62, 8.25 Hz), 3.86 (3 H, s),3.26-3.40 (3 H, m),
2.93-3.06 (2 H,m), 0.89-1.04 (1 H, m),0.52-0.66 (2 H, m), 0.41-0.49
(1 H,m), 0.27-0.36 (1 H, m) 127 ##STR00467## 6 441 1H NMR (500 MHz,
chloroform-d) .delta. ppm 7.22-7.28 (3 H, m),7.16-7.22 (2 H, m),
6.90-7.03 (4 H,m), 4.14 (1 H, dd, J = 9.35, 3.30Hz), 4.04 (1 H, dd,
J = 9.35, 7.15Hz), 3.24-3.41 (3 H, m), 2.93-3.05(2 H, m), 2.27 (3
H, s),0.99-1.09 (1 H, m), 0.55-0.70 (2 H,m), 0.43-0.51 (1 H,
m),0.29-0.39 (1 H, m) 128 ##STR00468## 6 449 1H NMR (500 MHz,
chloroform-d) .delta. ppm 7.47 (1 H, d, J = 2.75 Hz),7.21-7.34 (3
H, m), 6.88-7.10 (5 H,m), 3.89 (2 H, s), 3.27-3.37 (2 H,m),
2.97-3.06 (2 H, m), 1.40(6 H, s) 129 ##STR00469## 6 429 1H NMR (500
MHz, chloroform-d) .delta. ppm 7.23-7.31 (3 H, m),7.16-7.22 (2 H,
m), 6.86-7.09 (4 H,m), 3.84 (2 H, s), 3.27-3.35 (2 H,m), 2.96-3.05
(2 H, m), 2.29(3 H, s), 1.38 (6 H, s) 130 ##STR00470## 6 443 1H NMR
(500 MHz, chloroform-d) .delta. ppm 7.24-7.30 (2 H, m),7.17-7.22 (2
H, m), 6.86-7.11 (5 H,m), 3.84 (2 H, s), 3.24-3.38 (2 H,m),
2.96-3.08 (2 H, m), 2.71 (2 H,q, J = 7.70 Hz), 1.38 (6 H, s),1.23
(3 H, t, J = 7.56 Hz) 131 ##STR00471## 6 445 1H NMR (500 MHz,
chloroform-d) .delta. ppm 7.20-7.38 (2 H, m),6.83-7.14 (7 H, m),
3.86 (5 H, s),3.23-3.40 (2 H, m), 2.93-3.10 (2 H,m), 1.36 (6 H, s)
132 ##STR00472## 6 457 1H NMR (500 MHz, chloroform-d) .delta. ppm
7.24-7.31 (2 H, m), 7.07(1 H, d, J = 7.42 Hz), 6.96-7.04 (4 H,m),
6.87-6.96 (2 H, m), 4.20(1 H, dd, J = 9.62, 2.75 Hz), 4.03 (1 H,dd,
J = 9.90, 8.25 Hz), 3.86 (5 H,s), 3.26-3.43 (3 H, m), 2.96-3.06(2
H, m), 0.91-1.03 (1 H, m),0.52-0.68 (2 H, m), 0.41-0.50(1 H, m),
0.26-0.35 (1 H, m)
TABLE-US-00002 TABLE 2 3-Oxa substituted-1-arylpyrazin-2(1H)-ones
##STR00473## Ex. Aniline/Bromide No. Structure Component 133
##STR00474## ##STR00475## 134 ##STR00476## ##STR00477## 135
##STR00478## ##STR00479## 136 ##STR00480## ##STR00481## 137
##STR00482## ##STR00483## 138 ##STR00484## ##STR00485## 139
##STR00486## ##STR00487## 140 ##STR00488## ##STR00489## 141
##STR00490## ##STR00491## 142 ##STR00492## ##STR00493## 143
##STR00494## ##STR00495## 144 ##STR00496## ##STR00497## 145
##STR00498## ##STR00499## 146 ##STR00500## ##STR00501## 147
##STR00502## ##STR00503## 148 ##STR00504## ##STR00505## 149
##STR00506## ##STR00507## 150 ##STR00508## ##STR00509## 151
##STR00510## ##STR00511## 152 ##STR00512## ##STR00513## 153
##STR00514## ##STR00515## 154 ##STR00516## ##STR00517## 155
##STR00518## ##STR00519## 156 ##STR00520## ##STR00521## Ex. Alcohol
Yield HNMR Data No. Component Method (%) HPLC LC-MS (CDCl.sub.3)
133 ##STR00522## 1 18 3.71 353 7.27 (m, 5 H), 6.93 (m, 5 H), 4.55
(t, J =7.5 Hz, 2 H), 3.92 (s, 3 H), 3.89 (s,3 H), 3.17 (t, J = 7.5
Hz, 2 H). 134 ##STR00523## 1 26 3.96 387/389 7.25 (m, 4 H), 6.92
(m, 5 H), 4.52 (t, J =7.2 Hz, 2 H), 3.92 (s, 3 H), 3.89 (s,3 H),
3.12 (t, J = 7.2 Hz, 2 H). 135 ##STR00524## 1 68 3.83 373/375 7.37
(d, J = 8.4 Hz, 2 H), 7.25 (d, J =8.4 Hz, 2 H), 6.60 (m, 5 H), 5.32
(s,2 H), 3.84 (s, 3 H), 3.80 (s, 3 H) 136 ##STR00525## 7 445 1H NMR
(500 MHz, chloroform-d) .delta.ppm 7.30 (1 H, s), 7.22 (3 H, d,J =
4.95 Hz), 6.94-7.00 (2 H, m),6.83-6.91 (3 H, m), 4.54 (2 H, t, J =
7.42Hz), 3.86 (5 H, s), 3.15 (2 H, t, J = 7.42Hz), 1.36 (6 H, s)
137 ##STR00526## 4 3.59 403/405 7.42 (d, J = 8.9 Hz, 2 H), 7.18 (d,
J =8.9 Hz, 2 H), 7.02 (m, 2 H), 6.80 (d, J =4.6 Hz, 1 H), 6.93 (dd,
J = 2.2 and 8.4Hz, 1 H), 6.81 (d, J = 4.6 Hz, 1 H) 4.25(m, 1 H),
4.05 (dd, J = 3.0 and 9.6 Hz,1 H), 3.88 (s, 3 H), 3.86 (dd, J =
1.0and 9.6 Hz, 1 H), 2.73 (broad s, 1 H),1.27 (d, J = 4.3 Hz, 3 H).
138 ##STR00527## 1 5 3.86 411 7.32 (m, 5 H), 7.23 (m, 1 H), 6.96
(m,2 H), 6.87 (m, 2 H), 4.55 (t, J = 2.0 Hz,2 H), 3.86 (s, 5 H),
3.18 (t, J = 2.0 Hz,2 H), 1.35 (s, 6 H). 139 ##STR00528## 7 399 1H
NMR (500 MHz, chloroform-d) .delta.ppm 7.23-7.38 (4 H, m),
6.95-7.05(4 H, m), 6.84 (2 H, s), 4.51 (2 H, t,J = 7.29 Hz), 3.83
(2 H, s), 3.14 (2 H,s), 1.36 (6 H, s) 140 ##STR00529## 7 417 1H NMR
(500 MHz, chloroform-d) .delta.ppm 7.25-7.30 (2 H, m), 7.21 (1
H,dd, J = 11.00, 2.47 Hz), 6.96-7.15 (4 H,m), 6.75-6.90 (2 H, m),
4.51 (2 H,t, J = 7.29 Hz), 3.89 (2 H, s), 3.13 (2 H,t, J = 7.15
Hz), 1.38 (6 H, s) 141 ##STR00530## 7 433 1H NMR (500 MHz,
chloroform-d) .delta.ppm 7.45 (1 H, d, J = 2.75 Hz),7.22-7.35 (3 H,
m), 6.94-7.07 (3 H, m),6.75-6.88 (2 H, m), 4.51 (2 H, t,J = 7.15
Hz), 3.89 (2 H, s), 3.13 (2 H, t,J = 7.15 Hz), 1.40 (6 H, s) 142
##STR00531## 7 413 1H NMR (500 MHz, chloroform-d) .delta.ppm
7.24-7.31 (2 H, m), 7.15-7.21(2 H, m), 6.99 (2 H, t, J = 8.66
Hz),6.89 (1 H, d, J = 7.97 Hz), 6.83 (2 H,s), 4.50 (2 H, t, J =
7.29), 3.84 (2 H,s), 3.13 (2 H, t, J = 7.29 Hz), 2.29 (3 H,s), 1.38
(6 H, s) 143 ##STR00532## 7 427 1H NMR (500 MHz, chloroform-d)
.delta.ppm 7.24-7.31 (2 H, m), 7.16-7.21(2 H, m), 6.99 (2 H, t, J =
8.66 Hz),6.90 (1 H, d, J = 9.35 Hz), 6.82-6.86(2 H, m) 4.51 (2 H,
t, J = 7.29 Hz),3.84 (2 H, s), 3.14 (2 H, t, J = 7.29 Hz),2.71 (2
H, q), 1.39 (6 H, s), 1.24 (3 H,t, J = 7.56 Hz) 144 ##STR00533## 7
429 1H NMR (500 MHz, chloroform-d) .delta.ppm 7.23-7.32 (2 H, m),
6.94-7.03(4 H, m), 6.82-6.90 (3 H, m), 4.51 (2 H,t, J = 7.29 Hz),
3.85 (5 H, s), 3.14 (2 H,t, J = 7.29 Hz), 1.36 (6 H, s) 145
##STR00534## 7 441 1H NMR (500 MHz, chloroform-d) .delta.ppm
7.24-7.32 (2 H, m), 6.95-7.04(4 H, m), 6.83-6.91 (3 H, m), 4.51 (2
H,t, J = 7.29 Hz), 4.20 (1 H, dd,J = 9.76, 2.89 Hz), 4.03 (1 H,
dd,J = 9.90, 8.25 Hz), 3.31-3.43 (1 H,m), 3.14 (2 H, t, J = 7.29
Hz), 0.90-1.05(1 H, m), 0.52-0.68 (2 H, m),0.41-0.49 (1 H, m),
0.26-0.35 (1 H,m) 146 ##STR00535## 7 425 1H NMR (500 MHz,
chloroform-d) .delta.ppm 7.25-7.31 (2 H, m), 7.16-7.20(2 H, m),
6.95-7.02 (2 H, m), 6.90-6.94(1 H, m), 6.81-6.86 (2 H, m),4.50 (2
H, t, J = 7.29 Hz), 4.14 (1 H,dd, J = 9.35, 3.30 Hz), 4.04 (1 H,
dd,J = 9.35, 7.15 Hz), 3.36 (1 H, dt,J = 8.45, 3.61 Hz), 3.13 (2 H,
t, J = 7.15Hz), 2.27 (3 H, s), 0.99-1.09 (1 H,m), 0.55-0.70 (2 H,
m), 0.43-0.51(1 H, m), 0.30-0.39 (1 H, m) 147 ##STR00536## 7 415 1H
NMR (500 MHz, chloroform-d) .delta.ppm 7.32 (2 H, d), 7.23-7.29 (4
H,m), 7.02 (2 H, d), 6.84 (2 H, s), 4.51(2 H, t, J = 7.29 Hz), 3.83
(2 H, s), 3.13(2 H, t, J = 7.15 Hz), 1.36 (6 H, s) 148 ##STR00537##
7 433 1H NMR (500 MHz, chloroform-d) .delta.ppm 7.18-7.31 (5 H, m),
7.03-7.15(2 H, m), 6.75-6.89 (2 H, m), 4.51 (2 H,t, J = 7.15 Hz),
3.89 (2 H, s), 3.13 (2 H,t, J = 7.15 Hz), 1.38 (6 H, s) 149
##STR00538## 7 449 1H NMR (500 MHz, chloroform-d) .delta.ppm 7.45
(1 H, d, J = 2.75 Hz), 7.22-7.32(5 H, m), 7.00 (1 H, d, J =
8.80Hz), 6.77-6.90 (2 H, m), 4.51 (2 H, t,J = 7.29 Hz), 3.89 (2 H,
s), 3.13 (2 H, t,J = 7.15 Hz), 1.40 (6 H, s) 150 ##STR00539## 7 429
1H NMR (500 MHz, chloroform-d) .delta.ppm 7.23-7.30 (4 H, m),
7.14-7.20(2 H, m), 6.88 (1 H, d, J = 8.25 Hz),6.83 (2 H, s), 4.51
(2 H, t, J = 7.15 Hz),3.84 (2 H, s), 3.13 (2 H, t, J = 7.15
Hz),2.29 (3 H, s), 1.38 (6 H, s) 151 ##STR00540## 7 443 1H NMR (500
MHz, chloroform-d) .delta.ppm 7.23-7.29 (4 H, m), 7.16-7.21(2 H,
m), 6.90 (1 H, d, J = 9.35 Hz),6.84 (2 H, q, J = 4.49 Hz), 4.51 (2
H, t,J = 7.29 Hz), 3.84 (2 H, s), 3.13 (2 H, t,J = 7.29 Hz), 2.71
(2 H, q, J = 7.51 Hz),1.39 (6 H, s), 1.23 (3 H, t, J = 7.56 Hz) 152
##STR00541## 7 445 1H NMR (500 MHz, chloroform-d) .delta.ppm
7.18-7.33 (4 H, m), 6.93-7.04(2 H, m), 6.79-6.91 (3 H, m), 4.51 (2
H,t, J = 7.15 Hz), 3.85 (5 H, s), 3.14 (2 H,t, J = 7.29 Hz), 1.36
(6 H, s) 153 ##STR00542## 7 441 1H NMR (500 MHz, chloroform-d)
.delta.ppm 7.23-7.29 (4 H, m), 7.16-7.20(2 H, m), 6.92 (1 H, d),
6.80-6.85 (2 H,m), 4.51 (2 H, t, J = 7.29 Hz), 4.14(1 H, dd, J =
9.35, 3.57 Hz), 4.04 (1 H,dd, J = 9.35, 7.15 Hz), 3.31-3.42 (1
H,m), 3.13 (2 H, t, J = 7.29 Hz), 2.27(3 H, s), 0.97-1.11 (1 H, m),
0.55-0.70(2 H, m), 0.42-0.51 (1 H, m),0.30-0.40 (1 H, m) 154
##STR00543## 7 457 1H NMR (500 MHz, chloroform-d) .delta.ppm
7.23-7.29 (4 H, m), 7.01 (1 H,d, J = 8.80 Hz), 6.97 (1 H, d, J =
2.47Hz), 6.82-6.91 (3 H, m), 4.51 (2 H, t,J = 7.15 Hz), 4.20 (1 H,
dd, J = 9.76,2.89 Hz), 4.03 (1 H, dd, J = 9.62, 8.25Hz), 3.86 (3 H,
s), 3.30-3.41 (1 H,m), 3.14 (2 H, t, J = 7.15 Hz), 0.89-1.04(1 H,
m), 0.52-0.68 (2 H, m),0.42-0.50 (1 H, m), 0.25-0.37 (1 H,m) 155
##STR00544## 7 429 1H NMR (500 MHz, chloroform-d) .delta.ppm 7.30
(1 H, s), 7.16-7.25 (5 H,m), 6.89 (1 H, d, J = 8.52 Hz), 6.83 (2
H,s), 4.53 (2 H, t, J = 7.42 Hz), 3.84 (2 H,s), 3.14 (2 H, t, J =
7.29 Hz), 2.29 (3 H,s), 1.38 (6 H, s) 156 ##STR00545## 7 443 1H NMR
(500 MHz, chloroform-d) .delta.ppm 7.30 (1 H, s), 7.16-7.25 (5
H,m), 6.90 (1 H, d, J = 9.35 Hz), 6.82-6.87(2 H, m), 4.53 (2 H, t,
J = 7.42Hz), 3.84 (2 H, s), 3.15 (2 H, t, J = 7.29Hz), 2.65-2.76 (2
H, m), 1.38 (6 H,s), 1.24 (3 H, t, J = 7.56 Hz)
TABLE-US-00003 TABLE 3 3-Substituted-1-heteroarylpyrazin-2(1H)-ones
##STR00546## Ex. Aniline/Bromide No. Structure Component 157
##STR00547## ##STR00548## 158 ##STR00549## ##STR00550## 159
##STR00551## ##STR00552## 160 ##STR00553## ##STR00554## 161
##STR00555## ##STR00556## 162 ##STR00557## ##STR00558## 163
##STR00559## ##STR00560## 164 ##STR00561## ##STR00562## 165
##STR00563## ##STR00564## 166 ##STR00565## ##STR00566## 167
##STR00567## ##STR00568## 168 ##STR00569## ##STR00570## 168
##STR00571## ##STR00572## 169 ##STR00573## ##STR00574## 170
##STR00575## ##STR00576## 171 ##STR00577## ##STR00578## 172
##STR00579## ##STR00580## 173 ##STR00581## ##STR00582## 174
##STR00583## ##STR00584## 175 ##STR00585## ##STR00586## 176
##STR00587## ##STR00588## 177 ##STR00589## ##STR00590## 178
##STR00591## ##STR00592## 179 ##STR00593## ##STR00594## 180
##STR00595## ##STR00596## 181 ##STR00597## ##STR00598## 182
##STR00599## ##STR00600## 183 ##STR00601## ##STR00602## 184
##STR00603## ##STR00604## 185 ##STR00605## ##STR00606## 186
##STR00607## ##STR00608## 187 ##STR00609## ##STR00610## 188
##STR00611## ##STR00612## 189 ##STR00613## ##STR00614## 190
##STR00615## ##STR00616## 191 ##STR00617## ##STR00618## 192
##STR00619## ##STR00620## Ex. Alcohol Yield HNMR Data No. Component
Method (%) HPLC LC-MS (CDCl.sub.3) 157 ##STR00621## 8 438 1H NMR
(500 MHz, methanol-d.sub.3) .delta.ppm 8.41 (1 H, d, J = 2.47 Hz),
8.09(1 H, dd, J = 9.07, 2.75 Hz), 7.72-7.79(4 H, m), 7.35 (1 H, d,
J = 4.40Hz), 7.24 (1 H, d, J = 9.07 Hz), 7.19(1 H, d, J = 4.67 Hz),
4.25 (2 H, s),1.33 (6 H, s). 158 ##STR00622## 8 454 1H NMR (500
MHz, methanol-d.sub.3) .delta.ppm 8.25 (1 H, d, J = 2.47 Hz),
7.84(1 H, dd, J = 8.80, 2.75 Hz), 7.63-7.69(2 H, m), 7.37 (2 H, d,
J = 7.97Hz), 7.31 (1 H, d, J = 4.40 Hz), 7.17(1 H, d, J = 4.67 Hz),
7.00 (1 H, d,J = 8.80 Hz), 4.19 (2 H, s), 1.31 (6 H,s) 159
##STR00623## 8 398 1H NMR (400 MHz, methanol-d.sub.3) .delta.ppm
8.23 (1 H, d, J = 2.64 Hz), 7.80(1 H, dd, J = 8.90, 2.75 Hz), 7.39
(1 H,d, J = 4.39 Hz), 7.15-7.33 (6 H,m), 6.98 (1 H, d, J = 8.79
Hz), 4.18 (2 H,s), 3.30-3.38 (2 H, m),2.91-3.08 (2 H, m), 1.31 (6
H, s) 160 ##STR00624## 8 416 1H NMR (400 MHz, methanol-d.sub.3)
.delta.ppm 8.22 (1 H, d, J = 2.64 Hz), 7.80(1 H, dd, J = 8.90, 2.75
Hz), 7.37 (1 H,d, J = 4.61 Hz), 7.28-7.35 (1 H,m), 7.17-7.28 (2 H,
m), 6.88-7.16(3 H, m), 4.18 (1 H, s), 3.25-3.43 (2 H,m), 3.04 (2 H,
t, J = 7.47 Hz), 1.30(6 H, s) 161 ##STR00625## 8 416 1H NMR (400
MHz, methanol-d.sub.3) .delta.ppm 8.23 (1 H, d, J = 2.64 Hz),
7.80(1 H, dd, J = 8.90, 2.75 Hz), 7.40 (1 H,d, J = 4.61 Hz),
7.23-7.34 (2 H,m), 6.89-7.14 (4 H, m), 4.18 (1 H,s), 3.29-3.40 (2
H, m), 2.95-3.06(2 H, m), 1.30 (6 H, s) 162 ##STR00626## 8 416 1H
NMR (400 MHz, methanol-d.sub.3) .delta.ppm 8.15 (1 H, d, J = 2.42
Hz), 7.73(1 H, dd, J = 8.90, 2.75 Hz), 7.31 (1 H,d, J = 4.39 Hz),
7.15-7.26 (3 H,m), 6.85-7.00 (3 H, m), 4.10 (2 H,s), 3.22-3.29 (2
H, m), 2.89 (2 H, t,J = 7.58 Hz), 1.23 (6 H, s) 163 ##STR00627## 8
399 1H NMR (400 MHz, methanol-d.sub.3) .delta.ppm 8.40-8.54 (1 H,
m), 8.22 (1 H,d, J = 2.20 Hz), 7.72-7.86 (2 H, m),7.35-7.44 (2 H,
m), 7.23-7.32 (2 H,m), 6.98 (1 H, J = 9.01 Hz), 4.18(2 H, s), 3.47
(2 H, t, J = 7.36 Hz),3.19 (2 H, t, J = 7.36 Hz), 1.30 (6 H,s) 164
##STR00628## 8 472 1H NMR (500 MHz, chloroform-d) .delta.ppm 8.11
(1 H, d, J = 2.47 Hz), 7.89(1 H, d, J = 2.47 Hz), 7.71 (4 H,
s),7.16 (1 H, d, J = 4.40 Hz), 6.95 (1 H,d, J = 4.40 Hz), 4.30 (2
H, s), 1.38 (6 H,s) 165 ##STR00629## 8 488 1H NMR (500 MHz,
chloroform-d) .delta.ppm 8.10 (1 H, d, J = 2.47 Hz), 7.88(1 H, d, J
= 2.47 Hz), 7.61 (2 H, d,J = 8.80 Hz), 7.30 (2 H, d, J = 7.97Hz),
7.16 (1 H, d, J = 4.67 Hz), 6.94(1 H, d, J = 4.40 Hz), 4.30 (2 H,
s),1.38 (6 H, s) 166 ##STR00630## 8 432 1H NMR (400 MHz,
chloroform-d) .delta.ppm 8.09 (1 H, d, J = 2.42 Hz), 7.86(1 H, d, J
= 2.64 Hz), 7.21-7.37 (6 H,m), 6.91 (1 H, d, J = 4.39 Hz), 4.29 (2
H,s), 3.28-3.43 (2 H, m),2.94-3.09 (2 H, m), 1.37 (6 H, s) 167
##STR00631## 8 450 1H NMR (400 MHz, chloroform-d) .delta.ppm 8.08
(1 H, d, J = 2.42 Hz), 7.86(1 H, d, J = 2.42 Hz), 7.16-7.33 (3
H,m), 6.98-7.13 (2 H, m), 6.90 (1 H,d, J = 4.61 Hz), 4.29 (2 H, s),
3.29-3.41(2 H, m), 3.07 (2 H, t, J = 7.69Hz), 1.37 (6 H, s) 168
##STR00632## 8 450 1H NMR (500 MHz, chloroform-d) .delta.ppm 8.09
(1 H, d, J = 2.20 Hz), 7.86(1 H, d, J = 2.47 Hz), 7.26-7.34 (2
H,m), 7.06 (1 H, d, J = 7.70 Hz), 6.98-7.03(1 H, m), 6.89-6.97 (2
H, m),4.29 (2 H, s), 3.27-3.40 (2 H, m),2.94-3.10 (2 H, m), 1.37 (6
H, s) 168 ##STR00633## 8 450 1H NMR (500 MHz, chloroform-d)
.delta.ppm 8.08 (1 H, d, J = 2.47 Hz), 7.86(1 H, d, J = 2.47 Hz),
7.30 (1 H, d,J = 4.40 Hz), 7.21-7.25 (2 H, m),7.00 (2 H, t, J =
8.66 Hz), 6.91 (1 H,J = 4.67 Hz), 4.29 (2 H, s), 3.23-3.39(2 H, m),
2.91-3.05 (2 H, m),1.37 (6 H, s) 169 ##STR00634## 8 433 1H NMR (500
MHz, chloroform-d) .delta.ppm 8.57 (1 H, d, J = 3.85 Hz), 8.08(1 H,
d, J = 2.47 Hz), 7.85 (1 H, d,J = 2.47 Hz), 7.63 (1 H, td, J =
7.63,1.79 Hz), 7.31 (1 H, d, J = 4.67 Hz),7.24 (1 H, d, J = 7.70
Hz), 7.11-7.18(1 H, m), 6.90 (1 H, d, J = 4.40 Hz),4.29 (2 H, s),
3.45-3.59 (2 H, m),3.22 (2 H, t, J = 7.42 Hz), 1.37 (6 H,s) 170
##STR00635## 8 452 1H NMR (500 MHz, chloroform-d) .delta.ppm 8.00
(1 H, d, J = 2.75 Hz), 7.67-7.76(4 H, m), 7.60 (1 H, d, J =
1.92Hz), 7.14 (1 H, d, J = 4.40 Hz), 6.96(1 H, d, J = 4.40 Hz),
4.28 (2 H, s),2.30 (3 H, s), 1.36 (6 H, s) 171 ##STR00636## 8 468
1H NMR (500 MHz, chloroform-d) .delta.ppm 8.00 (1 H, d, J = 2.75
Hz), 7.57-7.65(3 H, m), 7.29 (2 H, d, J = 7.97Hz), 7.14 (1 H, d, J
= 4.40 Hz), 6.94(1 H, d, J = 4.40 Hz), 4.28 (2 H, s),2.29 (3 H, s),
1.35 (6 H, s) 172 ##STR00637## 8 412 1H NMR (500 MHz, chloroform-d)
.delta.ppm 7.98 (1 H, d, J = 2.20 Hz), 7.58(1 H, d, J = 1.65 Hz),
7.27-7.36 (5 H,m), 7.21-7.25 (1 H, m), 6.91 (1 H,d, J = 4.40 Hz),
4.27 (2 H, s), 3.27-3.40(2 H, m), 2.95-3.11 (2 H, m),2.28 (3 H, s),
1.35 (6 H, s) 173 ##STR00638## 8 430 1H NMR (500 MHz, chloroform-d)
.delta.ppm 7.98 (1 H, d, J = 2.75 Hz), 7.58(1 H, d, J = 1.92 Hz),
7.27-7.33 (2 H,m), 7.18-7.24 (1 H, m), 7.00-7.12(2 H, m), 6.91 (1
H, d, J = 4.40 Hz),4.27 (2 H, s), 3.29-3.41 (2 H, m),3.07 (2 H, t,
J = 7.70 Hz), 2.28 (3 H,s), 1.35 (6 H, s) 174 ##STR00639## 8 430 1H
NMR (500 MHz, chloroform-d) .delta.ppm 7.98 (1 H, d, J = 2.47 Hz),
7.58(1 H, d, J = 1.92 Hz), 7.27-7.32 (1 H,m), 7.26 (1 H, d, J =
7.70 Hz), 7.06 (1 H,d, J = 7.70 Hz), 6.98-7.04 (1 H,m), 6.89-6.95
(2 H, m), 4.27 (2 H,s), 3.25-3.38 (2 H, m), 2.94-3.08(2 H, m), 2.28
(3 H, s), 1.35 (6 H, s) 175 ##STR00640## 8 430 1H NMR (500 MHz,
chloroform-d) .delta.ppm 7.98 (1 H, d, J = 2.75 Hz), 7.58(1 H, d, J
= 1.92 Hz), 7.28 (1 H, d,J = 4.67 Hz), 7.21-7.25 (2 H, m),7.00 (2
H, t, J = 8.66 Hz), 6.91 (1 H,d, J = 4.40 Hz), 4.27 (2 H, s),
3.22-3.38(2 H, m), 2.92-3.07 (2 H, m),2.28 (3 H, s), 1.35 (6 H, s)
176 ##STR00641## 8 413 1H NMR (500 MHz, chloroform-d) .delta.ppm
8.57 (1 H, d, J = 3.85 Hz), 7.97(1 H, d, J = 2.20 Hz), 7.62 (1 H,
td,J = 7.63, 1.79 Hz), 7.57 (1 H, d,J = 1.92 Hz), 7.29 (1 H, d, J =
4.40Hz), 7.24 (1 H, d, J = 7.97 Hz), 7.15(1 H, dd, J = 6.60, 4.95
Hz), 6.90 (1 H,d, J = 4.67 Hz), 4.27 (2 H, s), 3.51(2 H, t, J =
7.42 Hz), 3.22 (2 H, t,J = 7.42 Hz), 2.27 (3 H, s), 1.35 (6 H,s)
177 ##STR00642## 6 518 1H NMR (500 MHz, methanol-d.sub.3) dppm 8.08
(1 H, d, J = 2.47 Hz), 7.93(1 H, d, J = 8.80 Hz), 7.65-7.74 (3
H,m), 7.43 (1 H, d, J = 4.67 Hz), 7.38 (2 H,d, J = 7.97 Hz), 7.22
(1 H, d,J = 4.40 Hz), 6.98 (1 H, d, J = 1.10Hz), 4.31 (2 H, s),
2.66 (3 H, d,J = 1.10 Hz), 1.34 (6 H, s) 178 ##STR00643## 6 518 1H
NMR (500 MHz, methanol-d.sub.3) .delta.ppm 8.09 (1 H, d, J = 9.35
Hz), 7.96(1 H, d, J = 2.47 Hz), 7.64-7.75 (3 H,m), 7.29-7.49 (3 H,
m), 7.21 (1 H,d, J = 4.40 Hz), 6.69 (1 H, s), 4.38-4.58(2 H, m),
2.54 (3 H, s), 1.28 (6 H,s) 179 ##STR00644## 6 504 1H NMR (500 MHz,
methanol-d.sub.3) .delta.ppm 8.21 (1 H, d, J = 8.80 Hz),
7.90-7.98(2 H, m), 7.73 (1 H, dd, J = 8.80,2.47 Hz), 7.67 (2 H, d),
7.35-7.42(3 H, m), 7.21 (1 H, d, J = 4.40 Hz),7.11 (1 H, d, J =
9.07 Hz), 4.34 (2 H,s), 1.35 (6 H, s). 180 ##STR00645## 6 504 1H
NMR (500 MHz, methanol-d.sub.3) .delta.ppm 8.08 (1 H, d, J = 9.35
Hz), 7.97(1 H, d, J = 9.35 Hz), 7.84 (1 H, d,J = 2.47 Hz),
7.63-7.73 (3 H, m),7.31-7.42 (3 H, m) 7.20 (1 H, d,J = 4.40 Hz),
6.78 (1 H, d, J = 9.35Hz), 4.50 (2 H, br. s.), 1.29 (6 H, s). 181
##STR00646## 6 502 1H NMR (400 MHz, chloroform-d) .delta.ppm
7.89-8.00 (2 H, m), 7.68-7.79(4 H, m), 7.64 (1 H, dd, J = 8.79,
2.42Hz), 7.19 (1 H, d, J = 4.39 Hz), 7.11(1 H, d, J = 4.39 Hz),
6.92 (1 H, d,J = 0.88 Hz), 4.41 (2 H, s), 2.64 (3 H,s), 1.36 (6 H,
s) 182 ##STR00647## 6 488 1H NMR (400 MHz, chloroform-d) .delta.ppm
8.06 (1 H, d, J = 8.79 Hz), 7.94(1 H, d, J = 9.01 Hz), 7.85 (1 H,
d,J = 2.42 Hz), 7.64-7.78 (5 H, m),7.18 (1 H, d, J = 4.61 Hz), 7.11
(1 H,d, J = 4.39 Hz), 7.06 (1 H, d, J = 9.01Hz), 4.43 (2 H, s),
1.38 (6 H, s) 183 ##STR00648## 6 448 1H NMR (400 MHz, chloroform-d)
.delta.ppm 8.04 (1 H, d, J = 8.78 Hz), 7.92(1 H, d, J = 9.04 Hz),
7.83 (1 H, d,J = 2.51 Hz), 7.65 (1 H, dd, J = 8.91,2.38 Hz),
7.28-7.36 (5 H, m), 7.20-7.28(1 H, m), 7.02-7.09 (2 H, m),4.42 (2
H, s), 3.28-3.44 (2 H, m),2.93-3.12 (2 H, m), 1.37 (6 H, s) 184
##STR00649## 6 462 1H NMR (400 MHz, chloroform-d) .delta.ppm
7.88-7.98 (2 H, m), 7.62 (1 H,dd, J = 8.91, 2.38 Hz), 7.20-7.37 (6
H,m), 7.07 (1 H, d, J = 4.27 Hz), 6.90(1 H, s), 4.40 (2 H, s), 3.30
3.39 (2 H,m), 2.98-3.12 (2 H, m), 2.63 (3 H,s), 1.35 (6 H, s) 185
##STR00650## 6 466 1H NMR (500 MHz, chloroform-d) .delta.ppm 8.04
(1 H, d, J = 8.80 Hz), 7.92(1 H, d, J = 9.07 Hz), 7.83 (1 H, d,J =
2.20 Hz), 7.65 (1 H, dd, J = 8.94,2.34 Hz), 7.32 (1 H, d, J = 4.40
Hz),7.23-7.30 (2 H, m), 6.92-7.12 (4 H,m), 4.42 (2 H, s), 3.43-3.57
(2 H,m), 3.25-3.33 (2 H, m), 2.91-3.08(2 H, m), 1.37 (6 H, s) 186
##STR00651## 6 480 1H NMR (500 MHz, chloroform-d) .delta.ppm
7.88-7.97 (2 H, m), 7.62 (1 H,dd, J = 8.80, 2.47 Hz), 7.33 (1 H,
d,J = 4.40 Hz), 7.23-7.29 (2 H, m),7.07 (1 H, d, J = 4.40 Hz), 7.01
(2 H,t, J = 8.66 Hz), 6.90 (1 H, s), 4.40 (2 H,s), 3.27-3.38 (2 H,
m), 2.95-3.08(2 H,
m), 2.63 (3 H, s), 1.35 (6 H,s) 187 ##STR00652## 6 466 1H NMR (500
MHz, chloroform-d) .delta.ppm 8.04 (1 H, d, J = 8.80 Hz), 7.92(1 H,
d, J = 9.07 Hz), 7.83 (1 H, d,J = 2.47 Hz), 7.65 (1 H, dd, J =
8.80,2.47 Hz), 7.34 (1 H, d, J = 4.40 Hz),7.27-7.31 (1 H, m),
6.99-7.10 (4 H,m), 6.89-6.97 (1 H, m), 4.42 (2 H,s), 3.30-3.38 (2
H, m),2.98-3.08 (2 H, m), 1.37 (6 H, s) 188 ##STR00653## 6 480 1H
NMR (500 MHz, chloroform-d) .delta.ppm 7.95 (1 H, d, J = 2.20 Hz),
7.91(1 H, d, J = 8.80 Hz), 7.62 (1 H, dd,J = 8.94, 2.34 Hz), 7.34
(1 H, d,J = 4.67 Hz), 7.28 (1 H, dd, J = 7.97,1.92 Hz), 7.00-7.10
(3 H, m), 6.89-6.97(2 H, m), 4.40 (2 H, s), 3.28-3.41(2 H, m),
2.97-3.10 (2 H, m),2.63 (3 H, s), 1.35 (6 H, s) 189 ##STR00654## 6
477 1H NMR (500 MHz, methanol-d.sub.3) .delta.ppm 8.28 (1 H, s),
7.70-7.80 (2 H,m), 7.55-7.61 (2 H, m), 7.25-7.32(4 H, m), 7.11 (1
H, d, J = 4.40 Hz),4.19 (2 H, s), 1.14 (6 H, s) 190 ##STR00655## 6
477 1H NMR (500 MHz, methanol-d.sub.3) .delta.ppm 8.30 (1 H, s),
7.76-7.85 (2 H,m), 7.65-7.71 (2 H, m), 7.34-7.42(3 H, m), 7.20 (1
H, d, J = 4.40 Hz),4.29 (2 H, s), 1.24 (6 H, s) 191 ##STR00656## 7
466 1H NMR (500 MHz, chloroform-d) .delta.ppm 8.04 (1 H, d, J =
8.80 Hz), 7.92(1 H, d, J = 8.80 Hz), 7.80 (1 H, d,J = 2.47 Hz),
7.64 (1 H, dd, J = 8.94,2.34 Hz), 7.23-7.30 (4 H, m), 7.04(1 H, d,
J = 8.80 Hz), 6.95 (1 H, d,J = 4.67 Hz), 6.90 (1 H, d, J = 4.67Hz),
4.54 (2 H, t, J = 7.15 Hz), 4.42(2 H, s), 3.15 (2 H, t, J = 7.29
Hz), 1.37(6 H, s) 192 ##STR00657## 7 480 1H NMR (500 MHz,
chloroform-d) .delta.ppm 7.88-7.95 (2 H, m), 7.61 (1 H,dd, J =
8.80, 2.47 Hz), 7.27-7.30 (4 H,m), 6.96 (1 H, d, J = 4.67 Hz),
6.90(2 H, d, J = 4.67 Hz), 4.54 (2 H, t,J = 7.15 Hz), 4.40 (2 H,
s), 3.15 (2 H,t, J = 7.15 Hz), 2.62 (3 H, s), 1.35 (6 H,s)
[0303] Prodrugs were prepared of selected secondary and tertiary
alcohols to improve solubility and exposure. Standard conditions,
employed to generate amino acid esters of all but the glycine ester
of the tertiary alcohols, are exemplified in Example 193.
Preparation of the glycine ester of the tertiary alcohols is
exemplified in Example 202. Preparation of a phosphate ester
prodrug is exemplified by Example 204.
Example 193
1-(2-Methoxy-4-(2-oxo-3-(4-(trifluoromethyl)phenylthio)pyrazin-1(2H)-yl)ph-
enoxy)-2-methylpropan-2-yl 2-aminoacetate
##STR00658##
[0304] Part A.
1-(2-Methoxy-4-(2-oxo-3-(4-(trifluoromethyl)phenylthio)pyrazin-1(2H)-yl)p-
henoxy)-2-methylpropan-2-yl 2-(tert-butoxycarbonylamino)acetate
##STR00659##
[0306] To a stirred suspension of the alcohol prepared in Example
36 (3.0 g, 6.4 mmol), 4-pyrrolidinopyridine (0.95 g, 6.4 mmol) and
BOC-glycine (3.4 g, 19 mmol) in CH.sub.2Cl.sub.2 (60 mL) at
42.degree. C. was added N,N'-diisopropylcarbodiimide 3.0 mL, 19
mmol) over 3.5 h. After stirring at reflux for 2.5 h, HPLC analysis
showed 25% alcohol still remained. More BOC-glycine (3.4 g, 19
mmol) was added followed by additional N,N'-diisopropylcarbodiimide
(3.0 mL, 19 mmol) which was slowly added over 3.5 h; whereupon,
HPLC analysis showed <5% alcohol remained. The reaction was
allowed to cool to RT prior to addition of hydrazine monohydrate
(18 mL, 370 mmol). After stirring for 5 minutes, the reaction
mixture was cooled to 0.degree. C. and filtered. The filtrates were
sequentially washed with cold 1M HCl (3.times.20 mL) and cold 2%
NaHCO.sub.3 (3.times.20 mL) prior to drying over MgSO.sub.4 and
concentrating under vacuum to afford 5.6 g of crude product.
Chromatography (silica gel 230-400 mesh, gradient elution: 0 to 60%
EtOAc/hexane over 47 min) of the residue afforded the desired ester
(3.9 g, 88% yield). HPLC 4.42 min. LC MS (M+1=624), H-NMR
(CDCl.sub.3) 7.72 (m, 4H), 7.12 (d, J=4.4 Hz, 1H), 7.02 (d, J=4.4
Hz, 1H), 7.00 (d, J=8.3 Hz, 1H), 6.99 (d, J=2.5 Hz, 1H), 6.90 (dd,
J=2.5 and 8.3 Hz, 1H), 4.21 (s, 2H), 3.87 (s, 3H), 3.78 (m, 2H),
1.61 (s, 6H), 1.45 (s, 9H).
Part B.
1-(2-Methoxy-4-(2-oxo-3-(4-(trifluoromethyl)phenylthio)pyrazin-1(2-
H)-yl)phenoxy)-2-methylpropan-2-yl 2-aminoacetate
##STR00660##
[0308] The BOC'd glycinate ester described in Part A (3.9 g, 6.2
mmol) was treated with 1:2 TFA/CH.sub.2Cl.sub.2 (145 mL) at RT for
25 min. After removal of the volatiles under vacuum, the residual
TFA was removed by co-evaporation with CH.sub.2Cl.sub.2 (3.times.8
mL) and drying under vacuum for 20 min. Following dissolution in
CH.sub.2Cl.sub.2 (70 mL), the solution was washed with cold 5%
NaHCO.sub.3 (3.times.30 mL) dried over MgSO.sub.4 and concentrated
to yield 3.3 g of crude product. Purification by flash
chromatography (120 g silica gel, 0 to 5% MeOH/CH.sub.2Cl.sub.2
over 24 min) afforded the desired free amine (2.5 g, 77% yield). ).
HPLC 3.72 min. LC MS 2.18 min (M+1=524), H-NMR (CDCl.sub.3) 7.75
(d, J=8.7 Hz, 2H), 7.72 (d, J=8.7 Hz, 2H), 7.14 (d 4.4 Hz, 1H),
7.02 (d, J=4.4 Hz, 1H), 7.00 (d, J=8.5 Hz, 1H), 6.99 (d, J=2.4 Hz,
1H), 6.92 (dd, J=2.4 and 8.5 Hz, 1H), 4.24 (s, 2H), 3.89 (s, 3H),
3.36 (m, 2H), 1.63 (s, 6H), 1.54 (broad s, 2H).
Examples 194 to 201
[0309] Examples 194 to 201 were prepared in a similar manner to
Example 193 using the appropriate alcohol and BOC glycine followed
by TFA removal of the BOC group.
TABLE-US-00004 TABLE 4 Glycine Prodrug Esters Glycine ester of HPLC
.sup.1H-NMR Example No. Example No. (Met1) LC MS (CDCl.sub.3) 194
38 3.86 540 7.55 (d, J = 9.3 Hz, 2H), 7.27 (d, J = 9.3 Hz, 2H),
7.18 (d, J = 4.4 Hz, 1H), 7.06 (d, J = 4.4 Hz, 1H), 7.01 (d, J =
2.2 Hz, 1H), 6.99 (d, J = 8.2 Hz, 1H), 6.86 (dd, J = 2.2 and 8.2
Hz, 1H), 4.15 (s, 2H), 3.76 (s, 3H), 3.17 (s, 2H), 1.50 (s, 6H).
195 32 3.59 470 7.47 (d, J = 8.7 Hz, 2H), 7.27 (d, J = 8.7 Hz, 2H),
7.11 (d, J = 4.4 Hz, 1H), 6.98 (d, J = 2.3 Hz, 1H), 6.97 (d, J =
8.5 Hz, 1H), 6.95 (d, J = 4.4 Hz, 1H), 6.88 (dd, J = 2.3 and 8.5
Hz, 1H), 4.20 (s, 2H), 3.86 (s, 3H), 3.33 (s, 2H), 2.40 (s, 3H),
1.50 (s, 6H). 196 50 3.78 484 7.34 (d, J = 8.3 Hz, 2H), 7.22 (d, J
= 8.3 Hz, 2H), 7.05 (d, J = 4.4 Hz, 1H), 6.92 (d, J = 2.2 Hz, 1H),
6.90 (d, J = 8.2 Hz, 1H), 6.87 (d, J = 4.4 Hz, 1H), 6.83 (dd, J =
2.2 and 8.2 Hz, 1H), 4.14 (s, 2H), 3.79 (s, 3H), 3.27 (s, 2H), 2.63
(q, H = 7.7 Hz, 2H), 1.54 (s, 6H), 1.19 (t, J = 7.7 Hz, 3H). 197 65
482 7.25-7.09 (m, 8H), 6.87 (d, J = 4.4 Hz, 1H), 6.80 (d, J = 9.4
Hz, 1H), 4.09 (s, 2H), 3.30 (2, 2H), 3.23 (dd, J = 7.2, 9.8 Hz,
2H), 2.94 (dd, J = 7.2 and 8.2 Hz, 2H), 2.58 (q, J = 7.6 Hz, 2H),
1.55 (s, 6H), 1.13 (t, J = 7.6 Hz, 3H). 198 87 524 1H NMR (400 MHz,
chloroform-d) .delta. ppm 8.40 (2H, br. s.), 7.59 (2H, d, J = 8.78
Hz), 7.28 (2H, d, J = 8.03 Hz), 7.09-7.23 (3H, m), 6.97 (2H, d, J =
4.27 Hz), 4.22 (2H, br. s.), 3.79 (2H, br. s.), 2.27 (3H, s), 1.62
(6H, s) 199 88 544 1H NMR (500 MHz, methanol-d.sub.3) .delta. ppm
7.65 (2H, d, J = 9.07 Hz), 7.61 (1H, d, J = 2.47 Hz), 7.34-7.43
(3H, m), 7.23-7.29 (2H, m), 7.16 (1H, d, J = 4.40 Hz), 4.38 (2H,
s), 3.75 (2H, s), 1.68 (6H, s) 200 123 486 1H NMR (500 MHz,
methanol-d.sub.3) .delta. ppm 7.38 (1H, d, J = 4.40 Hz), 7.29 (2H,
dd, J = 8.52, 5.50 Hz), 7.19-7.25 (3H, m), 6.98-7.05 (3H, m), 4.29
(2H, s), 3.74 (2H, s), 3.31-3.35 (2H, m), 2.98 (2H, t, J = 7.56
Hz), 2.28 (3H, s), 1.67 (6H, s) 201 113 468 1H NMR (500 MHz,
methanol-d.sub.3) .delta. ppm 7.39 (1H, d, J = 4.40 Hz), 7.25-7.31
(4H, m), 7.17-7.25 (4H, m), 7.03 (1H, d, J = 8.25 Hz), 4.28 (2H,
s), 3.74 (2H, s), 3.24-3.39 (2H, m), 2.91-3.04 (2H, m), 2.28 (3H,
s), 1.67 (6H, s)
[0310] If desired the amino acid prodrug esters may be converted to
the corresponding HCl salt. For example, the HCl salt of Example
197 was prepared by dissolving the compound (0.655 mg, 1.36mmoles)
in CH.sub.2Cl.sub.2 (10 mL) and MeOH (1 mL) and cooling to
-30.degree. C. IN HCl in ether (2.3 mL, 1.7 eq) was added with
stirring. Evaporation in vacuo afforded the desired salt. (0.71 g).
LC MS was identical to the free base. H-NMR (CD.sub.3OD) 7.30 (d,
J=4.4 Hz, 1H), 7.20 (m, 4H), 7.13 (m, 4H), 6.93 (d, J=8.5 Hz, 1H),
4.19 (s, 2H), 3.64 (s, 2H), 3.23 (dd, J=7.4, 15.4 Hz, 2H), 2.90
(dd, J=8.0 and 15.4 Hz, 2H), 2.62 (q, J=7.5 Hz, 2H), 1.59 (s, 6H),
1.14 (t, J=7.5 Hz, 3H).
Example 202
1-(2-Methoxy-4-(2-oxo-3-(4-(trifluoromethyl)phenylthio)pyrazin-1(2H)-yl)ph-
enoxy)propan-2-yl 2-amino-3-methylbutanoate
##STR00661##
[0312] To a stirred mixture of the alcohol described in Example 71
(0.882 g, 1.949 mmol), 4-dimethylaminopyridine (0.714 g, 5.85 mmol)
and N-(t-butoxycarbonyl)-L-valine (1.271 g, 5.85 mmol) in 18 mL of
CH.sub.2Cl.sub.2 at rt was added WSC (1.121 g, 5.85 mmol). After
stirring at ambient temperature for 30 min, the reaction mixture
was transferred to a separatory funnel, washed with cold 5%
H.sub.2SO.sub.4 (3.times.), 5% Na.sub.2CO.sub.3 (2.times.), and
water and dried over MgSO.sub.4. Evaporation of the solvent
afforded 1.03 g of crude product as the BOC amine. The crude
product was dissolved in a 1:2 mixture of TFA/CH.sub.2Cl.sub.2 (18
mL). After stirring for 15 min the solvent was evaporated in vacuo.
The residue was transferred to a separatory funnel with
CH.sub.2Cl.sub.2, washed with cold 5% Na.sub.2CO.sub.3 (2.times.),
and dried over MgSO.sub.4 to afford crude 790 mg of product after
evaporation of the solvent. The product was purified by flash
chromatography (80 g silica gel, gradient elution: 1 to 8%
MeOH/CH.sub.2Cl.sub.2 over 24 min) to afforded the desired valine
ester as a free base (0.69 g, 64% yield).
[0313] HPLC (Method 1) 3.84 min. LC MS 2.26 min (M+1=552), H-NMR
(CDCl.sub.3) 7.74 (d, J=8.7 Hz, 2H), 7.72 (d, J=8.7 Hz, 2H), 7.13
(d, J=4.4 Hz, 1H), 7.02 (d, J=4.4 Hz, 1H), 7.00 (d, J=8.5 Hz, 1H),
6.99 (d, J=2.4 Hz, 1H), 6.91 (dd, J=2.4 and 8.5 Hz, 1H), 5.34 (m,
1H), 4.12 (m, 2H), 3.86 (d, 3H), 3.30 (t, J=5.2 Hz, 1H), 2.05 (m,
1H), 1.40 (d, J=6.4 Hz), 0.98 (m, 3H), 0.92 (m, 3H).
[0314] The HCl salt of Example 176 was prepared by dissolving the
compound in CH.sub.2Cl.sub.2 (9 mL). After cooling the solution to
-30.degree. C., IN HCl in ether (2.85 mL, 1.7 eq) was added with
stirring. The yellow precipitate was collected and dried to afford
the HCl salt (0.74 g).
[0315] LC MS was identical to the free base. H-NMR (CDCl.sub.3)
7.74 (d, J=8.7 Hz, 2H), 7.79 (m, 4H), 7.33 (d, J=4.4 Hz, 1H), 7.18
(d, J=8.5 Hz, 1H), 7.15 (d, J=2.4 Hz, 1H), 7.02 (dd, J=2.4 and 8.5
Hz, 1H), 5.51 (m, 1H), 4.24 (m, 2H), 3.86 (d, 3H), 3.33 (s, 1H),
2.30 (m, 1H), 1.41 (d, J=6.4 Hz), 1.12 (m, 6H).
Example 203
(2S)-1,1,1-Trifluoro-3-(2-methoxy-4-(2-oxo-3-(4-(trifluoromethyl)phenylthi-
o)pyrazin-1(2H)-yl)phenoxy)propan-2-yl
2-amino-3-methylbutanoate
##STR00662##
[0317] In an analogous fashion to that described in Example 202,
the valine ester of the alcohol described in Example 74 was
prepared.
[0318] LC MS at t=2.35 min. (m+1=606 ) Phenomenex S5 C18
4.6.times.30 mm column/water-MeOH-TFA 90:10:0.1 to 10:90:0.1
gradient over 2 min at 5 mL/min with 1 min hold at the end of the
gradient.
[0319] .sup.1H NMR (500 MHz, CDCl.sub.3) .delta. ppm 0.97 (dd,
J=35.13, 6.92 Hz, 6 H), 1.97-2.20 (m, 1 H), 3.42 (d, J=4.78 Hz, 1
H), 3.86 (s, 4 H), 4.26-4.36 (m, 1 H), 4.44 (dd, J=11.08, 3.53 Hz,
1 H), 5.73-5.87 (m, 1 H), 6.91 (dd, J=8.56, 2.27 Hz, 1 H),
6.97-7.06 (m, 2 H), 7.13 (d, J=4.53 Hz, 1 H), 7.58 (s, 1 H),
7.66-7.77 (m, 4 H).
Example 204
Sodium
3,3-difluoro-1-((2-methoxy-4-(2-oxo-3-(4-(trifluoromethoxy)-phenylt-
hio)pyrazin-1(2H)-yl)phenoxy)methyl)cyclobutyl phosphate
##STR00663##
[0320] Part A. Dibenzyl
3,3-difluoro-1-((2-methoxy-4-(2-oxo-3-(4-(trifluoromethoxy)phenylthio)pyr-
azin-1(2H)-yl)phenoxy)methyl)cyclobutyl phosphate
##STR00664##
[0322] To a mixture of dibenzyl diisopropylphosphoramidite (135 mg,
0.390 mmol),
1-(4-((3,3-difluoro-1-hydroxycyclobutyl)methoxy)-3-methoxyphenyl)--
3-(4-(trifluoromethoxy)phenylthio)pyrazin-2(1H)-one (Example 75)
(69 mg, 0.130 mmol) and 1H-1,2,4-triazole (27.0 mg, 0.390 mmol) in
DCE (20 mL) was stirred at reflux for 6 hours. The mixture was
cooled to RT. 30% hydrogen peroxide in water (10 ml) was slowly
added and the mixture was stirred at RT for 30 min. The mixture was
diluted with a solution of aqueous 10% sodium thiosulfate (40 ml)
and was extracted with DCM (50 ml). The DCM layer was dried over
sodium sulfate and concentrated. The crude product was purified by
ISCO silica gel Column (40 g) and the product was eluted with
hexane to 100% ethyl acetate in 10 min. Yield dibenzyl
3,3-difluoro-1-((2-methoxy-4-(2-oxo-3-(4-(trifluoromethoxy)pheny-
lthio)pyrazin-1 (2H)-yl)phenoxy)methyl)cyclobutyl phosphate (79 mg,
0. 100 mmol, 77% yield) as off-white solid. 1H NMR (400 MHz,
chloroform-d) .delta. ppm 7.57-7.66 (2 H, m), 7.27-7.39 (12 H, m),
7.13 (1 H, d, J=4.53 Hz), 6.81-7.00 (4 H, m), 4.97-5.14 (4 H, m),
4.29 (2 H, s), 3.75 (3 H, s), 2.93-3.20 (4 H, m).
Part B. Sodium
3,3-difluoro-1-((2-methoxy-4-(2-oxo-3-(4-(trifluoromethoxy)phenylthio)pyr-
azin-1(2H)-yl)phenoxy)methyl)cyclobutyl phosphate
##STR00665##
[0324] To a solution of dibenzyl
3,3-difluoro-1-((2-methoxy-4-(2-oxo-3-(4-(trifluoromethoxy)phenylthio)pyr-
azin-1 (2H)-yl)phenoxy)methyl)cyclobutyl phosphate (79 mg, 0.100
mmol) in TFA (2 mL) was stirred at RT for 3.5 hours. The mixture
was concentrated. The crude product was purified by prep-HPLC
(Phenomenex, Luna 5 micron 25.times.250 mm, flow rate=30 ml/min.,
gradient=20% A to 100% B in 10 min., A=90% H2O/10% MeOH/0.1% TFA,
B=10% H2O/90% MeOH/0.1% TFA). Yield 46 mg, 0.075 mmol. as yellow
gum. The yellow gum in ACN (2 ml) was added 0.5 N aqueous sodium
bicarbonate (302 .mu.l, 0.151 mmol.), the mixture was diluted with
water (5 ml). The solution was then lyopholized. Yield sodium
3,3-difluoro-1-((2-methoxy-4-(2-oxo-3-(4-(trifluoromethoxy)phenylt-
hio)pyrazin-1 (2H)-yl)phenoxy)methyl)cyclobutyl phosphate (51.08
mg, 0.078 mmol, 78% yield) as off-white powder. MS (M+H=611). 1H
NMR (400 MHz, MeOD) .delta. ppm 7.54-7.63 (2 H, m), 7.19-7.33 (3 H,
m), 7.02-7.17 (3 H, m), 6.91 (1 H, dd, J=8.44, 2.39 Hz), 4.28 (2 H,
s), 3.80 (3 H, s), 3.13-3.32 (2 H, m), 2.75-2.90 (2 H, m).
Example 205
Sodium
1-(2-methoxy-4-(2-oxo-3-(4-(trifluoromethoxy)phenylthio)pyrazin-1(2-
H)-yl)phenoxy)-2-methylpropan-2-yl phosphate
##STR00666##
[0326] In an analogous fashion to that described in Example 204,
the phosphate prodrug of the alcohol described in Example 38 was
prepared. MS (M-H=561). 1H NMR (400 MHz, MeOD) .delta. ppm 7.57 (2
H, d, J=8.56 Hz), 7.28 (2 H, d, J=8.31 Hz), 7.20 (1 H, d, J=4.28
Hz), 6.97-7.12 (3 H, m), 6.88 (1 H, dd, J=8.56, 2.27 Hz), 4.00 (2
H, s), 3.78 (3 H, s), 1.48 (6 H, s).
[0327] The following experimental descriptions exemplify the
preparation of specific compounds as set out in Examples 27, 95,
110, 113, and 124.
EXAMPLE 27
##STR00667##
[0328]
1-(4-(2-Hydroxy-2-methylpropoxy)-3-methoxyphenyl)-3-(2-(pyridin-2-y-
l)-ethylthio)pyrazin-2(1H)-one
[0329] Following the procedures described in parts A-D of example
134, 2-methoxy-4-nitrophenol was converted to
1-(4-(2-hydroxy-2-methylpropoxy)-3-methoxyphenyl)pyrazine-2,3(1H,4H)-dion-
e. A solution of
1-(4-(2-hydroxy-2-methylpropoxy)-3-methoxyphenyl)pyrazine-2,3(1H,4H)-dion-
e prepared in Part ? (2.28 g, 7.44 mmol), EtN(iPr).sub.2 (3.9 mL,
22.3 mmol), PyBOP (6.78 g, 13.0 mmol) in DMF (35 mL) was stirred at
ambient temperature for 1.5 h. After addition of 2-pyridylethyl
mercaptan (1.24 g, 8.93 mmol), the reaction was stirred at ambient
temperature. After stirring overnight the reaction mixture was
partially concentrated under reduced pressure, quenching by
addition of aq. NaHCO.sub.3 and extracted with EtOAc. The EtOAc
extracts were washed with brine, dried over MgSO.sub.4 and
concentrated. Chromatography on silica employing a gradient elution
with 2.5-10% methanol/methylene chloride, followed by
chromatography on silica eluting with EtOAc, and trituration with
EtOAc/Hexanes afforded the desired product
1-(4-(2-hydroxy-2-methylpropoxy)-3-methoxyphenyl)-3-(2-(pyridin-2-yl)ethy-
lthio)pyrazin-2(1H)-one (2.15g, 68% yield).
Example 95
##STR00668##
[0330]
1-(4-(2-Hydroxy-2-methylpropoxy)-3-methylphenyl)-3-(5-(trifluoromet-
hyl)pyridin-2-ylthio)pyrazin-2(1H)-one
Part A. 2-Methyl-1-(2-methyl-4-nitrophenoxy)propan-2-ol
##STR00669##
[0332] A mixture of 2-methyl-4-nitrophenol (5.50 g, 35.9 mmol),
2,2-dimethyloxirane (7.77 g, 108 mmol), K.sub.2CO.sub.3 (4.96 g,
35.9 mmol) and NaH.sub.2PO.sub.4 (4.31 g, 35.9 mmol) in MeCN (50
mL) and H.sub.2O (8.82 mL) was stirred at 140.degree. C. in a steel
bomb for 6 hours. After cooling to RT, the reaction was diluted
with aq. saturated NaHCO.sub.3 (80 ml) prior to extraction with
EtOAc (100 ml). The EtOAc layer was dried over Na.sub.2SO.sub.4 and
concentrated. The crude product was purified by silica gel
chromatography employing a solvent gradient (hexane to 60% ethyl
acetate) to elute 2-methyl-1-(2-methyl-4-nitrophenoxy)propan-2-ol
(7.3 g, 32.4 mmol, 90% yield) as yellow oil. MS (M+1=226). 1H NMR
(500 MHz, chloroform-d) .delta. ppm 8.00-8.15 (2 H, m), 6.86 (1 H,
d, J=8.80 Hz), 3.90 (2 H, s), 2.33 (3 H, s), 1.40 (6 H, s).
Part B. 1-(4-Amino-2-methylphenoxy)-2-methylpropan-2-ol
##STR00670##
[0334] A mixture of 2-methyl-1-(2-methyl-4-nitrophenoxy)propan-2-ol
(7.30 g, 32.4 mmol) and 10% Pd/C (0.345 g, 3.24 mmol) in MeOH (150
mL) was hydrogenated at 1 atm of H.sub.2 for 18 hours. After
removal of the Pd/C by filtration, the solution was concentrated to
yield 1-(4-amino-2-methylphenoxy)-2-methylpropan-2-ol (6. 10 g,
29.7 mmol, 92% yield) as clear gum which was carried forward
without further purification.
Part C.
N1-(2,2-Dimethoxyethyl)-N2-(4-(2-hydroxy-2-methylpropoxy)-3-methyl-
phenyl)oxalamide
##STR00671##
[0336] Slow addition of a solution of ethyl 2-chloro-2-oxoacetate
(4.69 g, 34.4 mmol) in THF (30 ml) to a solution of
1-(4-amino-2-methylphenoxy)-2-methylpropan-2-ol (6.10 g, 3 1.2
mmol) in THF (100 mL) resulted in formation of a precipitate as the
reaction stirred at RT for 30 min. At which time a solution of
Et.sub.3N (13.06 mL, 94 mmol) and 2,2-dimethoxyethanamine (3.94 g,
37.5 mmol) in EtOAc (100 mL) was added prior to heating the mixture
at reflux for 25 hours. After cooling and concentration under
vacuum, the residue, following dilution with CH.sub.2Cl.sub.2, was
extracted with aqueous 0.5 N HCl (2.times.150 ml). The
CH.sub.2Cl.sub.2 layer was dried over sodium sulfate and
concentrated to yield
N1-(2,2-dimethoxyethyl)-N2-(4-(2-hydroxy-2-methylpropoxy)-3-methylphenyl)-
-oxalamide (1 1.40 g, 30.6 mmol, 98% yield) as white solid which
was carried forward without further purification.
Part D.
3-Hydroxy-1-(4-(2-hydroxy-2-methylpropoxy)-3-methylphenyl)pyrazin--
2(1H)-one
##STR00672##
[0338] A solution of
N1-(2,2-dimethoxyethyl)-N2-(4-(2-hydroxy-2-methylpropoxy)-3-methylphenyl)-
oxalamide (1 1.4 g, 32.2 mmol) and TFA (2.97 mL, 38.6 mmol) in AcOH
(120 mL) was stirred at 135.degree. C. in a seal tube for 60 min.
After cooling and concentration under vacuum, addition of
CH.sub.2Cl.sub.2 (300 ml) produced a precipitate which was
collected by filtration and was washed with CH.sub.2Cl.sub.2 (150
ml) to yield
3-hydroxy-1-(4-(2-hydroxy-2-methylpropoxy)-3-methylphenyl)pyrazin-2(1H)-o-
ne (7.19 g, 23.53 mmol, 73.1% yield) as brown solid. MS (M+1=226).
1H NMR (500 MHz, methanol-d.sub.3) .delta. ppm 7.13-7.26 (2 H, m),
6.98 (1 H, d, J=8.52 Hz), 6.50 (1 H, d, J=5.77 Hz), 6.41 (1 H, d,
J=6.05 Hz), 3.82 (2 H, s), 2.29 (3 H, s), 1.35 (6 H, s).
Part E.
1-(4-(2-Hydroxy-2-methylpropoxy)-3-methylphenyl)-3-(5-(trifluorome-
thyl)-pyridin-2-ylthio)pyrazin-2(1H)-one
##STR00673##
[0340] A mixture of
3-hydroxy-1-(4-(2-hydroxy-2-methylpropoxy)-3-methylphenyl)pyrazin-2(1H)-o-
ne (100 mg, 0.344 mmol), PyBOP (314 mg, 0.603 mmol) and
EtN(iPr).sub.2 (0.180 mL, 1.033 mmol) in DMF (6 mL) was stirred at
RT for 3 hours prior to addition of
5-(trifluoromethyl)pyridine-2-thiol (74.1 mg, 0.413 mmol). After
stirring for 3 days, The reaction was diluted with aq. saturated
NaHCO.sub.3 (15 ml) prior to extraction with EtOAc (20 ml). The
EtOAc layer was dried over Na.sub.2SO.sub.4 and concentrated. The
crude product was purified by prep-HPLC (Phenomenex, Luna 5 micron
30.times.250 mm, flow rate=30 ml/min., gradient=20% A to 100% B in
30 min., A=90% H.sub.2O/10% MeOH/0.1% TFA, B=10% H.sub.2O/90%
MeOH/0.1% TFA). After concentration, the residue in EtOAc (30 ml)
was converted to the free base by washing with aq. saturated
NaHCO.sub.3 (30 ml). The EtOAc layer was dried over
Na.sub.2SO.sub.4 and concentrated. To yield
1-(4-(2-hydroxy-2-methylpropoxy)-3-methylphenyl)-3-(5-(trifluoromethyl)py-
ridin-2-ylthio)pyrazin-2(1 H)-one (22.76 mg, 14%) as off-white
solid. MS (M+1=452). 1H NMR (500 MHz, chloroform-d) .epsilon. ppm
8.88 (1 H, s), 7.89-7.99 (2 H, m), 7.16-7.24 (3 H, m), 7.07 (1 H,
d, J=4.40 Hz), 6.90 (1 H, d, J=8.52 Hz), 3.84 (2 H, s), 2.30 (3 H,
s), 1.39 (6 H, s).
Example 110
##STR00674##
[0341]
1-(4-(2-Hydroxy-2-methylpropoxy)-3-methylphenyl)-3-(2-(pyridin-2-yl-
)ethylthio)pyrazin-2(1H)-one
##STR00675##
[0343] A mixture of 3-(2-(pyridin-2-yl)ethylthio)pyrazin-2(1H)-one
(100 mg, 0.429 mmol), which was prepared by the procedure described
in Method 7 except for substitution of 2-(2-pyridylethylthiol) for
2-(4-chlorophenethanol),
1-(4-bromo-2-methylphenoxy)-2-methylpropan-2-ol (133 mg, 0.514
mmol), N1,N2-dimethylethane-1,2-diamine (113 mg, 1.286 mmol),
K.sub.3PO.sub.4 (0.106 mL, 1.286 mmol) and copper(1) iodide (82 mg,
0.429 mmol) in dioxane (1.0 mL) was stirred at 115.degree. C. for
90 min. The reaction mixture, after cooling to RT, was filtered and
the filtrate was concentrated. The crude product was purified by
silica gel chromatography employing a solvent gradient (hexane to
100% ethyl acetate) to yield
1-(4-(2-hydroxy-2-methylpropoxy)-3-methylphenyl)-3-(2-(pyridin-2-yl)ethyl-
thio)pyrazin-2(1H)-one (140 mg, 0.340 mmol, 79% yield) as white
solid. MS (M+H 412). 1H NMR (400 MHz, MeOD) .delta. ppm 8.67 (1 H,
d), 8.48 (1 H, td, J=7.91, 1.51 Hz), 8.02 (1 H, d, J=8.28 Hz),
7.81-7.95 (1 H, m), 7.07-7.29 (4 H, m), 6.93 (1 H, d, J=8.78 Hz),
3.76 (2 H, s), 3.35-3.57 (4 H, m), 2.22 (3 H, s), 1.27 (6 H,
s).
Example 113
##STR00676##
[0344]
1-(4-(2-Hydroxy-2-methylpropoxy)-3-methylphenyl)-3-(phenethylthio)p-
yrazin-2(1H)-one
##STR00677##
[0346] A mixture of 3-(phenethylthio)pyrazin-2(1H)-one (25 mg,
0.108 mmol), which was prepared by the procedure described in
Method 7 except for substitution of 2-phenethylthiol for
2-(4-chlorophenethanol),
1-(4-bromo-2-methylphenoxy)-2-methylpropan-2-ol (33.5 mg, 0.129
mmol), copper iodide (20.50 mg, 0.108 mmol), K.sub.3PO.sub.4 (70
mg, 0.323 mmol) and N,N'-dimethylethylenediamine (28.5 mg, 0.323
mmol) in dioxane (1.0 ml) was stirred at 115.degree. C. for 2
hours. The reaction mixture, after cooling to RT, was filtered and
the filtrate was concentrated. The crude product was purified by
silica gel chromatography employing a solvent gradient (hexane to
100% ethyl acetate) to elute to yield
1-(4-(2-hydroxy-2-methylpropoxy)-3-methylphenyl)-3-(phenethylthio)-pyrazi-
n-2(1H)-one (26.74 mg, 0.062 mmol, 57.5% yield) as off-white solid.
MS (M+1=41 1). 1H NMR (500 MHz, methanol-d.sub.3) .delta. ppm 7.38
(1 H, d, J=4.40 Hz), 7.25-7.32 (4 H, m), 7.16-7.24 (4 H, m), 7.00
(1 H, d, J=8.25 Hz), 3.83 (1 H, s), 3.24-3.39 (2 H, m), 2.90-3.05
(2 H, m), 2.29 (3 H, s), 1.35 (6 H, s).
Radioligand Binding Assay for Assessment of MCHR1 Activity
Assay and Biological Evaluation
[0347] Compounds of Formula I were initially characterized in an in
vitro binding assay to determine their Ki or ability to antagonize
binding of a peptide agonist to the human melanin concentrating
hormone receptor (MCHR1).
Radioligand Binding Assay for Assessment of MCHR1 Activity
[0348] Membranes from stably transfected HEK-293 cells expressing a
mutated (E4Q, A5T) hMCHR1 receptor were prepared by dounce
homogenization and differential centrifugation. Binding experiments
were carried out with 0.5-1.0 ug of membrane protein incubated in a
total of 0.2 ml in 25 mM HEPES (pH 7.4) with 10 mM MgCl.sub.2, 2 mM
EGTA, and 0.1% BSA (Binding Buffer) for 90 min. For competition
binding assays, reactions were carried out in the presence of with
0.06-0.1 nM [Phe.sup.13, [.sup.125I]Tyr.sup.19]-MCH and increasing
concentrations of unlabeled test molecules. Reactions were
terminated by rapid vacuum filtration over 96 well-GFC Unifilter
plates pre-coated with 0.075 ml binding buffer containing 1% BSA,
and washed 3 times with 0.4 ml of Phospho-buffered Saline (pH 7.4)
containing 0.01% TX-100. Filters were dried; 0.05 ml microscint 20
was added to each well and radioactivity was subsequently
quantified by scintillation counting on a TopCount.TM. microplate
scintillation counter (Packard). Inhibitory constants were
determined by nonlinear least squares analysis using a four
parameter logistic equation.
Biological Data
[0349] The following representative in vitro biological data was
measured in a binding assay for the compounds from the Examples
herein above:
TABLE-US-00005 Example Ki (nM) 113 8 124 9 65 10 110 17 125 17 131
18 38 20 181 21 67 28 36 33 95 41 155 45 69 49 71 62 27 63 151 64
141 78 172 85 59 125 170 132 10 141 46 232 178 290 3 576 169 1294
39 1580 157 1730 49 3043 19 3127 28 3153 40 3218 50 4664
Evaluation of Prodrugs
[0350] The relative ability of the prodrug to enhance exposure
(bioavailability) was assessed in an eight hour PK study using
cannulated Sprague Dawley (CD, Charles River Breeding Laboratory)
rats. The compounds (parent and prodrug esters) were administered
p.o. at 2.0 ml/kg as a suspension in 0.5% methyl cellulose, 0.1%
Tween 80 in water at 10 mg/kg p.o. Blood samples were taken at 1,
2, 4 and 8 hr. After determination of parent concentration, an AUC
was calculated for the eight hour study.
Assessment of In Vivo MCHR1 Activity
[0351] Male Sprague Dawley (CD, Charles River Breeding Laboratory)
rats weighing approximately 240 grams were placed in individual
plastic cages with AlphaDri bedding. The room was maintained at
72.degree. F. and 50% humidity, and a 12/12 light dark cycle with
lights out at 1600 hours. The rats were conditioned for 5 days
prior to the start of the study to having a choice of foods. A
normal chow (Harlan Teklad, 2018) that contains 18% protein, 5% fat
and 73% carbohydrate and a high fat high sugar diet (Research Diets
(D2327) that contains 20% protein, 40% fat and 40% carbohydrate
where the carbohydrate is entirely sucrose and the fat is soybean
and coconut oil. Studies have revealed that rats exhibit a high
preference for the high fat/high sucrose diet (80% preference).
Body weight and consumption of both kinds of food as well as water
intake were measured daily. Water was available ad lib throughout
the study. Food consumption is presented as daily caloric
consumption which is the sum of grams of chow multiplied by the
Kcal per gram (3.5) plus grams of high fat high sugar multiplied by
Kcal per gram (4.59).
[0352] Baseline body weight was measured prior to drug treatment on
day 0 of the study. Baseline food consumption was the average of
the 3 days prior to the first drug treatment. Drug was administered
daily p.o. at 2.0 ml/kg at 1500 hours beginning on day 0 and
continuing daily through day 4 as a suspension in 0.5% methyl
cellulose, 0.1% Tween 80 in water at 3.0, 10 and 30 mg/kg p.o. All
data were evaluated using ANOVA and Fishers PLSD statistics.
Biological Data
TABLE-US-00006 [0353] Dose Weight Reduction Example (mg/kg) versus
Vehicle 193 3 0.7% 10 2.1% 30 3.4% 194 3 0.9% 10 2.7% 30 7.4% 202
30 2.2% 27 45 4.1% 113 45 4.2%
[0354] While the invention has been described according to several
embodiments, various modifications thereto, in addition to those
described herein, may become apparent to those skilled in the art
from the foregoing description. Such modifications are also
intended to fall within the scope of the appended claims.
* * * * *